<SEC-DOCUMENT>0001193125-23-071344.txt : 20230315
<SEC-HEADER>0001193125-23-071344.hdr.sgml : 20230315
<ACCEPTANCE-DATETIME>20230315161932
ACCESSION NUMBER:		0001193125-23-071344
CONFORMED SUBMISSION TYPE:	POSASR
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20230315
DATE AS OF CHANGE:		20230315
EFFECTIVENESS DATE:		20230315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sana Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001770121
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POSASR
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-266547
		FILM NUMBER:		23735457

	BUSINESS ADDRESS:	
		STREET 1:		188 EAST BLAINE STREET, SUITE 400
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102
		BUSINESS PHONE:		(206) 701-7914

	MAIL ADDRESS:	
		STREET 1:		188 EAST BLAINE STREET, SUITE 400
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102
</SEC-HEADER>
<DOCUMENT>
<TYPE>POSASR
<SEQUENCE>1
<FILENAME>d457972dposasr.htm
<DESCRIPTION>POSASR
<TEXT>
<HTML><HEAD>
<TITLE>POSASR</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on March 15, 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-266547 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>POST-EFFECTIVE
AMENDMENT NO. 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-3</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES ACT
OF 1933 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Sana Biotechnology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">83-1381173</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation&nbsp;or&nbsp;organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S.&nbsp;Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification&nbsp;Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>188 East Blaine Street, Suite 400 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Seattle, Washington 98102 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(206) <FONT STYLE="white-space:nowrap">701-7914</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Steven D. Harr, M.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Sana Biotechnology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>188 East Blaine Street, Suite 400 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Seattle, Washington 98102 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(206) <FONT STYLE="white-space:nowrap">701-7914</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Bernard J. Cassidy</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Sana Biotechnology, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>188 East Blaine Street, Suite 400</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Seattle, Washington 98102</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(206) <FONT STYLE="white-space:nowrap">701-7914</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>B. Shayne Kennedy</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Latham&nbsp;&amp; Watkins&nbsp;LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>140 Scott Drive</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park,
California 94025</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Telephone: <FONT STYLE="white-space:nowrap">(650)&nbsp;328-4600</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Facsimile: <FONT STYLE="white-space:nowrap">(650)&nbsp;463-2600</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: </B>From time to time after the effective date of this registration statement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following
box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this
Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall
become effective on filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this Form
is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of Securities Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPLANATORY NOTE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-266547), or the Post-Effective Amendment No. 1, of Sana
Biotechnology, Inc., or the Company, is being filed because the Company expects that it will no longer be a &#147;well-known seasoned issuer&#148; (as such term is defined in Rule 405 of the Securities Act of 1933, as amended, or the Securities Act)
when it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2022. Accordingly, the Company is filing this Post-Effective Amendment No. 1 for the purpose of including disclosure required for a registrant other than a
well-known seasoned issuer, identifying the securities being registered, registering a specific amount of securities, and paying the associated filing fee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Post-Effective Amendment No. 1 contains two prospectuses: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a base prospectus covering the offering, issuance, and sale by the Company of up to $350,000,000 the
Company&#146;s common stock, preferred stock, debt securities, warrants, and/or units, in each case from time to time in one or more offerings; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a sales agreement prospectus covering the offering, issuance, and sale by the Company of up to a maximum
aggregate offering price of $148,735,500 of the Company&#146;s common stock that may be issued and sold under a sales agreement with Cowen and Company, LLC, or Cowen. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus will be
specified in a prospectus supplement to the base prospectus. The specific terms of the securities to be issued and sold under the sales agreement with Cowen are specified in the sales agreement prospectus that immediately follows the base
prospectus. The $148,735,500 of common stock that may be offered, issued, and sold under the sales agreement prospectus is included in the $350,000,000 of securities that may be offered, issued, and sold by the Company under the base prospectus.
Upon termination of the sales agreement with Cowen, any portion of the $148,735,500 included in the sales agreement prospectus that is not sold pursuant to the sales agreement will be available for sale in other offerings pursuant to the base
prospectus and a corresponding prospectus supplement, and if no shares are sold under the sales agreement, the full $350,000,000 of securities may be sold in other offerings pursuant to the base prospectus and a corresponding prospectus supplement.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g457972g23i89.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Sana Biotechnology, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$350,000,000 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell up to
$350,000,000 in the aggregate of the securities identified above from time to time in one or more offerings. This prospectus provides you with a general description of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time we offer and sell securities, we will provide a supplement to this prospectus that contains specific information about the offering and the amounts,
prices, and terms of the securities. The supplement may also add, update, or change information contained in this prospectus with respect to that offering. You should carefully read this prospectus and the applicable prospectus supplement before you
invest in any of our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or
more underwriters, dealers, and agents, or directly to purchasers, or through a combination of these methods. If any underwriters, dealers, or agents are involved in the sale of any of the securities, their names and any applicable purchase price,
fee, commission, or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus titled &#147;About this
Prospectus&#148; and &#147;Plan of Distribution&#148; for more information. No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering of such securities.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE &#147;<A HREF="#toc457972_4">RISK FACTORS</A>&#148; ON PAGE&nbsp;6 OF THIS PROSPECTUS AND ANY SIMILAR
SECTION CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock
is listed on the Nasdaq Global Select Market under the symbol &#147;SANA.&#148; On March&nbsp;14, 2023, the last reported sale price of our common stock on the Nasdaq Global Select Market was $3.44 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus
is&nbsp;March 15, 2023. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc457972_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc457972_2">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY
REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc457972_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc457972_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc457972_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc457972_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc457972_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc457972_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc457972_9">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc457972_10">GLOBAL SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc457972_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc457972_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc457972_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc457972_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, as a &#147;well-known seasoned
issuer&#148; as defined in Rule 405 under the Securities Act, using a &#147;shelf&#148; registration process. By using a shelf registration statement, we may sell securities from time to time and in one or more offerings up to a total dollar amount
of $350,000,000, as described in this prospectus. Each time that we offer and sell securities, we will provide a prospectus supplement to this prospectus that contains specific information about the securities being offered and sold and the specific
terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement or free writing prospectus may also add, update,
or change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or free writing prospectus, you should rely on the
prospectus supplement or free writing prospectus, as applicable. Before purchasing any securities, you should carefully read both this prospectus and the applicable prospectus supplement (and any applicable free writing prospectuses), together with
the additional information described under the heading &#147;Where You Can Find More Information; Incorporation by Reference.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not
authorized anyone to provide you with any information or to make any representations other than those contained in, or incorporated by reference into, this prospectus, any applicable prospectus supplement, or any free writing prospectuses prepared
by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We will not make an offer to sell these securities in any
jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus and the applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover, that the
information appearing in any applicable free writing prospectus is accurate only as of the date of that free writing prospectus, and that any information incorporated by reference is accurate only as of the date of the document incorporated by
reference, unless we indicate otherwise. Our business, financial condition, results of operations and prospects may have changed since those dates. This prospectus incorporates by reference, and any prospectus supplement or free writing prospectus
may contain and incorporate by reference, market data and industry statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe these sources are reliable, we do not
guarantee the accuracy or completeness of this information and we have not independently verified this information. In addition, the market and industry data and forecasts that may be included or incorporated by reference in this prospectus, any
prospectus supplement or any applicable free writing prospectus may involve estimates, assumptions, and other risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#147;Risk
Factors&#148; contained in this prospectus, the applicable prospectus supplement and any applicable free writing prospectus, and under similar headings in other documents that are incorporated by reference into this prospectus. Accordingly,
investors should not place undue reliance on this information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When we refer to &#147;Sana Biotechnology,&#148; &#147;Sana,&#148; the
&#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; in this prospectus, we mean Sana Biotechnology, Inc. and its subsidiaries, unless otherwise specified. When we refer to &#147;you,&#148; we mean the potential holders of the
applicable series of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;SANA BIOTECHNOLOGY,&#148; the Sana Biotechnology logos, and other trade names, trademarks, or service marks of
Sana Biotechnology appearing in this prospectus are the property of Sana Biotechnology. Other trade names, trademarks, or service marks appearing in this prospectus are the property of their respective holders. Solely for convenience, trade names,
trademarks, and service marks referred to in this prospectus appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, and SM symbols, but those references are not
intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trade names, trademarks, and service marks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc457972_2"></A>WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file reports, proxy
statements, and other information with the SEC. The SEC maintains a website that contains reports, proxy, and information statements and other information about issuers, including us, who file electronically with the SEC. The address of that website
is <I>www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our website address is <I>www.sana.com</I>. The information on, or accessible through, our website, however, is not, and should
not be deemed to be, a part of this prospectus or any prospectus supplement. We have included our website address as an inactive textual reference only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any prospectus supplement are part of a registration statement that we filed with the SEC and do not contain all of the information in the
registration statement. The full registration statement may be obtained from the SEC or us, as provided above. Forms of the indenture and other documents establishing the terms of the offered securities are or may be filed as exhibits to the
registration statement or documents incorporated by reference in the registration statement. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference
to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incorporation by
Reference </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC&#146;s rules allow us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose
important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information that we file with the SEC will
automatically update and supersede that information. Any statement contained in this prospectus or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a
statement contained in this prospectus or a subsequently filed document incorporated by reference modifies or replaces that statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by
reference our documents listed below and any future filings made by us with the SEC under Sections&nbsp;13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, between the date of this prospectus and the
termination of the offering of the securities described in this prospectus. We are not, however, incorporating by reference any documents or portions thereof, whether specifically listed below or filed in the future, that are not deemed
&#147;filed&#148; with the SEC, including any Compensation Committee report and performance graph or any information furnished pursuant to Items 2.02 or 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> or related exhibits furnished pursuant
to Item 9.01 of Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any accompanying prospectus supplement incorporate by reference the
documents set forth below that have previously been filed with the SEC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31,
2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000156459022010539/sana-10k_20211231.htm">March&nbsp;16, 2022</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information specifically incorporated by reference into our Annual Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> from our Definitive Proxy Statement on Schedule&nbsp;14A, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312522118701/d295002ddef14a.htm">April&nbsp;26,
2022</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the quarters ended
March&nbsp;31, 2022, June&nbsp;30, 2022 and September&nbsp;30, 2022, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000156459022019299/sana-10q_20220331.htm">May&nbsp;10,
2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000156459022028036/sana-10q_20220630.htm">August&nbsp;
4, 2022</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1770121/000156459022036375/sana-10q_20220930.htm">November&nbsp;2, 2022</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;
8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000156459022000913/sana-8k_20220107.htm">January&nbsp;
11, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000119312522165186/d303939d8k.htm">June&nbsp;
1, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000119312522171023/d366546d8k.htm">June&nbsp;
9, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000156459022036057/sana-8k_20221027.htm">November&nbsp;
1, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000119312522294309/d191955d8k.htm">November&nbsp;
29, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000119312523016245/d642303d8k.htm">January&nbsp;
26, 2023</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000156459023000832/sana-8k_20230126.htm">January&nbsp;26, 2023</A>; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in <A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312521092650/d124805dex43.htm">Exhibit
 4.3</A> to the Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December 31, 2020, filed with the SEC on March 24, 2021, including any amendments or reports filed with the SEC for the purposes of updating
this description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All reports and other documents we subsequently file pursuant to Section&nbsp;13(a), 13(c), 14, or 15(d) of the
Exchange Act prior to the termination of this offering but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of
the filing of such reports and documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a free copy of any of the documents incorporated by reference in this prospectus by writing or
telephoning us at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sana Biotechnology, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 East Blaine Street, Suite 400 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Seattle, Washington 98102 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(206) <FONT
STYLE="white-space:nowrap">701-7914</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus or any
accompanying prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc457972_3"></A>THE COMPANY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. Damage to
cells is the underlying pathology of almost every human disease, and we believe the ability to replace or repair damaged cells through cellular engineering can address the underlying root cause of a host of diseases. We view engineered cells as
having the potential to be as&nbsp;therapeutically disruptive as biologics to clinical practice. Our long-term aspirations are to be able to control or modify any gene in the body, to replace any cell that is damaged or missing, and to markedly
improve access to cellular and gene-based medicines. We have brought together an experienced group of scientists, engineers, and company builders and equipped them with technologies to move this vision forward. We are developing <I>ex vivo</I> and
<I>in vivo</I> cell engineering platforms to revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, and genetic disorders, among others. We expect
clinical data from our CD19-targeted allogenic chimeric antigen receptor (CAR) T program, SC291, in 2023. We also continue to make progress on developing our cell engineering platforms and advancing our product candidates through preclinical
development, with the goal of submitting multiple Investigational New Drug applications, or INDs, in 2023 and beyond. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frequently in disease, cells are
damaged or missing entirely, and an effective therapy needs to replace the entire cell, an approach referred to as cell therapy or <I>ex vivo</I> cell engineering. A successful therapeutic requires <FONT STYLE="white-space:nowrap">large-scale</FONT>
manufacturing of cells that engraft, function, and persist in the body. Of these, we view cell persistence as the greatest current limitation to dramatically expanding the impact of this class of therapeutics, and in particular, overcoming the
barrier of immune rejection of transplanted allogeneic cells. This challenge has led many to focus on autologous, or a patient&#146;s own, cells as the therapeutic source. However, autologous therapies require a complex process of harvesting cells
from patients, manipulating them outside the body, and returning them to the patient. Products using this approach have had to manage significant challenges such as scalability, product variability, product quality, cost, patient accessibility, and
limits with respect to the types of cells that are amenable to this approach. Given these limitations, rather than using autologous cells to address the challenge of immune rejection, we have invested in developing our hypoimmune technology to
create cells that can &#147;hide&#148; from the patient&#146;s immune system to enable persistence of allogeneic cells. We are striving to make therapies using pluripotent stem cells with our hypoimmune genetic modifications as the starting
material, which we then differentiate into a specific cell type, such as a pancreatic islet cell, before treating the patient. Additionally, there are cell types for which effective differentiation protocols from a stem cell have not yet been
developed, such as T cells. For such cell types, instead of starting from a pluripotent stem cell, we can use a fully differentiated allogeneic cell, sourced from a donor, as the starting material to which we then apply our hypoimmune genetic
modifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process of repairing and controlling genes in the body, referred to as gene therapy or <I>in vivo</I> cell engineering, requires both
<I>in vivo</I> delivery of a therapeutic payload and genome modification. Of these, we view effective <I>in vivo </I>delivery as the greatest current limitation to dramatically expanding the impact of this class of therapeutics. To this end, our
initial focus is on cell-specific delivery as well as increasing the diversity and size of payloads, with our ultimate goal being the delivery of any payload, to any cell, in a specific and repeatable way. We have shown in preclinical studies that
our fusogen technology can specifically target numerous cell surface receptors that, when combined with delivery vehicles to form fusosomes, allow cell-specific delivery across multiple different cell types. We have initially chosen to focus our
fusogen technology on two cell types: T cells and hematopoietic stem cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the time is right to develop engineered cell therapies across a
broad range of therapeutic areas. Substantial progress in the understanding of genetics, gene editing, gene control, protein engineering, stem cell biology, immunology, process analytics, and computational biology have converged to create an
opportunity to markedly increase the breadth and depth of the potential impact of genetic and cellular medicines. We are focused on creating transformative <I>ex vivo</I> and <I>in vivo</I> engineered cell therapies across a range of therapeutic
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
areas. We are in the early stages of development across a broad pipeline of product candidates, which are summarized below: </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g457972g01q01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were founded in July 2018 as a Delaware corporation. Our principal executive offices are located at 188 East Blaine
Street, Suite 400, Seattle, Washington 98102, and our telephone number is (206) <FONT STYLE="white-space:nowrap">701-7914.</FONT> Our website address is <I>www.sana.com</I>. The information on, or that can be accessed through, our website is not
part of this prospectus and is not incorporated by reference herein. We have included our website address as an inactive textual reference only. We also use our website as a means of disclosing material
<FONT STYLE="white-space:nowrap">non-public</FONT> information and for complying with our disclosure obligations under Regulation FD. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc457972_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investment in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves risks. You should carefully consider the
risk factors included in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and any subsequent Annual Reports on Form 10-K, Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> or Current Reports on
Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and all other information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act, and the risk factors and other information
contained in the applicable prospectus supplement and any applicable free writing prospectus before acquiring any of such securities. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered
securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc457972_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of the securities as set forth in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc457972_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation, our amended and
restated bylaws, the amended and restated investors&#146; rights agreement to which we and certain of our stockholders are parties, and of the General Corporation Law of the State of Delaware, or the DGCL. Because the following is only a summary, it
does not contain all of the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation, amended and restated bylaws, and amended and restated investors&#146; rights
agreement, copies of which are incorporated by reference as exhibits to the registration statement of which this prospectus is a part. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 750,000,000 shares of common stock, par value $0.0001 per share, and 50,000,000 shares of preferred stock,
par value $0.0001 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Outstanding Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, we had
191,033,332 shares of our common stock outstanding, including 11,675 shares of unvested restricted common stock outstanding as of December 31, 2022, held of record by 53 stockholders. The actual number of stockholders is greater than the number of
record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other
entities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each holder of our
common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders
of a majority of the voting shares are able to elect all of the directors. In addition, the affirmative vote of holders of <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the voting power of all of the then outstanding voting stock is required to
take certain actions, including amending certain provisions of our amended and restated certificate of incorporation, such as the provisions relating to amending our amended and restated bylaws, the classified board and director liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to preferences that may be
applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of our liquidation,
dissolution or winding up, holders of our common stock are entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any
liquidation preference granted to the holders of any then outstanding shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights, Preferences, and Privileges </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of our common stock have no preemptive, conversion, or subscription rights, and there are no redemption or sinking fund provisions applicable to our
common stock. The rights, preferences, and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in
the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has the authority, without further action by our stockholders, to issue up to 50,000,000 shares of preferred stock in one or more series
and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and
the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of our common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and
the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other
corporate action. As of December 31, 2022, no shares of preferred stock were outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, we had outstanding options to purchase an aggregate of 23,686,340 shares of our common stock, with a weighted-average exercise price
of $7.79 per share, under our 2018 Equity Incentive Plan and 2021 Incentive Award Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restricted Stock Units </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, we had 884,878 outstanding restricted stock units subject to vesting conditions under our Restricted Stock Unit Plan and 2021
Incentive Award Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain
holders of shares of our common stock are entitled to certain rights with respect to registration of their shares under the Securities Act. These shares are referred to as registrable securities. The holders of these registrable securities possess
registration rights pursuant to the terms of our amended and restated investors&#146; rights agreement and are described in additional detail below. The registration of shares of our common stock pursuant to the exercise of the registration rights
described below would enable the holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. We will pay the registration expenses, other than underwriting discounts,
selling commissions and stock transfer taxes, of the shares registered pursuant to the demand, piggyback, and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registrations described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, in an underwritten offering, the managing underwriter, if any, has the right, subject to specified conditions and limitations, to limit the number
of shares the holders may include. The demand, piggyback, and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights described below will terminate upon the earliest of (i)&nbsp;with respect to each stockholder, such date on which all
registrable shares held by such stockholder may immediately be sold during any <FONT STYLE="white-space:nowrap">90-day</FONT> period pursuant to Rule 144 of the Securities Act, or Rule 144; and (ii)&nbsp;the occurrence of a deemed liquidation event,
as defined in our amended and restated certificate of incorporation, as currently in effect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, holders of approximately 82.3 million shares of our common stock were entitled to certain demand registration rights. Certain major
investors holding, collectively, at least 40% of registrable securities may, on not more than two occasions, request that we register all or a portion of their shares, subject to certain specified exceptions. If any of these holders exercises its
demand registration rights, then holders of approximately 82.3 million shares of our common stock are entitled to register their shares, subject to specified conditions and limitations in the corresponding offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that
we propose to register any of our securities under the Securities Act in an underwritten registered offering, either for our own account or for the account of other security holders, the holders of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registrable securities will be entitled to certain &#147;piggyback&#148; registration rights allowing them to include their shares in such registration, subject to specified conditions and
limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, holders of approximately 82.3&nbsp;million shares of our common stock were entitled to certain Form
<FONT STYLE="white-space:nowrap">S-3</FONT> registration rights. Certain major investors holding at least 25% of registrable securities may, on not more than two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> within any <FONT
STYLE="white-space:nowrap">12-month</FONT> period, request that we register all or a portion of their shares on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we are qualified to file a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> subject to specified exceptions. Such request for registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> must cover securities with an aggregate offering price which equals or exceeds
$15.0&nbsp;million, net of selling expenses. The right to have such shares registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> is further subject to other specified conditions and limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Provisions of our Amended and Restated Certificate of Incorporation, our Amended and Restated Bylaws, Delaware Law, and Washington
Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some provisions of Delaware law, Washington law, our amended and restated certificate of incorporation, and our amended and restated bylaws could
make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could
make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are
also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or
unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Business Combination Statute </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
elected to be subject to Section&nbsp;203 of the DGCL. Section&nbsp;203 prevents an &#147;interested stockholder,&#148; which is defined generally as a person owning 15% or more of a corporation&#146;s voting stock, or any affiliate or associate of
that person, from engaging in a broad range of &#147;business combinations&#148; with the corporation for three years after becoming an interested stockholder unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the board of directors of the corporation had previously approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, that
person owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, other than statutorily excluded shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following the transaction in which that person became an interested stockholder, the business combination is
approved by the board of directors of the corporation and holders of at least two-thirds of the outstanding voting stock not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;203, the restrictions described above also do not apply to specific business combinations proposed by an interested stockholder following
the announcement or notification of designated extraordinary transactions involving the corporation and a person who had not been an interested stockholder during the previous three years or who became an interested stockholder with the approval of
a majority of the corporation&#146;s directors, if such extraordinary transaction is approved or not opposed by a majority of the directors who were directors prior to any person becoming an interested stockholder during the previous three years or
were recommended for election or elected to succeed such directors by a majority of such directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 may make it more difficult for a person who would be an interested stockholder to effect
various business combinations with a corporation for a three-year period. Section&nbsp;203 also may have the effect of preventing changes in our management and could make it more difficult to accomplish transactions that our stockholders may
otherwise deem to be in their best interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Washington Business Corporation Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The laws of Washington, where our principal executive offices are located, impose restrictions on certain transactions between certain foreign corporations and
significant stockholders. In particular, the Washington Business Corporation Act, or WBCA, prohibits a &#147;target corporation,&#148; with certain exceptions, from engaging in certain &#147;significant business transactions&#148; with a person or
group of persons that beneficially owns 10% or more of the voting securities of the target corporation, an &#147;acquiring person,&#148; for a period of five years after such acquisition, unless the transaction or acquisition of shares is approved
by a majority of the members of the target corporation&#146;s board of directors prior to the time of acquisition. Such prohibited transactions may include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation with, disposition of assets to, or issuance or redemption of stock to or from, the
acquiring person; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any termination of 5% or more of the employees of the target corporation as a result of the acquiring
person&#146;s acquisition of 10% or more of the shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allowing the acquiring person to receive any disproportionate benefit as a stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the five-year period, a significant business transaction may take place as long as it complies with certain fair price provisions of the statute or is
approved at an annual or special meeting of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will be considered a &#147;target corporation&#148; so long as our principal executive
office is located in Washington, and: (i)&nbsp;a majority of our employees are residents of the state of Washington or we employ more than one thousand residents of the state of Washington; (ii)&nbsp;a majority of our tangible assets, measured by
market value, are located in the state of Washington or we have more than $50.0&nbsp;million worth of tangible assets located in the state of Washington; and (iii)&nbsp;any one of the following: (a)&nbsp;more than 10% of our stockholders of record
are resident in the state of Washington; (b)&nbsp;more than 10% of our shares are owned of record by state residents; or (c) 1,000 or more of our stockholders of record are resident in the state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we meet the definition of a target corporation, the WBCA may have the effect of delaying, deferring, or preventing a change of control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Election and Removal of Directors; Vacancies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
directors are elected by a plurality of the votes of the shares of our capital stock present in person or represented by proxy at a meeting and entitled to vote on the election of directors. Because our stockholders do not have cumulative voting
rights, stockholders holding a majority of the shares of our common stock outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation provides for the removal of any of our directors only for cause
only by an affirmative vote of shares representing not less than a majority of the shares then entitled to vote at an election of directors. Furthermore, any vacancy occurring on our board of directors and any newly created directorship may be
filled only by a majority of the remaining directors in office. This system of electing and removing directors and filling vacancies may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us,
because it generally makes it more difficult for stockholders to replace a majority of the directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Staggered Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors is divided into three classes. The directors in each class serve for a three-year term, one class being elected each year by our
stockholders, with staggered three-year terms. Only one class of directors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitation on Action by Written Consent </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
amended and restated certificate of incorporation and our amended and restated bylaws provide that holders of our common stock are not able to act by written consent without a meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Meetings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated
certificate of incorporation and our amended and restated bylaws provide that special meetings of our stockholders may be called only by the chairman of the board, our chief executive officer (or president, in the absence of a chief executive
officer), or a majority of the directors. Our amended and restated certificate of incorporation and our amended and restated bylaws specifically deny any power of any other person to call a special meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forum Selection </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated
certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i)&nbsp;any derivative action
or proceeding brought on behalf of us; (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director, officer, or other employee of our company to us or our stockholders; (iii)&nbsp;any action asserting a claim arising
pursuant to any provision of the DGCL or our amended and restated certificate of incorporation and bylaws; or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine. This provision would not apply to claims brought to
enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, our
amended and restated certificate of incorporation also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any
complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in our shares of capital stock shall be deemed to have notice of and consented to the foregoing forum
selection provisions. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws preclude stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to
applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations
thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules, and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The enforceability of similar
federal court choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find this type of provision to be inapplicable or unenforceable. If a
court were to find either of the choice of forum provisions contained in our amended and restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated
with resolving such action in other jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The choice of forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial
forum that it finds favorable for disputes with the company or its directors, officers, or other employees, which may discourage such lawsuits against the company and its directors, officers and other employees and result in increased costs for
investors to bring a claim. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Certificate of Incorporation and Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of our amended and restated certificate of incorporation described under &#147;&#151;Election and Removal of Directors; Vacancies,&#148;
&#147;&#151;Stockholder Meetings,&#148; &#147;&#151;Limitation on Action by Written Consent,&#148; &#147;&#151;Limitations of Liability of Directors and Officers and Indemnification Matters,&#148; &#147;&#151;Common Stock&#151;Voting Rights,&#148;
and &#147;&#151; Forum Selection&#148; and provisions relating to amendments to our amended and restated certificate of incorporation may be amended only by the affirmative vote of holders of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT>
of the voting power of our outstanding shares of voting stock. The affirmative vote of holders of at least a majority of the voting power of our outstanding shares of stock will generally be required to amend other provisions of our amended and
restated certificate of incorporation. The provisions of the DGCL, our amended and restated certificate of incorporation, and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a
consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management.
It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain provisions of our amended and restated bylaws may generally be altered, amended, or repealed, and new bylaws may be adopted, with the affirmative vote
of a majority of directors present at any regular or special meeting of the board of directors called for that purpose, provided that any alteration, amendment, or repeal of, or adoption of any bylaw inconsistent with specified provisions of the
bylaws, including those related to special and annual meetings of stockholders, action of stockholders by written consent, nomination of directors, transfers of capital stock and dividends requires the affirmative vote of at least <FONT
STYLE="white-space:nowrap">66-2/3%</FONT> of all directors in office at a meeting called for that purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All other provisions of our amended and
restated bylaws may generally be altered, amended, or repealed, and new bylaws may be adopted, with the affirmative vote of holders of <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the voting power of our outstanding shares of voting stock.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Limitations on Stockholder Actions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
amended and restated bylaws impose some procedural requirements on stockholders who wish to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make nominations in the election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">propose that a director be removed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">propose any repeal or change in our amended and restated bylaws; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">propose any other business to be brought before an annual or special meeting of stockholders.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under these procedural requirements, in order to bring a proposal before a meeting of stockholders, a stockholder must deliver timely
notice of a proposal pertaining to a proper subject for presentation at the meeting to our corporate secretary along with the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a description of the business or nomination to be brought before the meeting and the reasons for conducting such
business at the meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the stockholder&#146;s name and address; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any material interest of the stockholder in the proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares beneficially owned by the stockholder and evidence of such ownership; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names and addresses of all persons with whom the stockholder is acting in concert and a description of all
arrangements and understandings with those persons, and the number of shares such persons beneficially own. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be timely, a stockholder must generally deliver notice not less than 90 nor more than 120 days prior to
the date on which the annual meeting of stockholders was held in the immediately preceding year, but in the event that the date of the annual meeting is more than 30 days before or more than 60 days after the anniversary date of the preceding annual
meeting of stockholders, a stockholder notice will be timely if received by us not later than the close of business on the later of (i)&nbsp;the 90th day prior to the date of the annual meeting and (ii)&nbsp;the 10th day following the day on which
we first publicly announce the date of the annual meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to submit a nomination for our board of directors, a stockholder must also submit all
information with respect to the nominee that would be required to be included in a proxy statement, as well as other information. If a stockholder fails to follow the required procedures, the stockholder&#146;s proposal or nominee will be ineligible
and will not be voted on by our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability of Directors and Officers and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation contains provisions that limit the liability of our directors for monetary damages to the fullest extent
permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to our company or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of
the DGCL; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, neither we nor our stockholders have the right, through stockholders&#146; derivative suits on our behalf, to recover monetary damages against a
director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior, except in the situations described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation also provides that, to the fullest extent permitted by law, we will indemnify any officer or director of
our company against all damages, claims, and liabilities arising out of the fact that the person is or was our director or officer or served any other enterprise at our request as a director or officer. Amending this provision will not reduce our
indemnification obligations relating to actions taken before an amendment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;SANA.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and
registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. The transfer agent and registrar&#146;s address is 6201 15th Avenue, Brooklyn, New York 11219. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc457972_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we include in any applicable prospectus supplement or free writing prospectus, summarizes
certain general terms and provisions of the debt securities that we may offer under this prospectus. When we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a supplement to this prospectus.
We will also indicate in the supplement to what extent the general terms and provisions described in this prospectus apply to a particular series of debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities either separately, or together with, or upon the conversion or exercise of or in exchange for, other securities described in this
prospectus. Debt securities may be our senior, senior subordinated or subordinated obligations and, unless otherwise specified in a supplement to this prospectus, the debt securities will be our direct, unsecured obligations and may be issued in one
or more series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The debt securities will be issued under an indenture between us and a third party to be identified therein, as trustee. We have
summarized select portions of the indenture below. The summary is not complete. The form of the indenture has been filed as an exhibit to the registration statement and you should read the indenture for provisions that may be important to you. In
the summary below, we have included references to the section numbers of the indenture so that you can easily locate these provisions. Capitalized terms used in the summary and not defined herein have the meanings specified in the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this section only, &#147;Sana Biotechnology,&#148; &#147;Sana,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148;
refer to Sana Biotechnology, Inc., unless expressly stated or the context otherwise requires. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or determined in the
manner provided in a resolution of our board of directors, in an officer&#146;s certificate or by a supplemental indenture. (Section 2.2) The particular terms of each series of debt securities will be described in a prospectus supplement relating to
such series (including any pricing supplement or term sheet). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We can issue an unlimited amount of debt securities under the indenture that may be in one
or more series with the same or various maturities, at par, at a premium, or at a discount. (Section 2.1) We will set forth in a prospectus supplement (including any pricing supplement or term sheet) relating to any series of debt securities being
offered, the aggregate principal amount and the following terms of the debt securities, if applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and ranking of the debt securities (including the terms of any subordination provisions);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices (expressed as a percentage of the principal amount) at which we will sell the debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit on the aggregate principal amount of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which the principal of the securities of the series is payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates
(including any commodity, commodity index, stock exchange index or financial index) at which the debt securities will bear interest, the date or dates from which interest will accrue, the date or dates on which interest will commence and be payable
and any regular record date for the interest payable on any interest payment date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where principal of, and interest, if any, on the debt securities will be payable (and the
method of such payment), where the securities of such series may be surrendered for registration of transfer or exchange, and where notices and demands to us in respect of the debt securities may be delivered; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the period or periods within which, the price or prices at which and the terms and conditions upon which we may
redeem the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous
provisions or at the option of a holder of debt securities and the period or periods within which, the price or prices at which and in the terms and conditions upon which securities of the series shall be redeemed or purchased, in whole or in part,
pursuant to such obligation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which and the price or prices at which we will repurchase debt securities at the option of the
holders of debt securities and other detailed terms and provisions of these repurchase obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any
integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in the form of certificated debt securities or global debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity
date, if other than the principal amount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of denomination of the debt securities, which may be U.S. dollars or any foreign currency, and if
such currency of denomination is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the currency, currencies or currency units in which payment of principal of, premium and
interest on the debt securities will be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if payments of principal of, premium or interest on the debt securities will be made in one or more currencies or
currency units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the amounts of payment of principal of, premium, if any, or interest on the debt securities
will be determined, if these amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions relating to any security provided for the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion of or change in the Events of Default described in this prospectus or in the indenture
with respect to the debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion of or change in the covenants described in this prospectus or in the indenture with
respect to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect
to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions, if any, relating to conversion or exchange of any debt securities of such series, including if
applicable, the conversion or exchange price and period, provisions as to whether conversion or exchange will be mandatory, the events requiring an adjustment of the conversion or exchange price and provisions affecting conversion or exchange;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the debt securities, which may supplement, modify or delete any provision of the indenture as
it applies to that series, including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of the securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether any of our direct or indirect subsidiaries will guarantee the debt securities of that series, including
the terms of subordination, if any, of such guarantees. (Section 2.2) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities that provide for an amount less than their stated principal amount to be due
and payable upon declaration of acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax considerations and other special considerations applicable to any of these debt
securities in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we denominate the purchase price of any of the debt securities in a foreign currency or currencies
or a foreign currency unit or units, or if the principal of and any premium and interest on any series of debt securities is payable in a foreign currency or currencies or a foreign currency unit or units, we will provide you with information on the
restrictions, elections, general tax considerations, specific terms and other information with respect to that issue of debt securities and such foreign currency or currencies or foreign currency unit or units in the applicable prospectus
supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer and Exchange </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each debt
security will be represented by either one or more global securities registered in the name of The Depository Trust Company, or the Depositary, or a nominee of the Depositary (we will refer to any debt security represented by a global debt security
as a &#147;book-entry debt security&#148;), or a certificate issued in definitive registered form (we will refer to any debt security represented by a certificated security as a &#147;certificated debt security&#148;) as set forth in the applicable
prospectus supplement. Except as set forth under the heading &#147;Global Debt Securities and Book-Entry System&#148; below, book-entry debt securities will not be issuable in certificated form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certificated Debt Securities. You may transfer or exchange certificated debt securities at any office we maintain for this purpose in accordance with the
terms of the indenture. (Section 2.4) No service charge will be made for any transfer or exchange of certificated debt securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection
with a transfer or exchange. (Section 2.7) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may effect the transfer of certificated debt securities and the right to receive the principal of, premium
and interest on certificated debt securities only by surrendering the certificate representing those certificated debt securities and either reissuance by us or the trustee of the certificate to the new holder or the issuance by us or the trustee of
a new certificate to the new holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Global Debt Securities and Book-Entry System. Each global debt security representing book-entry debt securities will
be deposited with, or on behalf of, the Depositary, and registered in the name of the Depositary or a nominee of the Depositary. Please see &#147;Global Securities.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable prospectus
supplement any restrictive covenants applicable to any issue of debt securities. (Article IV) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Protection in the Event of a Change of Control
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions which may afford holders of the
debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction (whether or not such transaction results in a change in control) that could adversely affect holders of debt securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger and Sale of Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not consolidate with or merge with or into, or convey, transfer, or lease all or substantially all of our properties and assets to any person (we will
refer to such person as a &#147;successor person&#148;) unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are the surviving entity or the successor person (if other than Sana) is a corporation, partnership, trust or
other entity organized and validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes our obligations on the debt securities and under the indenture; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately after giving effect to the transaction, no Default or Event of Default, shall have occurred and be
continuing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, any of our subsidiaries may consolidate with, merge into or transfer all or part of its
properties to us. (Section 5.1) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Event of Default&#148; means with respect to any series of debt securities, any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of any interest upon any debt security of that series when it becomes due and payable, and
continuance of such default for a period of 30 days (unless the entire amount of the payment is deposited by us with the trustee or with a paying agent prior to the expiration of the 30-day period); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of principal of any security of that series at its maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the performance or breach of any other covenant or warranty by us in the indenture (other than a
covenant or warranty that has been included in the indenture solely for the benefit of a series of debt securities other than that series), which default continues uncured for a period of 60 days after we receive written notice from the trustee or
Sana and the trustee receive written notice from the holders of not less than 25% in principal amount of the outstanding debt securities of that series as provided in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain voluntary or involuntary events of bankruptcy, insolvency or reorganization of Sana; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other Event of Default provided with respect to debt securities of that series that is described in the
applicable prospectus supplement. (Section 6.1) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Event of Default with respect to a particular series of debt securities (except as
to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an Event of Default with respect to any other series of debt securities. (Section 6.1) The occurrence of certain Events of Default or an acceleration under the
indenture may constitute an event of default under certain indebtedness of ours or our subsidiaries outstanding from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide the
trustee written notice of any Default or Event of Default within 30 days of becoming aware of the occurrence of such Default or Event of Default, which notice will describe in reasonable detail the status of such Default or Event of Default and what
action we are taking or propose to take in respect thereof. (Section&nbsp;6.1) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an Event of Default with respect to debt securities of any series at
the time outstanding occurs and is continuing, then the trustee or the holders of not less than 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the trustee if given by the holders),
declare to be due and payable immediately the principal of (or, if the debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) and accrued and unpaid interest, if
any, on all debt securities of that series. In the case of an Event of Default resulting from certain events of bankruptcy, insolvency or reorganization, the principal (or such specified amount) of and accrued and unpaid
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interest, if any, on all outstanding debt securities will become and be immediately due and payable without any declaration or other act on the part of the trustee or any holder of outstanding
debt securities. At any time after a declaration of acceleration with respect to debt securities of any series has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a majority in
principal amount of the outstanding debt securities of that series may rescind and annul the acceleration if all Events of Default, other than the <FONT STYLE="white-space:nowrap">non-payment</FONT> of accelerated principal and interest, if any,
with respect to debt securities of that series, have been cured or waived as provided in the indenture. (Section 6.2) We refer you to the prospectus supplement relating to any series of debt securities that are discount securities for the particular
provisions relating to acceleration of a portion of the principal amount of such discount securities upon the occurrence of an Event of Default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
indenture provides that the trustee may refuse to perform any duty or exercise any of its rights or powers under the indenture unless the trustee receives indemnity satisfactory to it against any cost, liability, or expense that might be incurred by
it in performing such duty or exercising such right or power. (Section 7.1(e)) Subject to certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the
time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that series. (Section 6.12) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No holder of any debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the indenture or for the
appointment of a receiver or trustee, or for any remedy under the indenture, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that holder has previously given to the trustee written notice of a continuing Event of Default with respect to
debt securities of that series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of not less than 25% in principal amount of the outstanding debt securities of that series have made
written request, and offered indemnity or security satisfactory to the trustee, to the trustee to institute the proceeding as trustee, and the trustee has not received from the holders of not less than a majority in principal amount of the
outstanding debt securities of that series a direction inconsistent with that request and has failed to institute the proceeding within 60 days. (Section 6.7) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision in the indenture, the holder of any debt security will have an absolute and unconditional right to receive payment of the
principal of, premium and any interest on that debt security on or after the due dates expressed in that debt security and to institute suit for the enforcement of payment. (Section&nbsp;6.8) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with the indenture.
(Section 4.3) If a Default or Event of Default occurs and is continuing with respect to the securities of any series and if it is known to a responsible officer of the trustee, the trustee shall mail to each holder of the securities of that series
notice of a Default or Event of Default within 90 days after it occurs or, if later, after a responsible officer of the trustee has knowledge of such Default or Event of Default. The indenture provides that the trustee may withhold notice to the
holders of debt securities of any series of any Default or Event of Default (except in payment on any debt securities of that series) with respect to debt securities of that series if the trustee determines in good faith that withholding notice is
in the interest of the holders of those debt securities. (Section&nbsp;7.5) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification and Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and the trustee may modify, amend, or supplement the indenture or the debt securities of any series without the consent of any holder of any debt security:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with covenants in the indenture described above under the heading &#147;Consolidation, Merger and Sale
of Assets&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated securities in addition to or in place of certificated securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add guarantees with respect to debt securities of any series or secure debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to surrender any of our rights or powers under the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add covenants or events of default for the benefit of the holders of debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the applicable procedures of the applicable depositary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the rights of any holder of debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of debt securities of any series
as permitted by the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to effect the appointment of a successor trustee with respect to the debt securities of any series and to add to
or change any of the provisions of the indenture to provide for or facilitate administration by more than one trustee; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under
the Trust Indenture Act. (Section 9.1) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also modify and amend the indenture with the consent of the holders of at least a
majority in principal amount of the outstanding debt securities of each series affected by the modifications or amendments. We may not make any modification or amendment without the consent of the holders of each affected debt security then
outstanding if that amendment will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of debt securities whose holders must consent to an amendment, supplement or waiver;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the rate of or extend the time for payment of interest (including default interest) on any debt security;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal of or premium on or change the fixed maturity of any debt security or reduce the amount of,
or postpone the date fixed for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal amount of discount securities payable upon acceleration of maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a default in the payment of the principal of, premium or interest on any debt security (except a rescission
of acceleration of the debt securities of any series by the holders of at least a majority in aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from such
acceleration); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make the principal of or premium or interest on any debt security payable in currency other than that stated in
the debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change to certain provisions of the indenture relating to, among other things, the right of holders of
debt securities to receive payment of the principal of, premium and interest on those debt securities and to institute suit for the enforcement of any such payment and to waivers or amendments; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a redemption payment with respect to any debt security. (Section 9.3) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series may on behalf
of the holders of all debt securities of that series waive our compliance with provisions of the indenture. (Section 9.2) The holders of a majority in principal amount of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding debt securities of any series may on behalf of the holders of all the debt securities of such series waive any past default under the indenture with respect to that series and its
consequences, except a default in the payment of the principal of, premium or any interest on any debt security of that series; provided, however, that the holders of a majority in principal amount of the outstanding debt securities of any series
may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration. (Section 6.13) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance
of Debt Securities and Certain Covenants in Certain Circumstances </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Legal Defeasance</I>. The indenture provides that, unless otherwise provided by
the terms of the applicable series of debt securities, we may be discharged from any and all obligations in respect of the debt securities of any series (subject to certain exceptions). We will be so discharged upon the irrevocable deposit with the
trustee, in trust, of money and/or U.S. government obligations or, in the case of debt securities denominated in a single currency other than U.S. dollars, government obligations of the government that issued or caused to be issued such currency,
that, through the payment of interest and principal in accordance with their terms, will provide money or U.S. government obligations in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or
investment bank to pay and discharge each installment of principal, premium and interest on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in accordance with the
terms of the indenture and those debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discharge may occur only if, among other things, we have delivered to the trustee an opinion of
counsel stating that we have received from, or there has been published by, the U.S. Internal Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable U.S. federal income tax law, in either
case to the effect that, and based thereon such opinion shall confirm that, the holders of the debt securities of that series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit, defeasance and
discharge and will be subject to U.S. federal income tax on the same amounts, in the same manner and at the same times as would have been the case if the deposit, defeasance, and discharge had not occurred. (Section 8.3) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Defeasance of Certain Covenants</I>. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, upon
compliance with certain conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may omit to comply with the covenant described under the heading &#147;Consolidation, Merger and Sale of
Assets&#148; and certain other covenants set forth in the indenture, as well as any additional covenants that may be set forth in the applicable prospectus supplement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any omission to comply with those covenants will not constitute a Default or an Event of Default with respect to
the debt securities of that series, or covenant defeasance. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conditions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing with the trustee money and/or U.S. government obligations or, in the case of debt securities
denominated in a single currency other than U.S. dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will provide
money in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on and any mandatory sinking fund payments
in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivering to the trustee an opinion of counsel to the effect that the holders of the debt securities of that
series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to U.S. federal income tax on the same amounts, in the same manner, and at the same
times as would have been the case if the deposit and related covenant defeasance had not occurred. (Section 8.4) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Personal Liability of Directors, Officers, Employees or Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of our past, present, or future directors, officers, employees, or stockholders, as such, will have any liability for any of our obligations under the
debt securities or the indenture or for any claim based on, or in respect or by reason of, such obligations or their creation. By accepting a debt security, each holder waives and releases all such liability. This waiver and release is part of the
consideration for the issue of the debt securities. However, this waiver and release may not be effective to waive liabilities under U.S. federal securities laws, and it is the view of the SEC that such a waiver is against public policy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture and the debt securities,
including any claim or controversy arising out of or relating to the indenture or the securities, will be governed by the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture will provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably waive, to the
fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to the indenture, the debt securities or the transactions contemplated thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture will provide that any legal suit, action or proceeding arising out of or based upon the indenture or the transactions contemplated thereby may
be instituted in the federal courts of the United States of America or the courts of the State of New York, in each case located in the City of New York, and we, the trustee and the holder of the debt securities (by their acceptance of the debt
securities) irrevocably submit to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of such courts in any such suit, action or proceeding. The indenture will further provide that service of any process, summons, notice or
document by mail (to the extent allowed under any applicable statute or rule of court) to such party&#146;s address set forth in the indenture will be effective service of process for any suit, action or other proceeding brought in any such court.
The indenture will further provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other
proceeding in the courts specified above and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum. (Section 10.10) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc457972_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of shares of our common stock or preferred stock or of debt securities. We may issue warrants independently or together
with other securities, and the warrants may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and the investors or a warrant agent. The
following summary of material provisions of the warrants and warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of
warrants. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. We urge you to read the applicable prospectus supplement and any related free writing prospectus, as well as the complete warrant
agreements and warrant certificates that contain the terms of the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The particular terms of any issue of warrants will be described in the
prospectus supplement relating to the issue. Those terms may include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of common stock or preferred stock purchasable upon the exercise of warrants to purchase
such shares and the price at which such number of shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, stated value and terms (including, without limitation, liquidation, dividend, conversion and
voting rights) of the series of preferred stock purchasable upon exercise of warrants to purchase preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise
price for the warrants, which may be payable in cash, securities or other property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the warrants and the related debt securities, preferred stock or common
stock will be separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants will commence and the date on which the right will expire;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal income tax consequences applicable to the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including terms, procedures, and limitations relating to the exchange,
exercise and settlement of the warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of equity warrants will not be entitled: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to vote, consent or receive dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or
any other matter; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercise any rights as stockholders of Sana. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each warrant will entitle its holder to purchase the principal amount of debt securities or the number of shares of preferred stock or common stock at the
exercise price set forth in, or calculable as set forth in, the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified
time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of warrant certificates may exchange them for new warrant certificates of different denominations, present them for registration of transfer and
exercise them at the corporate trust office of the warrant agent or any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other office indicated in the applicable prospectus supplement. Until any warrants to purchase debt securities are exercised, the holder of the warrants will not have any rights of holders of the
debt securities that can be purchased upon exercise, including any rights to receive payments of principal, premium or interest on the underlying debt securities or to enforce covenants in the applicable indenture. Until any warrants to purchase
common stock or preferred stock are exercised, the holders of the warrants will not have any rights of holders of the underlying common stock or preferred stock, including any rights to receive dividends or payments upon any liquidation, dissolution
or winding up on the common stock or preferred stock, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc457972_9"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We may evidence each
series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the
unit agent in the applicable prospectus supplement relating to a particular series of units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional
information included in any applicable prospectus supplement, summarizes the general features of the units that we may offer under this prospectus. You should read any prospectus supplement and any free writing prospectus that we may authorize to be
provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms of the units. Specific unit agreements will contain additional important terms and provisions and we will file as an exhibit
to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file with the SEC, the form of each unit agreement relating to units offered under this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we offer any units, certain terms of that series of units will be described in the applicable prospectus supplement, including, without limitation, the
following, as applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identification and description of the separate constituent securities comprising the units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which the units will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the constituent securities comprising the units will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of certain U.S. federal income tax considerations applicable to the units; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the units and their constituent securities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc457972_10"></A>GLOBAL SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry, Delivery, and Form </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we indicate
differently in any applicable prospectus supplement or free writing prospectus, the securities initially will be issued in book-entry form and represented by one or more global notes or global securities, or, collectively, global securities. The
global securities will be deposited with, or on behalf of, The Depository Trust Company, New York, New York, as depositary, or DTC, and registered in the name of Cede&nbsp;&amp; Co., the nominee of DTC. Unless and until it is exchanged for
individual certificates evidencing securities under the limited circumstances described below, a global security may not be transferred except as a whole by the depositary to its nominee or by the nominee to the depositary, or by the depositary or
its nominee to a successor depositary or to a nominee of the successor depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC has advised us that it is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited-purpose trust company organized under the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;banking organization&#148; within the meaning of the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a member of the Federal Reserve System; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;clearing corporation&#148; within the meaning of the New York Uniform Commercial Code; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;clearing agency&#148; registered pursuant to the provisions of Section 17A of the Exchange Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC holds securities that its participants deposit with DTC. DTC also facilitates the settlement among its participants of securities
transactions, such as transfers and pledges, in deposited securities through electronic computerized book-entry changes in participants&#146; accounts, thereby eliminating the need for physical movement of securities certificates. &#147;Direct
participants&#148; in DTC include securities brokers and dealers, including underwriters, banks, trust companies, clearing corporations and other organizations. DTC is a wholly-owned subsidiary of The Depository Trust&nbsp;&amp; Clearing
Corporation, or DTCC. DTCC is the holding company for DTC, National Securities Clearing Corporation and Fixed Income Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by the users of its regulated subsidiaries.
Access to the DTC system is also available to others, which we sometimes refer to as indirect participants, that clear through or maintain a custodial relationship with a direct participant, either directly or indirectly. The rules applicable to DTC
and its participants are on file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchases of securities under the DTC system must be made by or through direct participants, which will
receive a credit for the securities on DTC&#146;s records. The ownership interest of the actual purchaser of a security, which we sometimes refer to as a beneficial owner, is in turn recorded on the direct and indirect participants&#146; records.
Beneficial owners of securities will not receive written confirmation from DTC of their purchases. However, beneficial owners are expected to receive written confirmations providing details of their transactions, as well as periodic statements of
their holdings, from the direct or indirect participants through which they purchased securities. Transfers of ownership interests in global securities are to be accomplished by entries made on the books of participants acting on behalf of
beneficial owners. Beneficial owners will not receive certificates representing their ownership interests in the global securities, except under the limited circumstances described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To facilitate subsequent transfers, all global securities deposited by direct participants with DTC will be registered in the name of DTC&#146;s partnership
nominee, Cede&nbsp;&amp; Co., or such other name as may be requested by an authorized representative of DTC. The deposit of securities with DTC and their registration in the name of Cede&nbsp;&amp; Co. or such other nominee will not change the
beneficial ownership of the securities. DTC has no knowledge of the actual beneficial owners of the securities. DTC&#146;s records reflect only the identity of the direct participants to whose accounts the securities are credited, which may or may
not be the beneficial owners. The participants are responsible for keeping account of their holdings on behalf of their customers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long as the securities are in book-entry form, you will receive payments and may transfer securities only
through the facilities of the depositary and its direct and indirect participants. We will maintain an office or agency in the location specified in the prospectus supplement for the applicable securities, where notices and demands in respect of the
securities and the indenture may be delivered to us and where certificated securities may be surrendered for payment, registration of transfer or exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conveyance of notices and other communications by DTC to direct participants, by direct participants to indirect participants and by direct participants and
indirect participants to beneficial owners will be governed by arrangements among them, subject to any legal requirements in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redemption notices will be sent to DTC. If less than all of the securities of a particular series are being redeemed, DTC&#146;s practice is to determine by
lot the amount of the interest of each direct participant in the securities of such series to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither DTC nor Cede&nbsp;&amp; Co. (or such
other DTC nominee) will consent or vote with respect to the securities. Under its usual procedures, DTC will mail an omnibus proxy to us as soon as possible after the record date. The omnibus proxy assigns the consenting or voting rights of
Cede&nbsp;&amp; Co. to those direct participants to whose accounts the securities of such series are credited on the record date, identified in a listing attached to the omnibus proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long as securities are in book-entry form, we will make payments on those securities to the depositary or its nominee, as the registered owner of such
securities, by wire transfer of immediately available funds. If securities are issued in definitive certificated form under the limited circumstances described below and unless if otherwise provided in the description of the applicable securities
herein or in the applicable prospectus supplement, we will have the option of making payments by check mailed to the addresses of the persons entitled to payment or by wire transfer to bank accounts in the United States designated in writing to the
applicable trustee or other designated party at least 15 days before the applicable payment date by the persons entitled to payment, unless a shorter period is satisfactory to the applicable trustee or other designated party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redemption proceeds, distributions and dividend payments on the securities will be made to Cede&nbsp;&amp; Co., or such other nominee as may be requested by
an authorized representative of DTC. DTC&#146;s practice is to credit direct participants&#146; accounts upon DTC&#146;s receipt of funds and corresponding detail information from us on the payment date in accordance with their respective holdings
shown on DTC records. Payments by participants to beneficial owners will be governed by standing instructions and customary practices, as is the case with securities held for the account of customers in bearer form or registered in &#147;street
name.&#148; Those payments will be the responsibility of participants and not of DTC or us, subject to any statutory or regulatory requirements in effect from time to time. Payment of redemption proceeds, distributions and dividend payments to
Cede&nbsp;&amp; Co., or such other nominee as may be requested by an authorized representative of DTC, is our responsibility, disbursement of payments to direct participants is the responsibility of DTC, and disbursement of payments to the
beneficial owners is the responsibility of direct and indirect participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except under the limited circumstances described below, purchasers of
securities will not be entitled to have securities registered in their names and will not receive physical delivery of securities. Accordingly, each beneficial owner must rely on the procedures of DTC and its participants to exercise any rights
under the securities and the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The laws of some jurisdictions may require that some purchasers of securities take physical delivery of
securities in definitive form. Those laws may impair the ability to transfer or pledge beneficial interests in securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC may discontinue providing
its services as securities depositary with respect to the securities at any time by giving reasonable notice to us. Under such circumstances, in the event that a successor depositary is not obtained, securities certificates are required to be
printed and delivered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As noted above, beneficial owners of a particular series of securities generally will not receive
certificates representing their ownership interests in those securities. However, if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DTC notifies us that it is unwilling or unable to continue as a depositary for the global security or securities
representing such series of securities or if DTC ceases to be a clearing agency registered under the Exchange Act at a time when it is required to be registered and a successor depositary is not appointed within 90 days of the notification to us or
of our becoming aware of DTC&#146;s ceasing to be so registered, as the case may be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we determine, in our sole discretion, not to have such securities represented by one or more global securities;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an Event of Default has occurred and is continuing with respect to such series of securities,
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">we will prepare and deliver certificates for such securities in exchange for beneficial interests in the global securities. Any
beneficial interest in a global security that is exchangeable under the circumstances described in the preceding sentence will be exchangeable for securities in definitive certificated form registered in the names that the depositary directs. It is
expected that these directions will be based upon directions received by the depositary from its participants with respect to ownership of beneficial interests in the global securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Euroclear and Clearstream </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If so provided in the
applicable prospectus supplement, you may hold interests in a global security through Clearstream Banking S.A., which we refer to as &#147;Clearstream,&#148; or Euroclear Bank S.A./N.V., as operator of the Euroclear System, which we refer to as
&#147;Euroclear,&#148; either directly if you are a participant in Clearstream or Euroclear or indirectly through organizations which are participants in Clearstream or Euroclear. Clearstream and Euroclear will hold interests on behalf of their
respective participants through customers&#146; securities accounts in the names of Clearstream and Euroclear, respectively, on the books of their respective U.S. depositaries, which in turn will hold such interests in customers&#146; securities
accounts in such depositaries&#146; names on DTC&#146;s books. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clearstream and Euroclear are securities clearance systems in Europe. Clearstream and
Euroclear hold securities for their respective participating organizations and facilitate the clearance and settlement of securities transactions between those participants through electronic book-entry changes in their accounts, thereby eliminating
the need for physical movement of certificates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments, deliveries, transfers, exchanges, notices and other matters relating to beneficial interests in
global securities owned through Euroclear or Clearstream must comply with the rules and procedures of those systems. Transactions between participants in Euroclear or Clearstream, on one hand, and other participants in DTC, on the other hand, are
also subject to DTC&#146;s rules and procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors will be able to make and receive through Euroclear and Clearstream payments, deliveries,
transfers and other transactions involving any beneficial interests in global securities held through those systems only on days when those systems are open for business. Those systems may not be open for business on days when banks, brokers and
other institutions are open for business in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cross-market transfers between participants in DTC, on the one hand, and participants in
Euroclear or Clearstream, on the other hand, will be effected through DTC in accordance with the DTC&#146;s rules on behalf of Euroclear or Clearstream, as the case may be, by their respective U.S. depositaries; however, such cross-market
transactions will require delivery of instructions to Euroclear or Clearstream, as the case may be, by the counterparty in such system in accordance with the rules and procedures and within the established deadlines (European time) of such system.
Euroclear or Clearstream, as the case may be, will, if the transaction meets its settlement requirements, deliver instructions to its U.S. depositary to take action to effect final settlement on its behalf by delivering or receiving interests in the
global securities through DTC, and making or receiving payment in accordance with normal procedures for <FONT STYLE="white-space:nowrap">same-day</FONT> fund settlement. Participants in Euroclear or Clearstream may not deliver instructions directly
to their respective U.S. depositaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to time zone differences, the securities accounts of a participant in Euroclear or Clearstream
purchasing an interest in a global security from a direct participant in DTC will be credited, and any such crediting will be reported to the relevant participant in Euroclear or Clearstream, during the securities settlement processing day (which
must be a business day for Euroclear or Clearstream) immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream as a result of sales of interests in a global security by or through a participant in Euroclear or
Clearstream to a direct participant in DTC will be received with value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream cash account only as of the business day for Euroclear or Clearstream following
DTC&#146;s settlement date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
information in this section of this prospectus concerning DTC, Clearstream, Euroclear and their respective book-entry systems has been obtained from sources that we believe to be reliable, but we do not take responsibility for this information. This
information has been provided solely as a matter of convenience. The rules and procedures of DTC, Clearstream and Euroclear are solely within the control of those organizations and could change at any time. Neither we nor the trustee nor any agent
of ours or of the trustee has any control over those entities and none of us takes any responsibility for their activities. You are urged to contact DTC, Clearstream and Euroclear or their respective participants directly to discuss those matters.
In addition, although we expect that DTC, Clearstream and Euroclear will perform the foregoing procedures, none of them is under any obligation to perform or continue to perform such procedures and such procedures may be discontinued at any time.
Neither we nor any agent of ours will have any responsibility for the performance or nonperformance by DTC, Clearstream and Euroclear or their respective participants of these or any other rules or procedures governing their respective operations.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc457972_11"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, &#147;at the market&#148; offerings, negotiated transactions, block
trades or a combination of these methods or through underwriters or dealers, through agents and/or directly to one or more purchasers. The securities may be distributed from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time that we sell securities covered by this prospectus, we will provide a prospectus supplement or supplements that will describe the method of
distribution and set forth the terms and conditions of the offering of such securities, including the offering price of the securities and the proceeds to us, if applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offers to purchase the securities being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers to purchase the
securities from time to time. Any agent involved in the offer or sale of our securities will be identified in a prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a dealer is
utilized in the sale of the securities being offered by this prospectus, the securities will be sold to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of
resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an underwriter is utilized in the sale of the securities being offered by this prospectus, an underwriting agreement will be executed with the
underwriter at the time of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we or the
purchasers of securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities to or through dealers, and those dealers may receive
compensation in the form of discounts, concessions, or commissions from the underwriters and/or commissions from the purchasers for which they may act as agent. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best
efforts basis and a dealer will purchase securities as a principal, and may then resell the securities at varying prices to be determined by the dealer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any compensation paid to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions, or commissions
allowed by underwriters to participating dealers will be provided in the applicable prospectus supplement. Underwriters, dealers, and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of
the Securities Act, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters,
dealers and agents against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse those persons for certain expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any common stock that we issue and sell will be listed on the Nasdaq Global Select Market, but any other securities may or may not be listed on a national
securities exchange. To facilitate the offering of securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. This may include over-allotments or
short sales of the securities, which involve the sale by persons participating in the offering of more securities than were sold to them. In these circumstances, these persons would cover such over-allotments or short positions by making purchases
in the open market or by exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain the price of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if
securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the
open market. These transactions may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may engage in at the market offerings into an existing trading market in accordance
with Rule&nbsp;415(a)(4) under the Securities Act. In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable
prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use
securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of
stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge
securities to a financial institution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short
position to investors in our securities or in connection with a concurrent offering of other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The specific terms of any <FONT
STYLE="white-space:nowrap">lock-up</FONT> provisions in respect of any given offering will be described in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
underwriters, dealers, and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for which they receive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc457972_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP, Menlo Park, California, will pass upon certain legal matters relating to the issuance and sale of the securities offered hereby
on behalf of Sana Biotechnology, Inc. Additional legal matters may be passed upon for us or any underwriters, dealers, or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc457972_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements
are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PROSPECTUS </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #334998">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>$148,735,500 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g457972g85h19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We
previously entered into a sales agreement, or the sales agreement, with Cowen and Company, LLC, or Cowen, relating to shares of our common stock, $0.0001 par value per share, offered by this prospectus. In accordance with the terms of the sales
agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $148,735,500 from time to time through Cowen acting as our agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;SANA.&#148; On March&nbsp;14, 2023, the last reported sale price of our common
stock on the Nasdaq Global Select Market was $3.44 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Sales of our common stock, if any, under this prospectus will be made by any method deemed to be an
&#147;at the market offering&#148; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Cowen is not required to sell any specific amount of securities, but will act as our sales agent using
commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms set forth in the sales agreement. There is no
arrangement for funds to be received in any escrow, trust, or similar arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The compensation to Cowen for sales of common stock pursuant to the sales
agreement will be an amount up to 3.0% of the gross proceeds of the sales price per share of common stock sold under the sales agreement. See &#147;Plan of Distribution&#148; beginning on page <FONT STYLE="white-space:nowrap">S-22</FONT> for
additional information regarding the compensation to be paid to Cowen. In connection with the sale of the common stock on our behalf, Cowen will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation
of Cowen will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Cowen with respect to certain liabilities, including liabilities under the Securities Act or the Securities
Exchange Act of 1934, as amended, or the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as defined by the Jumpstart Our Business Startups Act of 2012,
and as such, have elected to comply with reduced public company reporting requirements for this prospectus and the documents incorporated by reference herein and may elect to comply with reduced public company reporting requirements in future
filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our business and an investment in our common stock involve significant risks. These risks are described under the caption &#147;<A HREF="#tx457972_5">Risk
 Factors</A>&#148; beginning on page <FONT STYLE="white-space:nowrap">S-9</FONT> of this prospectus and in the documents incorporated by reference into this prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or
accuracy of this prospectus. Any representation to the contrary is a criminal offense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>TD Cowen </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The date of this prospectus is March 15, 2023 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>TABLE OF CONTENTS </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx457972_1">About This Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx457972_2">Market, Industry, and Other Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx457972_3">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx457972_5">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx457972_6">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx457972_7">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx457972_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx457972_8a">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx457972_9">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-22</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx457972_10">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-24</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx457972_11">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-24</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx457972_12">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-24</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#tx457972_13">Information Incorporated by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-24</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx457972_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This prospectus is part of a &#147;shelf&#148; registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the U.S.
Securities and Exchange Commission, or the SEC. Under this prospectus, we may offer and sell shares of our common stock having an aggregate offering price of up to $148,735,500 from time to time through Cowen acting as our agent at prices and on
terms to be determined by market conditions at the time of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This prospectus relates to the offering of our common stock. Before buying
any of the common stock that we are offering, we urge you to carefully read this prospectus, together with the information incorporated by reference as described under the headings &#147;Where You Can Find More Information&#148; and
&#147;Incorporation by Reference.&#148; These documents contain important information that you should consider when making your investment decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This prospectus describes the specific details regarding this offering and also adds to and updates information contained in the documents incorporated
by reference into this prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference in this prospectus, on the other
hand, you should rely on the information in this prospectus. However, if any statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference in this
prospectus&#151;the statement in the document having the later date modifies or supersedes the earlier statement as our business, financial condition, results of operations, and prospects may have changed since the earlier dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have not, and Cowen has not, authorized anyone to provide any information other than that contained in or incorporated by reference in this
prospectus, any applicable supplement, and any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and Cowen take no responsibility for, and can provide no assurance as to the reliability of, any other
information that others may give you. We are not, and Cowen is not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction where an offer or solicitation is not authorized or in which the person making that offer or
solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus, any applicable prospectus supplement, the documents incorporated by
reference into this prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of
operations, and prospects may have changed since those dates. You should read this prospectus the documents incorporated by reference into this prospectus, any applicable prospectus supplement, and any free writing prospectus that we may authorize
for use in connection with this offering, in their entirety before making an investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are offering to sell, and seeking offers to
buy, shares of common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who
come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus outside the United States. This prospectus does not constitute,
and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or
solicitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">When we refer to &#147;Sana Biotechnology,&#148; &#147;Sana,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and
&#147;our&#148; in this prospectus, we mean Sana Biotechnology, Inc. and its subsidiaries, unless otherwise specified. When we refer to &#147;you,&#148; we mean the potential holders of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">&#147;SANA BIOTECHNOLOGY,&#148; the Sana Biotechnology logos, and other trade names, trademarks, or
service marks of Sana Biotechnology appearing in this prospectus are the property of Sana Biotechnology. Other trade names, trademarks, or service marks appearing in this prospectus are the property of their respective holders. Solely for
convenience, trade names, trademarks, and service marks referred to in this prospectus appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, and SM symbols, but
those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trade names, trademarks, and service marks.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx457972_2"></A>MARKET, INDUSTRY, AND OTHER DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This prospectus, including the information incorporated by reference herein, contains estimates, projections, and other information concerning our
industry, our business, and the markets for certain drugs, including data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections, or similar methodologies is inherently subject to uncertainties
and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from reports, research surveys,
studies, and similar data prepared by third parties, industry, medical and general publications, government data, and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we
refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx457972_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>This summary provides a general overview of selected information and does not contain all of the information you should consider before buying our
common stock. Therefore, you should read the entire prospectus, including the information incorporated by reference herein, before deciding to invest in our common stock. Investors should carefully consider the information set forth under &#147;Risk
Factors&#148; beginning on <FONT STYLE="white-space:nowrap">page&nbsp;S-9</FONT> of this prospectus and in the documents incorporated by reference into this prospectus. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We were founded on the belief that engineered cells
will be one of the most important transformations in medicine over the next several decades. Damage to cells is the underlying pathology of almost every human disease, and we believe the ability to replace or repair damaged cells through cellular
engineering can address the underlying root cause of a host of diseases. We view engineered cells as having the potential to be as therapeutically disruptive as biologics to clinical practice. Our long-term aspirations are to be able to control or
modify any gene in the body, to replace any cell that is damaged or missing, and to markedly improve access to cellular and gene-based medicines. We have brought together an experienced group of scientists, engineers, and company builders and
equipped them with technologies to move this vision forward. We are developing <I>ex vivo</I> and <I>in vivo</I> cell engineering platforms to revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including
oncology, diabetes, central nervous system disorders, and genetic disorders, among others. We expect clinical data from our CD19-targeted allogenic chimeric antigen receptor (CAR) T program, SC291, in 2023. We also continue to make progress on
developing our cell engineering platforms and advancing our product candidates through preclinical development, with the goal of submitting multiple Investigational New Drug applications, or INDs, in 2023 and beyond. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Frequently in disease, cells are damaged or missing entirely, and an effective therapy needs to replace the entire cell, an approach referred to as cell
therapy or <I>ex vivo</I> cell engineering. A successful therapeutic requires large-scale manufacturing of cells that engraft, function, and persist in the body. Of these, we view cell persistence as the greatest current limitation to dramatically
expanding the impact of this class of therapeutics, and in particular, overcoming the barrier of immune rejection of transplanted allogeneic cells. This challenge has led many to focus on autologous, or a patient&#146;s own, cells as the therapeutic
source. However, autologous therapies require a complex process of harvesting cells from patients, manipulating them outside the body, and returning them to the patient. Products using this approach have had to manage significant challenges such as
scalability, product variability, product quality, cost, patient accessibility, and limits with respect to the types of cells that are amenable to this approach. Given these limitations, rather than using autologous cells to address the challenge of
immune rejection, we have invested in developing our hypoimmune technology to create cells that can &#147;hide&#148; from the patient&#146;s immune system to enable persistence of allogeneic cells. We are striving to make therapies using pluripotent
stem cells with our hypoimmune genetic modifications as the starting material, which we then differentiate into a specific cell type, such as a pancreatic islet cell, before treating the patient. Additionally, there are cell types for which
effective differentiation protocols from a stem cell have not yet been developed, such as T cells. For such cell types, instead of starting from a pluripotent stem cell, we can use a fully differentiated allogeneic cell, sourced from a donor, as the
starting material to which we then apply our hypoimmune genetic modifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The process of repairing and controlling genes in the body, referred
to as gene therapy or <I>in vivo</I> cell engineering, requires both <I>in vivo</I> delivery of a therapeutic payload and genome modification. Of </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
these, we view effective <I>in vivo</I> delivery as the greatest current limitation to dramatically expanding the impact of this class of therapeutics. To this end, our initial focus is on
cell-specific delivery as well as increasing the diversity and size of payloads, with our ultimate goal being the delivery of any payload, to any cell, in a specific and repeatable way. We have shown in preclinical studies that our fusogen
technology can specifically target numerous cell surface receptors that, when combined with delivery vehicles to form fusosomes, allow cell-specific delivery across multiple different cell types. We have initially chosen to focus our fusogen
technology on two cell types: T cells and hematopoietic stem cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe the time is right to develop engineered cell therapies across a
broad range of therapeutic areas. Substantial progress in the understanding of genetics, gene editing, gene control, protein engineering, stem cell biology, immunology, process analytics, and computational biology have converged to create an
opportunity to markedly increase the breadth and depth of the potential impact of genetic and cellular medicines. We are focused on creating transformative <I>ex vivo</I> and <I>in vivo</I> engineered cell therapies across a range of therapeutic
areas. We are in the early stages of development across a broad pipeline of product candidates, which are summarized below: </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g457972g01q01.jpg" ALT="LOGO">
 </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About Sana </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We were founded in July 2018 as a Delaware corporation. Our principal executive offices are located at 188 East Blaine Street, Suite 400, Seattle,
Washington 98102, and our telephone number is (206) <FONT STYLE="white-space:nowrap">701-7914.</FONT> Our website address is <I>www.sana.com</I>. The information on, or that can be accessed through, our website is not part of this prospectus and is
not incorporated by reference herein. We have included our website address as an inactive textual reference only. We also use our website as a means of disclosing material <FONT STYLE="white-space:nowrap">non-public</FONT> information and for
complying with our disclosure obligations under Regulation FD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and are eligible to take
advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. These include, but are not limited to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced obligations with respect to financial data, including presenting only two years of audited financial statements and
only two years of selected financial data; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced disclosure obligations regarding executive compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an exception from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or
the Sarbanes-Oxley Act; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">exemptions from the requirements of holding a non-binding advisory vote on executive compensation and the requirement to
obtain stockholder approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may take advantage of these exemptions
for up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company if we have equal to or more than $1.235 billion in annual revenue, we are deemed to be a large accelerated
filer under rules of the SEC, or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. We may choose to take advantage of some, but not all, of the available exemptions. We
have taken advantage of certain reduced reporting burdens in the registration statement of which this prospectus and the accompanying base prospectus is a part and the documents incorporated herein by reference and may elect to take advantage of
other reduced reporting requirements in future filings. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx457972_4"></A>THE OFFERING </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>Shares of our common stock having an aggregate offering price of up to $148,735,500. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock outstanding after this offering </P></TD>
<TD>Up to 233,928,147 shares, assuming sales of 43,237,063 shares in this offering at an assumed offering price of $3.44 per share, which was the closing price of our common stock on the Nasdaq Global Select Market on March&nbsp;14, 2023. The actual
number of shares issued will vary depending on the sales price under this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Plan of Distribution </P></TD>
<TD>&#147;At the market offering&#148; that may be made from time to time through our sales agent, Cowen and Company, LLC. See the section titled &#147;Plan of Distribution&#148; on <FONT STYLE="white-space:nowrap">page&nbsp;S-22.</FONT>
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Use of Proceeds </P></TD>
<TD>We intend to use the net proceeds from this offering, if any, for general corporate purposes, which may include, among other things, working capital and funding research and development and manufacturing, and capital expenditures, including
clinical program progression. See the section titled &#147;Use of Proceeds&#148; on page&nbsp;S-13. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Risk Factors </P></TD>
<TD>See the section titled &#147;Risk Factors&#148; on page&nbsp;S-9 of this prospectus and the other information included in, or incorporated by reference into, this prospectus for a discussion of certain factors to consider before deciding to
purchase shares of our common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Symbol on the Nasdaq Global Select Market </P></TD>
<TD>&#147;SANA&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The number of shares of common stock to be outstanding after this offering is based on 190,691,084 shares of
common stock outstanding as of September 30, 2022, including 805,638 shares of unvested restricted common stock outstanding as of September 30, 2022, and excludes, in each case as of September 30, 2022: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">25,542,561 shares of common stock issuable upon exercise of outstanding stock options as of September 30, 2022, with a
weighted-average exercise price of $8.00 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">5,957,064 shares of common stock issuable upon exercise of stock options granted subsequent to September 30, 2022, with a
weighted-average exercise price of $3.87 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">976,940 shares of common stock issuable upon the vesting and settlement of restricted stock units granted as of September
30, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,157,840 shares of common stock issuable upon the vesting and settlement of restricted stock units granted subsequent to
September 30, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">12,585,251 shares of common stock reserved for future issuance under our 2021 Incentive Award Plan, as well as any
automatic increases in the number of shares of our common stock reserved for future issuance under this plan; and </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">3,565,479 shares of common stock reserved for future issuance under our 2021 Employee Stock Purchase Plan, as well as any
automatic increases in the number of shares of our common stock reserved for future issuance under this plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Unless otherwise
indicated, the number of shares of our common stock described above assumes no exercise or settlement of outstanding options referred to above. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx457972_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>You should consider carefully the risks described below and discussed under the section captioned &#147;Risk Factors&#148; contained in our most
recent quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as updated by our subsequent filings under the Exchange Act, each of which is incorporated by reference in this prospectus in their entirety, together with other
information in this prospectus, and the information and documents incorporated by reference in this prospectus, and any free writing prospectus that we have authorized for use in connection with this offering before you make a decision to invest in
our common stock. If any of the following events actually occur, our business, operating results, prospects, or financial condition could be materially and adversely affected. This could cause the trading price of our common stock to decline and you
may lose all or part of your investment. The risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business operations. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Relating to this Offering </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our management team has broad
discretion to use the net proceeds from this offering and its investment of these proceeds may not yield a favorable return. They may invest the net proceeds from this offering in ways with which investors disagree. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our management will have broad discretion over the use of net proceeds from this offering and could spend the net proceeds in ways our stockholders may
not agree with or that do not yield a favorable return, if at all. If we do not invest or apply the net proceeds from this offering in ways that improve our operating results, we may fail to achieve expected financial results, which could cause our
stock price to decline. For additional details, see the section titled &#147;Use of Proceeds.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>You may experience immediate and substantial dilution in
the net tangible book value per share of the common stock you purchase. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The price per share of our common stock being offered may be higher
than the net tangible book value per share of our common stock outstanding prior to this offering. After giving effect to the sale of our common stock in this offering at the maximum aggregate offering amount of $148,735,500&nbsp;at an assumed
offering price of $3.44 per share, the last reported sale price of our common stock on the Nasdaq Global Select Market on March&nbsp;14, 2023, and after deducting estimated offering commissions and estimated fees payable by us, our net tangible book
value as of September 30, 2022 would have been $709.0&nbsp;million, or $3.03 per share of common stock. This represents an immediate increase in the net tangible book value of $0.06 per share to our existing stockholders and an immediate and
substantial dilution in net tangible book value of $0.41 per share to new investors who purchase our common stock in the offering. See the section titled &#147;Dilution&#148; below for a more detailed discussion of the dilution you will incur if you
purchase common stock in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>You may experience future dilution as a result of future equity offerings. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In order to raise additional capital, we expect to in the future offer additional shares of our common stock or other securities convertible into or
exchangeable for our common stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and
investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or other securities convertible into or exchangeable for
our common stock in future transactions may be higher or lower than the price per share in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The actual number of shares we will issue under the sales agreement, at any one time or in total, is uncertain.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Subject to certain limitations in the sales agreement and compliance with applicable law, we have the discretion to deliver a placement
notice to Cowen at any time throughout the term of the sales agreement. The number of shares that are sold by Cowen after delivering a placement notice will fluctuate based on the market price of the common shares during the sales period and limits
we set with Cowen. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of shares that will be ultimately issued.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The shares of common stock offered hereby will be sold in &#147;at the market offerings,&#148; and investors who buy shares of our common stock at different
times will likely pay different prices. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Investors who purchase shares of our common stock in this offering at different times will likely
pay different prices and may experience different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares of our common stock sold in
this offering. In addition, subject to the final determination by our board of directors, there is no minimum or maximum sales price for shares of our common stock to be sold in this offering. Investors may experience a decline in the value of the
shares of common stock they purchase in this offering as a result of sales made at prices lower than the prices they paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx457972_6"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This prospectus, including the documents incorporated by reference herein, contains forward-looking statements concerning our business, operations, and
financial performance and condition, as well as our plans, objectives, and expectations for our business, operations, and financial performance and condition. Any statements contained, or incorporated by reference, herein that are not statements of
historical facts may be deemed to be forward-looking statements. These statements involve known and unknown risks, uncertainties related to global events and macroeconomic conditions, and other important factors that are in some cases beyond our
control and may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148;
&#147;might,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;should,&#148; &#147;would,&#148; or &#147;will,&#148; the negative of these terms, and other comparable terminology. These forward-looking statements include, but
are not limited to, statements about: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our expectations regarding the potential market size and size of the potential patient populations for our product
candidates and any future product candidates, if approved for commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our clinical and regulatory development plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our expectations with regard to the results of our preclinical studies, clinical trials, and research and development
programs, including the timing and availability of data from such studies and trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of commencement of future preclinical studies, clinical trials, and research and development programs;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to acquire, discover, and develop product candidates and timely advance them into and through clinical data
readouts and successful completion of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our expectations regarding the potential safety, efficacy, or clinical utility of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our intentions with respect to and our ability to establish collaborations or partnerships; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing or likelihood of regulatory filings and approvals for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our commercialization, marketing, and manufacturing expectations, including with respect to the buildout of our
manufacturing facility and capabilities and the timing thereof; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">impact of future regulatory, judicial, and legislative changes or developments in the United States and foreign countries;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our intentions with respect to the commercialization of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential effects of public health crises, such as the ongoing COVID-19 pandemic, on our preclinical and clinical
programs and business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our expectations regarding the impact of global events and macroeconomic conditions, including the ongoing COVID-19
pandemic, on our business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the implementation of our business model and strategic plans for our business and product candidates, including additional
indications which we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to effectively manage our growth, including our ability to retain and recruit personnel and maintain our
culture; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our product
candidates, including the projected terms of patent protection; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">estimates of our expenses, future revenue, capital requirements, needs for additional financing, and ability to obtain
additional capital; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our expected use of proceeds from our initial public offering and our existing cash, cash equivalents, and marketable
securities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the performance of our third-party suppliers and manufacturers; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our use of proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our future financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business
Startups Act of 2012; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developments and projections relating to our competitors and our industry, including competing products; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other risks and uncertainties, including those listed under the caption &#147;Risk Factors.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">You should read this prospectus and the documents incorporated by reference herein completely and with the understanding that our actual results may
differ materially from what we expect as expressed or implied by our forward-looking statements. In light of the significant risks and uncertainties to which our forward-looking statements are subject, you should not place undue reliance on or
regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. Factors that may cause actual results to differ materially from current
expectations include, among other things, those listed under the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus and the discussion in our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> in
each of the sections titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; These forward-looking statements represent our estimates and assumptions only as of the
dates of this prospectus, the accompanying prospectus and the documents incorporated by reference herein and therein, and any free writing prospectus, as applicable, regardless of the time of delivery of this prospectus or any sale of our common
stock and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this prospectus. You should, however,
review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See &#147;Where You Can Find More Information.&#148; For all forward-looking statements, we claim the protection
of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx457972_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $148,735,500 from time to time. The amount of proceeds from
this offering will depend upon the number of shares of our common stock sold and the market price at which they are sold. There can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement with Cowen as a
source of financing. We intend to use the net proceeds, if any, from this offering for general corporate purposes, which may include, among other things, increasing our working capital and funding research and development and manufacturing, and
capital expenditures, including clinical program progression. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The amounts and timing of our actual expenditures will depend on numerous factors,
including our development and commercialization efforts with respect to our product candidates, as well as the amount of cash used in our operations. We therefore cannot estimate with certainty the amount of net proceeds to be used for the purposes
described above. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. Pending the uses described above, we plan to invest the net proceeds, if
any, from this offering in short-term, investment-grade, interest-bearing securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx457972_8"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our net tangible book value as of September 30, 2022 was approximately $566.0&nbsp;million, or $2.97 per share. Net tangible book value per share is
determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of September 30, 2022. Dilution in net tangible book value per share represents the difference between the amount
per share paid by purchasers of shares of common stock in this offering and the as adjusted net tangible book value per share of our common stock immediately after giving effect to this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After giving effect to the sale of our common stock in the aggregate amount of $148,735,500&nbsp;million in this offering at an assumed offering price
of $3.44 per share, the last reported sale price of our common stock on the Nasdaq Global Select Market on March 14, 2023, and after deducting commissions and estimated aggregate offering expenses payable by us, our as adjusted net tangible book
value as of September 30, 2022 would have been approximately $709.0&nbsp;million, or $3.03 per share. This represents an immediate increase in net tangible book value of $0.06 per share to existing stockholders and immediate dilution in net tangible
book value of $0.41 per share to new investors purchasing our common stock in this offering at the assumed public offering price. The following table illustrates this dilution on a per share basis: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net tangible book value per share as of September 30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in net tangible book value per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dilution per share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The above discussion and table are based on 190,691,084 shares of common stock outstanding as of September 30, 2022,
including 805,638 shares of unvested restricted common stock outstanding as of September&nbsp;30, 2022, and excludes, in each case as of September 30, 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">25,542,561 shares of common stock issuable upon exercise of outstanding stock options as of September 30, 2022, with a
weighted-average exercise price of $8.00 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">5,957,064 shares of common stock issuable upon exercise of stock options granted subsequent to September 30, 2022, with a
weighted-average exercise price of $3.87 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">976,940 shares of common stock issuable upon the vesting and settlement of restricted stock units granted as of September
30, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1,157,840 shares of common stock issuable upon the vesting and settlement of restricted stock units granted subsequent to
September 30, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">12,585,251 shares of common stock reserved for future issuance under our 2021 Incentive Award Plan, as well as any
automatic increases in the number of shares of our common stock reserved for future issuance under this plan; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">3,565,479 shares of common stock reserved for future issuance under our 2021 Employee Stock Purchase Plan, as well as any
automatic increases in the number of shares of our common stock reserved for future issuance under this plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The above
discussion and table do not give effect to the exercise of any outstanding options. To the extent such securities are exercised, there may be further dilution to new investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx457972_8a"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation, our amended
and restated bylaws, the amended and restated investors&#146; rights agreement to which we and certain of our stockholders are parties, and of the General Corporation Law of the State of Delaware, or the DGCL. Because the following is only a
summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation, amended and restated bylaws, and amended and restated
investors&#146; rights agreement, copies of which are incorporated by reference as exhibits to the registration statement of which this prospectus is a part. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our authorized capital stock consists of 750,000,000
shares of common stock, par value $0.0001 per share, and 50,000,000 shares of preferred stock, par value $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Outstanding Shares </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December 31, 2022, we had
191,033,332 shares of our common stock outstanding, including 11,675 shares of unvested restricted common stock outstanding as of December 31, 2022, held of record by 53 stockholders. The actual number of stockholders is greater than the number of
record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other
entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each holder of our
common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders
of a majority of the voting shares are able to elect all of the directors. In addition, the affirmative vote of holders of <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the voting power of all of the then outstanding voting stock is required to
take certain actions, including amending certain provisions of our amended and restated certificate of incorporation, such as the provisions relating to amending our amended and restated bylaws, the classified board and director liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Dividends </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Subject to preferences that may be
applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event of our liquidation,
dissolution or winding up, holders of our common stock are entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any
liquidation preference granted to the holders of any then outstanding shares of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Rights, Preferences, and Privileges </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Holders of our common stock have no preemptive, conversion, or subscription rights, and there are no redemption or sinking fund provisions applicable to
our common stock. The rights, preferences, and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue
in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preferred Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors has the authority, without further action by our stockholders, to issue up to 50,000,000 shares of preferred stock in one or more
series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund
terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of our common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common
stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company
or other corporate action. As of December 31, 2022, no shares of preferred stock are outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stock Options </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December 31, 2022, we had outstanding options to purchase an aggregate of 23,686,340 shares of our common stock, with a weighted-average exercise
price of $7.79 per share, under our 2018 Equity Incentive Plan and 2021 Incentive Award Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Restricted Stock Units </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December 31, 2022, we had 884,878 outstanding restricted stock units subject to vesting conditions under our Restricted Stock Unit Plan and 2021
Incentive Award Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Certain
holders of shares of our common stock are entitled to certain rights with respect to registration of their shares under the Securities Act. These shares are referred to as registrable securities. The holders of these registrable securities possess
registration rights pursuant to the terms of our amended and restated investors&#146; rights agreement and are described in additional detail below. The registration of shares of our common stock pursuant to the exercise of the registration rights
described below would enable the holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. We will pay the registration expenses, other than underwriting discounts,
selling commissions and stock transfer taxes, of the shares registered pursuant to the demand, piggyback, and <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registrations described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Generally, in an underwritten offering, the managing underwriter, if any, has the right, subject to specified conditions and limitations, to limit the
number of shares the holders may include. The demand, piggyback, and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights described below will terminate upon the earliest of (i)&nbsp;with respect to each stockholder, such date on
which all registrable shares held by such stockholder may immediately be sold during any <FONT STYLE="white-space:nowrap">90-day</FONT> period pursuant to Rule&nbsp;144 of the Securities Act, or Rule&nbsp;144; and (ii)&nbsp;the occurrence of a
deemed liquidation event, as defined in our amended and restated certificate of incorporation, as currently in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Demand Registration Rights
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December 31, 2022, holders of approximately 82.3 million shares of our common stock are entitled to certain demand registration
rights. Certain major investors holding, collectively, at least 40% of registrable securities may, on not more than two occasions, request that we register all or a portion of their shares, subject to certain specified exceptions. If any of these
holders exercises its demand registration rights, then holders of approximately 82.3 million shares of our common stock are entitled to register their shares, subject to specified conditions and limitations in the corresponding offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Piggyback Registration Rights </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event that we
propose to register any of our securities under the Securities Act in an underwritten registered offering, either for our own account or for the account of other security holders, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the holders of registrable securities will be entitled to certain &#147;piggyback&#148; registration rights allowing them to include their shares in such registration, subject to specified
conditions and limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December 31, 2022, holders of approximately 82.3 million shares of our common stock are entitled to certain
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights. Certain major investors holding at least 25% of registrable securities may, on not more than two registrations on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> within
any <FONT STYLE="white-space:nowrap">12-month</FONT> period, request that we register all or a portion of their shares on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> if we are qualified to file a registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> subject to specified exceptions. Such request for registration on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> must cover securities with an aggregate offering price which equals or exceeds
$15.0&nbsp;million, net of selling expenses. The right to have such shares registered on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> is further subject to other specified conditions and limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Anti-Takeover Effects of Provisions of our Amended and Restated Certificate of Incorporation, our Amended and Restated Bylaws, Delaware Law, and Washington Law
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Some provisions of Delaware law, Washington law, our amended and restated certificate of incorporation, and our amended and restated bylaws
could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions
could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for
our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These
provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an
unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Delaware Business Combination Statute </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have elected
to be subject to Section&nbsp;203 of the DGCL. Section&nbsp;203 prevents an &#147;interested stockholder,&#148; which is defined generally as a person owning 15% or more of a corporation&#146;s voting stock, or any affiliate or associate of that
person, from engaging in a broad range of &#147;business combinations&#148; with the corporation for three years after becoming an interested stockholder unless: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the board of directors of the corporation had previously approved either the business combination or the transaction that
resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, that person owned
at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, other than statutorily excluded shares; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">following the transaction in which that person became an interested stockholder, the business combination is approved by
the board of directors of the corporation and holders of at least two-thirds of the outstanding voting stock not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under Section&nbsp;203, the restrictions described above also do not apply to specific business combinations proposed by an interested stockholder
following the announcement or notification of designated extraordinary transactions involving the corporation and a person who had not been an interested stockholder during the previous three years or who became an interested stockholder with the
approval of a majority of the corporation&#146;s directors, if such extraordinary transaction is approved or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
not opposed by a majority of the directors who were directors prior to any person becoming an interested stockholder during the previous three years or were recommended for election or elected to
succeed such directors by a majority of such directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Section&nbsp;203 may make it more difficult for a person who would be an interested
stockholder to effect various business combinations with a corporation for a three-year period. Section&nbsp;203 also may have the effect of preventing changes in our management and could make it more difficult to accomplish transactions that our
stockholders may otherwise deem to be in their best interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Washington Business Corporation Act </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The laws of Washington, where our principal executive offices are located, impose restrictions on certain transactions between certain foreign
corporations and significant stockholders. In particular, the Washington Business Corporation Act, or WBCA, prohibits a &#147;target corporation,&#148; with certain exceptions, from engaging in certain &#147;significant business transactions&#148;
with a person or group of persons that beneficially owns 10% or more of the voting securities of the target corporation, an &#147;acquiring person,&#148; for a period of five years after such acquisition, unless the transaction or acquisition of
shares is approved by a majority of the members of the target corporation&#146;s board of directors prior to the time of acquisition. Such prohibited transactions may include, among other things: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any merger or consolidation with, disposition of assets to, or issuance or redemption of stock to or from, the acquiring
person; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any termination of 5% or more of the employees of the target corporation as a result of the acquiring person&#146;s
acquisition of 10% or more of the shares; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">and allowing the acquiring person to receive any disproportionate benefit as a stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After the five-year period, a significant business transaction may take place as long as it complies with certain fair price provisions of the statute
or is approved at an annual or special meeting of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will be considered a &#147;target corporation&#148; so long as our principal
executive office is located in Washington, and: (i)&nbsp;a majority of our employees are residents of the state of Washington or we employ more than one thousand residents of the state of Washington; (ii)&nbsp;a majority of our tangible assets,
measured by market value, are located in the state of Washington or we have more than $50.0&nbsp;million worth of tangible assets located in the state of Washington; and (iii)&nbsp;any one of the following: (a)&nbsp;more than 10% of our stockholders
of record are resident in the state of Washington; (b)&nbsp;more than 10% of our shares are owned of record by state residents; or (c)&nbsp;1,000 or more of our stockholders of record are resident in the state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we meet the definition of a target corporation, the WBCA may have the effect of delaying, deferring, or preventing a change of control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Election and Removal of Directors; Vacancies </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our
directors are elected by a plurality of the votes of the shares of our capital stock present in person or represented by proxy at a meeting and entitled to vote on the election of directors. Because our stockholders do not have cumulative voting
rights, stockholders holding a majority of the shares of our common stock outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation provides for the removal of any of our directors only for cause
only by an affirmative vote of shares representing not less than a majority of the shares then entitled to vote at an election of directors. Furthermore, any vacancy occurring on our board of directors and any newly created directorship may be
filled only by a majority of the remaining directors in office. This system of electing and removing directors and filling vacancies may tend to discourage a third party from making </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Staggered Board </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors is divided
into three classes. The directors in each class serve for a three-year term, one class being elected each year by our stockholders, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our
stockholders, with the other classes continuing for the remainder of their respective three-year terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Limitation on Action by Written Consent </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that holders of our common stock are not able to act by
written consent without a meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stockholder Meetings </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that special meetings of our stockholders may be called
only by the chairman of the board, our chief executive officer (or president, in the absence of a chief executive officer), or a majority of the directors. Our amended and restated certificate of incorporation and our amended and restated bylaws
specifically deny any power of any other person to call a special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Forum Selection </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the sole and exclusive forum
for the following types of actions or proceedings under Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on behalf of us; (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director,
officer, or other employee of our company to us or our stockholders; (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the DGCL or our amended and restated certificate of incorporation and bylaws; or (iv)&nbsp;any action
asserting a claim governed by the internal affairs doctrine. This provision would not apply to claims brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Furthermore, our amended and restated certificate of incorporation also provide that unless we consent in writing to the selection of an
alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. Any person or entity purchasing or
otherwise acquiring any interest in our shares of capital stock shall be deemed to have notice of and consented to the foregoing forum selection provisions. Nothing in our amended and restated certificate of incorporation and amended and restated
bylaws preclude stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and
our stockholders will not be deemed to have waived our compliance with these laws, rules, and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The enforceability of similar federal
court choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find this type of provision to be inapplicable or unenforceable. If a court were
to find either of the choice of forum provisions contained in our amended and restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with
resolving such action in other jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The choice of forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial
forum that it finds favorable for disputes with the company or its directors, officers, or other employees, which may discourage such lawsuits against the company and its directors, officers and other employees and result in increased costs for
investors to bring a claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Amendment of Certificate of Incorporation and Bylaws </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The provisions of our amended and restated certificate of incorporation described under &#147;&#151;Election and Removal of Directors; Vacancies,&#148;
&#147;&#151;Stockholder Meetings,&#148; &#147;&#151;Limitation on Action by Written Consent,&#148; &#147;&#151;Limitations of Liability of Directors and Officers and Indemnification Matters,&#148; &#147;&#151;Common Stock&#151;Voting Rights,&#148;
and &#147;&#151;Forum Selection&#148; and provisions relating to amendments to our amended and restated certificate of incorporation may be amended only by the affirmative vote of holders of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT>
of the voting power of our outstanding shares of voting stock. The affirmative vote of holders of at least a majority of the voting power of our outstanding shares of stock will generally be required to amend other provisions of our amended and
restated certificate of incorporation. The provisions of the DGCL, our amended and restated certificate of incorporation, and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a
consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management.
It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Certain provisions of our amended and restated bylaws may generally be altered, amended, or repealed, and new bylaws may be adopted, with the
affirmative vote of a majority of directors present at any regular or special meeting of the board of directors called for that purpose, provided that any alteration, amendment, or repeal of, or adoption of any bylaw inconsistent with specified
provisions of the bylaws, including those related to special and annual meetings of stockholders, action of stockholders by written consent, nomination of directors, transfers of capital stock and dividends requires the affirmative vote of at least <FONT
STYLE="white-space:nowrap">66-2/3%</FONT> of all directors in office at a meeting called for that purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">All other provisions of our amended and
restated bylaws may generally be altered, amended, or repealed, and new bylaws may be adopted, with the affirmative vote of holders of <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the voting power of our outstanding shares of voting stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Other Limitations on Stockholder Actions </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our
amended and restated bylaws impose some procedural requirements on stockholders who wish to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make nominations in the election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">propose that a director be removed; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">propose any repeal or change in our amended and restated bylaws; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">propose any other business to be brought before an annual or special meeting of stockholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under these procedural requirements, in order to bring a proposal before a meeting of stockholders, a stockholder must deliver timely notice of a
proposal pertaining to a proper subject for presentation at the meeting to our corporate secretary along with the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a description of the business or nomination to be brought before the meeting and the reasons for conducting such business
at the meeting; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the stockholder&#146;s name and address; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any material interest of the stockholder in the proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of shares beneficially owned by the stockholder and evidence of such ownership; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the names and addresses of all persons with whom the stockholder is acting in concert and a description of all arrangements
and understandings with those persons, and the number of shares such persons beneficially own. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To be timely, a stockholder must
generally deliver notice not less than 90 nor more than 120&nbsp;days prior to the date on which the annual meeting of stockholders was held in the immediately preceding year, but in the event that the date of the annual meeting is more than
30&nbsp;days before or more than 60&nbsp;days after the anniversary date of the preceding annual meeting of stockholders, a stockholder notice will be timely if received by us not later than the close of business on the later of (i)&nbsp;the
90th&nbsp;day prior to the date of the annual meeting and (ii)&nbsp;the 10th&nbsp;day following the day on which we first publicly announce the date of the annual meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In order to submit a nomination for our board of directors, a stockholder must also submit all information with respect to the nominee that would be
required to be included in a proxy statement, as well as other information. If a stockholder fails to follow the required procedures, the stockholder&#146;s proposal or nominee will be ineligible and will not be voted on by our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitations of Liability of Directors and Officers and Indemnification Matters </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation contains provisions that limit the liability of our directors for monetary damages to the fullest
extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any breach of the director&#146;s duty of loyalty to our company or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of
law;</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a result, neither we nor our stockholders have the right, through stockholders&#146; derivative suits on our behalf, to recover monetary damages
against a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior, except in the situations described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation also provides that, to the fullest extent permitted by law, we will indemnify any officer or
director of our company against all damages, claims, and liabilities arising out of the fact that the person is or was our director or officer or served any other enterprise at our request as a director or officer. Amending this provision will not
reduce our indemnification obligations relating to actions taken before an amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;SANA.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The transfer agent and
registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. The transfer agent and registrar&#146;s address is 6201&nbsp;15th Avenue, Brooklyn, New York 11219. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx457972_9"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We previously entered into a sales agreement with Cowen, under which we may issue and sell from time to time up to $148,735,500 of our common stock
through Cowen as our sales agent. Sales of our common stock, if any, will be made at market prices by any method that is deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4) under the Securities Act. If authorized by us in
writing, Cowen may purchase shares of our common stock as principal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Cowen will offer our common stock subject to the terms and conditions of the
sales agreement on a daily basis or as otherwise agreed upon by us and Cowen. We will designate the maximum amount of common stock to be sold through Cowen on a daily basis or otherwise determine such maximum amount together with Cowen. Subject to
the terms and conditions of the sales agreement, Cowen will use its commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us. We may instruct Cowen not to sell common stock if the sales
cannot be effected at or above the price designated by us in any such instruction. Cowen or we may suspend the offering of our common stock being made through Cowen under the sales agreement upon proper notice to the other party. Cowen and we each
have the right, by giving written notice as specified in the sales agreement, to terminate the sales agreement in each party&#146;s sole discretion at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The aggregate compensation payable to Cowen as sales agent will be up to 3.0% of the gross sales price of the shares sold through it pursuant to the
sales agreement. We have also agreed to reimburse Cowen up to $75,000 of Cowen&#146;s actual outside legal expenses incurred by Cowen in connection with this offering. We estimate that the total expenses of the offering payable by us, excluding
commissions payable to Cowen under the sales agreement, will be approximately $1.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The remaining sales proceeds, after deducting any
expenses payable by us and any transaction fees imposed by any governmental, regulatory, or self-regulatory organization in connection with the sales, will equal our net proceeds for the sale of such common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Cowen will provide written confirmation to us following the close of trading on the Nasdaq Global Select Market on each day in which common stock is
sold through it as sales agent under the sales agreement. Each confirmation will include the number of shares of common stock sold through it as sales agent on that day, the volume weighted average price of the shares sold, the percentage of the
daily trading volume, and the net proceeds to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will report at least quarterly the number of shares of common stock sold through Cowen under
the sales agreement, the net proceeds to us, and the compensation paid by us to Cowen in connection with the sales of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Settlement for
sales of common stock will occur, unless the parties agree otherwise, on the second business day that is also a trading day following the date on which any sales were made in return for payment of the net proceeds to us. There is no arrangement for
funds to be received in an escrow, trust, or similar arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with the sales of our common stock on our behalf, Cowen will be
deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act, and the compensation paid to Cowen will be deemed to be underwriting commissions or discounts. We have agreed in the sales agreement to provide indemnification and
contribution to Cowen against certain liabilities, including liabilities under the Securities Act. As sales agent, Cowen will not engage in any transaction that stabilizes our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our common stock is listed on the Nasdaq Global Select Market and trades under the symbol
&#147;SANA.&#148; The transfer agent of our common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Cowen and/or its affiliates have
provided, and may in the future provide, various investment banking and other financial services for us, for which services they have received and, may in the future receive, customary fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx457972_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The validity of the issuance of the securities offered hereby will be passed upon by our counsel, Latham&nbsp;&amp; Watkins&nbsp;LLP, Menlo Park,
California. Cowen and Company, LLC is being represented in connection with this offering by Cooley LLP, New York, New York. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx457972_11">
</A>EXPERTS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements
included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration
statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx457972_12"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, of which this
prospectus forms a part. For further information about us and the securities we are offering under this prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to
the statements contained in this prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed
as an exhibit to the registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We file reports, proxy statements, and other information with the SEC under the Exchange Act. The SEC
maintains an Internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is<I>&nbsp;www.sec.gov</I>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx457972_13"></A>INFORMATION INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The SEC allows us to &#147;incorporate by reference&#148; the information we file with them which means that we can disclose important information to
you by referring you to those documents instead of having to repeat the information in this prospectus. The information incorporated by reference is considered to be part of this prospectus, and later information that we file with the SEC will
automatically update and supersede this information. Any statement contained in a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement
contained in this prospectus modifies or replaces that statement. We incorporate by reference the documents listed below and any future information filed (rather than furnished) with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange
Act between the date of this prospectus and the termination of this offering, provided, however, that we are not incorporating any information furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of any current report on
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K:</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000156459022010539/sana-10k_20211231.htm">March
 16, 2022</A>; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the information specifically incorporated by reference into our Annual Report on Form 10-K from our Definitive Proxy
Statement on Schedule 14A, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312522118701/d295002ddef14a.htm">April 26, 2022</A>; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the quarters ended March&nbsp;31, 2022,
June&nbsp;30, 2022, and September&nbsp;30, 2022, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000156459022019299/sana-10q_20220331.htm">May&nbsp;
10, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000156459022028036/sana-10q_20220630.htm">August&nbsp;
4, 2022</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1770121/000156459022036375/sana-10q_20220930.htm">November&nbsp;2, 2022</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our Current Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;
8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000156459022000913/sana-8k_20220107.htm">January&nbsp;
11, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000119312522165186/d303939d8k.htm">June&nbsp;
1, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000119312522171023/d366546d8k.htm">June&nbsp;
9, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000156459022036057/sana-8k_20221027.htm">November&nbsp;
1, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000119312522294309/d191955d8k.htm">November&nbsp;
29, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000119312523016245/d642303d8k.htm">January&nbsp;
26, 2023</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001770121/000156459023000832/sana-8k_20230126.htm">January&nbsp;26, 2023</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the description of our common stock contained in <A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312521092650/d124805dex43.htm">Exhibit&nbsp;4.3
</A> to the Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2020, filed with the SEC on March&nbsp;24, 2021, including any amendments or reports filed with the SEC for the purposes of
updating this description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These documents may also be accessed on our website at<I>&nbsp;www.sana.com</I>. Except as otherwise
specifically incorporated by reference in this prospectus, information contained in, or accessible through, our website is not a part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will furnish without charge to you, upon written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits
to these documents by writing or telephoning us at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Sana Biotechnology, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">188 East Blaine Street, Suite 400 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Seattle, Washington
98102 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">(206) <FONT STYLE="white-space:nowrap">701-7914</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #334998">&nbsp;</P>
<P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>$148,735,500 </B></P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g457972g23i89.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:52pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>TD Cowen </B></P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center> <P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center">March 15, 2023 </P>
<P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #334998">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item 14. Other Expenses of Issuance and Distribution </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following is an estimate of the expenses (all of which are to be paid by us) that we may incur in connection with the securities being registered hereby. Each item listed is estimated, except for the Financial Industry Regulatory Authority, Inc., or
FINRA, filing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount to</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Be Paid</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,570</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;225,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue Sky, qualification fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trustee fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant agent fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be
estimated at this time. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount includes the registration fee of $13,905 previously paid in connection with the offering, issuance,
and sale of up to $150,000,000 of shares of common stock pursuant to this registration statement and a sales agreement, dated as of August 4, 2022, by and between the registrant and Cowen and Company, LLC. The $350,000,000 of shares of common stock
registered pursuant to this registration statement includes $148,735,500 of shares of common stock, or the Unsold Shares, registered pursuant to Registration Statement No. 333-266547 filed on August 4, 2022. Pursuant to Rule 415(a)(6) under the
Securities Act of 1933, as amended, the filing fees previously paid in connection with the Unsold Shares will continue to be applied to the Unsold Shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item 15. Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsection (a)&nbsp;of Section&nbsp;145 of the DGCL empowers a corporation to indemnify any person who was or is a party or who is threatened to be made a
party to any threatened, pending or completed action, suit, or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a
director, officer, employee, or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise, against
expenses (including attorneys&#146; fees), judgments, fines, and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit, or proceeding if the person acted in good faith and in a manner the
person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person&#146;s conduct was unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsection (b)&nbsp;of Section&nbsp;145 empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any
threatened, pending, or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted in any of the capacities set forth above, against expenses (including
attorneys&#146; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue, or matter as to which
such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of
liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of
any action, suit or proceeding referred to in subsections (a)&nbsp;and (b) of Section&nbsp;145, or in defense of any claim, issue, or matter therein, such person shall be indemnified against expenses (including attorneys&#146; fees) actually and
reasonably incurred by such person in connection therewith; that indemnification provided for by Section&nbsp;145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and that the indemnification provided
for by Section&nbsp;145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee, or agent and shall inure to the benefit of such person&#146;s heirs, executors, and
administrators. Section&nbsp;145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee, or agent of the corporation, or is or was serving at the request of the
corporation as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out
of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section&nbsp;145. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;102(b)(7) of the DGCL provides that a corporation&#146;s certificate of incorporation may contain a provision eliminating or limiting the
personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i)&nbsp;for any breach of
the director&#146;s duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section&nbsp;174 of the DGCL, or
(iv)&nbsp;for any transaction from which the director derived an improper personal benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any underwriting agreement or distribution agreement that the
registrant enters into with any underwriters or agents involved in the offering or sale of any securities registered hereby may require such underwriters or dealers to indemnify the registrant, some or all of its directors and officers and its
controlling persons, if any, for specified liabilities, which may include liabilities under the Securities Act of 1933, as amended, or the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and restated bylaws provide for the indemnification provisions described above and
elsewhere herein. We have entered into separate indemnification agreements with our directors and officers which may be broader than the specific indemnification provisions contained in the DGCL. These indemnification agreements generally require
us, among other things, to indemnify our officers and directors against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification
agreements also generally require us to advance any expenses incurred by the directors or officers as a result of any proceeding against them as to which they could be indemnified. In addition, we have purchased a policy of directors&#146; and
officers&#146; liability insurance that insures our directors and officers against the cost of defense, settlement, or payment of a judgment in some circumstances. These indemnification provisions and the indemnification agreements may be
sufficiently broad to permit indemnification of our officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item 16. Exhibits </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Exhibits </I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>Number</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incorporated&nbsp;by&nbsp;Reference&nbsp;to&nbsp;Filings<BR>Indicated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Provided</B><br><B>Herewith</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Form</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312522212687/d564938dex12.htm">Sales Agreement, dated August&nbsp;4, 2022, by and between the Registrant and Cowen and Company, LLC. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312522212687/d564938dex12.htm">4.5 </A></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">08/04/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312521032935/d112159dex31.htm">Amended and Restated Certificate of Incorporation. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312521032935/d112159dex31.htm">3.1 </A></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/08/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312521032935/d112159dex32.htm">Amended and Restated Bylaws. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312521032935/d112159dex32.htm">3.2 </A></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/08/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Reference is made to Exhibits&nbsp;3.1 through 3.2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312521019984/d60414dex42.htm">Form of Common Stock Certificate. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1/A</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312521019984/d60414dex42.htm">4.2 </A></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/28/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312521007483/d60414dex101.htm">Amended and Restated Investors&#146; Rights Agreement, dated February 13, 2019, by and among the Registrant and the investors listed therein.
 </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-1/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right"><A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312521007483/d60414dex101.htm">10.1<BR></A></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/13/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Preferred Stock Certificate.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312522212687/d564938dex45.htm">Form of Indenture. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312522212687/d564938dex45.htm">4.5 </A></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">08/04/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Note.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.7*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Warrant.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.8*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Warrant Agreement.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.9*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Unit Agreement.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d457972dex51.htm">Opinion of Latham &amp; Watkins LLP. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d457972dex231.htm">Consent of Independent Registered Public Accounting Firm. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d457972dex51.htm">Consent of Latham &amp; Watkins LLP (included in Exhibit&nbsp;5.1). </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312522212687/d564938ds3asr.htm#poa">Powers of Attorney.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><A HREF="http://www.sec.gov/Archives/edgar/data/1770121/000119312522212687/d564938ds3asr.htm#poa">24.1</A></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">08/04/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>25.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Statement of Eligibility on Form <FONT STYLE="white-space:nowrap">T-1</FONT> under the Trust Indenture Act of 1939, as amended, of the trustee, as trustee under the indenture filed herewith.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d457972dexfilingfees.htm">Filing Fee Table. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment or incorporated by reference in connection with the offering of the securities.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item 17. Undertakings </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The undersigned registrant hereby undertakes: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration
statement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the
most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of
securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with
the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20&nbsp;percent change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the
effective registration statement; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) To include any material information with respect to the plan of distribution
not previously disclosed in the registration statement or any material change to such information in the registration statement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>provided</I>, <I>however</I>, that paragraphs (a)(1)(i), (a)(1)(ii), and (a)(1)(iii) above do not apply if the information required to be
included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended, or the
Exchange Act, that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is a part of the registration statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be
deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain
unsold at the termination of the offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the Securities Act to
any purchaser: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in
reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a) of the Securities Act shall be deemed to be part of and included in the
registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for
liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus
relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. <I>Provided</I>, <I>however</I>, that no statement made in a registration statement or prospectus that is part of the
registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to
such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5) That, for the purpose of determining liability of the registrant under
the Securities Act to any purchaser in the initial distribution of the securities: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant undertakes
that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such
purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed
pursuant to Rule 424; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the
undersigned registrant or used or referred to by the undersigned registrant; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The portion of any other free writing
prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the
registrant&#146;s annual report pursuant to Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to Section&nbsp;15(d) of the Exchange Act) that is
incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona
fide</I> offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act
and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to
act under subsection (a)&nbsp;of Section&nbsp;310 of the Trust Indenture Act, or the Act, in accordance with the rules and regulations prescribed by the SEC under Section&nbsp;305(b)(2) of the Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Seattle, State of Washington, on the 15th day of March, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>SANA BIOTECHNOLOGY, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Steven D. Harr, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Steven D. Harr, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment
No.&nbsp;1 to the Registration Statement has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Steven D. Harr, M.D.</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">and Director (Principal Executive</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Officer)</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">March 15, 2023 </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Steven D. Harr, M.D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Nathan Hardy</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer (Principal</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial and Accounting Officer)</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">March 15, 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Nathan Hardy</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 15, 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Hans E. Bishop</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 15, 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Joshua H. Bilenker, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 15, 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Douglas Cole, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 15, 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Richard Mulligan, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 15, 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Robert Nelsen</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 15, 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Alise S. Reicin, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 15, 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Michelle Seitz</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 15, 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mary Agnes (Maggie) Wilderotter</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">March 15, 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Patrick Y. Yang, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*By: &nbsp;&nbsp;&nbsp;&nbsp;/s/ Steven D. Harr, M.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Steven D. Harr, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: &nbsp;&nbsp;&nbsp;Attorney-in-Fact</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d457972dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">140&nbsp;Scott&nbsp;Drive</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Menlo Park, California 94025</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Tel:&nbsp;+1.650.328.4600&nbsp;Fax:&nbsp;+1.650.463.2600</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">www.lw.com</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g457972g0315091637310.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">FIRM / AFFILIATE OFFICES</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Austin</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Milan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Beijing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Munich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Boston</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">New&nbsp;York</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brussels</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Orange&nbsp;County</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Century City</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Paris</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">March&nbsp;15, 2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chicago</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Riyadh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dubai</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">San Diego</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">D&uuml;sseldorf</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">San Francisco</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Frankfurt</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Seoul</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hamburg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Shanghai</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hong Kong</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Silicon Valley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Houston</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Singapore</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">London</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Tel Aviv</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Los&nbsp;Angeles</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Tokyo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Madrid</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Washington,&nbsp;D.C.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sana Biotechnology, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">188
East Blaine Street, Suite 400 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seattle, Washington 98102 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: <U>Post-Effective Amendment No.</U><U></U><U>&nbsp;1 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT></U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the addressee set forth above: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted
as special counsel to Sana Biotechnology, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with its filing on the date hereof with the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;)
of a Post-Effective Amendment No.&nbsp;1 to the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> filed by the Company on August&nbsp;4, 2022 (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-266547)</FONT> (as
amended, the &#147;<B><I>Registration Statement</I></B>&#148;), including a base prospectus dated March&nbsp;15, 2023 (the &#147;<B><I>Base Prospectus</I></B>&#148;), which provides that it will be supplemented by one or more prospectus supplements
(each such prospectus supplement, together with the Base Prospectus, a &#147;<B><I>Prospectus</I></B>&#148;), under the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;), relating to the registration for issue and sale by the
Company of up to $350,000,000.00 aggregate offering amount of (i)&nbsp;shares of the Company&#146;s common stock, par value $0.0001 per share (the &#147;<B><I>Common Stock</I></B>&#148;), (ii) shares of one or more series of the Company&#146;s
preferred stock, par value $0.0001 per share (the &#147;<B><I>Preferred Stock</I></B>&#148;), (iii) one or more series of the Company&#146;s debt securities (collectively, &#147;<B><I>Debt Securities</I></B>&#148;) to be issued under an indenture to
be entered into between the Company, as issuer, and a trustee (a form of which is included as Exhibit 4.5 to the Registration Statement) and one or more board resolutions, supplements thereto or officer&#146;s certificates thereunder (such
indenture, together with the applicable board resolution, supplement or officer&#146;s certificate pertaining to the applicable series of Debt Securities, the &#147;<B><I>Applicable Indenture</I></B>&#148;), (iv) warrants to purchase Debt
Securities, Common Stock or Preferred Stock (&#147;<B><I>Warrants</I></B>&#148;), and (v)&nbsp;units consisting of two or more of the Securities (as defined below) (&#147;<B><I>Units</I></B>&#148;). The Debt Securities, Common Stock, Preferred
Stock, Warrants and Units, plus any additional Debt Securities, Common Stock, Preferred Stock, Warrants and Units that may be registered pursuant to any subsequent registration statement that the Company may hereafter file with the Commission
pursuant to Rule 462(b) under the Act in connection with the offering by the Company contemplated by the Registration Statement, are referred to herein collectively as the &#147;<B><I>Securities</I></B>.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>March 15, 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 2
 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g457972g0315091637763.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have acted as special counsel to the Company in connection with the sale through
Cowen and Company, LLC as the sales agent (the &#147;<B><I>Sales Agent</I></B>&#148;) from time to time by the Company of shares of Common Stock (the &#147;<B><I>Sales Agreement Shares</I></B>&#148;) having an aggregate offering price of up to
$148,735,500 pursuant to the Registration Statement and the related sales agreement prospectus for the sale of the Sales Agreement Shares included in the Registration Statement (the &#147;<B><I>Sales Agreement Prospectus</I></B>&#148;), and that
certain Sales Agreement dated as of August&nbsp;4, 2022 between the Sales Agent and the Company (the &#147;<B><I>Sales Agreement</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT> under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related applicable Prospectus or the Sales Agreement Prospectus, other than as
expressly stated herein with respect to the issuance of the Securities, including the issuance of the Sales Agreement Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such
counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to
factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;), and with respect to the opinions set forth in numbered
paragraphs 3 through 5 below, the internal laws of the State of New York, and we express no opinion with respect to the applicability thereto, or the effect thereon, of the laws of any other jurisdiction or, in the case of Delaware, any other laws,
or as to any matters of municipal law or the laws of any local agencies within any state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters
set forth herein, it is our opinion that, as of the date hereof: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. When an issuance of Common Stock (other than an issuance of Sales
Agreement Shares) has been duly authorized by all necessary corporate action of the Company, upon issuance, delivery and payment therefor in an amount not less than the par value thereof in the manner contemplated by the applicable Prospectus and by
such corporate action, and in total amounts and numbers of shares that do not exceed the respective total amounts and numbers of shares (a)&nbsp;available under the certificate of incorporation and (b)&nbsp;authorized by the board of directors in
connection with the offering contemplated by the applicable Prospectus, such shares of Common Stock will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all
applicable notice requirements regarding uncertificated shares provided in the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. When a series of Preferred Stock has been duly
established in accordance with the terms of the Company&#146;s certificate of incorporation and authorized by all necessary corporate action of the Company, upon issuance, delivery and payment therefor in an amount not less than the par value
thereof in the manner contemplated by the applicable Prospectus and by such corporate action, and in total amounts and numbers of shares that do not exceed the respective total amounts </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>March 15, 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 3
 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g457972g0315091637763.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and numbers of shares (a)&nbsp;available under the certificate of incorporation and (b)&nbsp;authorized by the board of directors in connection with the offering contemplated by the applicable
Prospectus, such shares of such series of Preferred Stock will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding
uncertificated shares provided in the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. When the Applicable Indenture has been duly authorized, executed and delivered by all
necessary corporate action of the Company, and when the specific terms of a particular series of Debt Securities have been duly established in accordance with the terms of the Applicable Indenture and authorized by all necessary corporate action of
the Company and such Debt Securities have been duly executed, authenticated, issued and delivered against payment therefor in accordance with the terms of the Applicable Indenture and in the manner contemplated by the applicable Prospectus and by
such corporate action, such Debt Securities will be the legally valid and binding obligations of the Company, enforceable against the Company in accordance with their terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. When the applicable warrant agreement has been duly authorized, executed and delivered by all necessary corporate action of the Company,
and when the specific terms of a particular issuance of Warrants have been duly established in accordance with the terms of the applicable warrant agreement and authorized by all necessary corporate action of the Company, and such Warrants have been
duly executed, authenticated, issued and delivered against payment therefor in accordance with the terms of the applicable warrant agreement and in the manner contemplated by the applicable Prospectus and by such corporate action (assuming the
securities issuable upon exercise of such Warrants have been duly authorized and reserved for issuance by all necessary corporate action), such Warrants will be the legally valid and binding obligations of the Company, enforceable against the
Company in accordance with their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. When the applicable unit agreement has been duly authorized, executed and delivered by all
necessary corporate action of the Company, and when the specific terms of a particular issuance of Units have been duly authorized in accordance with the terms of the applicable unit agreement and authorized by all necessary corporate action of the
Company, and such Units have been duly executed, authenticated, issued and delivered against payment therefor in accordance with the terms of the applicable unit agreement and in the manner contemplated by the applicable Prospectus and by such
corporate action (assuming the securities issuable upon exercise of such Units have been duly authorized and reserved for issuance by all necessary corporate action), such Units will be the legally valid and binding obligations of the Company,
enforceable against the Company in accordance with their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Upon the completion of all Corporate Proceedings (as defined below)
relating to the Sales Agreement Shares, when the Sales Agreement Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against
payment therefor (not less than par value) in accordance with the Corporate Proceedings and the terms of the Sales Agreement, the issuance and sale of the Sales Agreement Shares will have been duly authorized by all necessary corporate action of the
Company, and the Sales Agreement Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that (i)&nbsp;the Company will comply with all applicable notice requirements regarding uncertificated
shares provided in the DGCL, (ii)&nbsp;upon </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>March 15, 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 4
 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g457972g0315091637763.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the issuance of any of the Sales Agreement Shares, the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is
then authorized to issue under the Company&#146;s certificate of incorporation and (iii)&nbsp;certain terms of the Sales Agreement Shares to be issued by the Company from time to time will be authorized and approved by the board of directors of the
Company or one or more committees thereof established by the board of directors of the Company with the authority to issue and sell Sales Agreement Shares pursuant to the Sales Agreement in accordance with the DGCL, the Company&#146;s certificate of
incorporation, the bylaws of the Company and certain resolutions of the board of directors of the Company and one or more committees thereof (with such approvals referred to herein as the &#147;<B><I>Corporate Proceedings</I></B>&#148;) prior to
issuance thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinions are subject to: (i)&nbsp;the effects of bankruptcy, insolvency, reorganization, preference, fraudulent
transfer, moratorium or other similar laws relating to or affecting the rights and remedies of creditors; (ii)&nbsp;the effects of general principles of equity, whether considered in a proceeding in equity or at law (including the possible
unavailability of specific performance or injunctive relief), concepts of materiality, reasonableness, good faith and fair dealing, and the discretion of the court before which a proceeding is brought; and (iii)&nbsp;the invalidity under certain
circumstances under law or court decisions of provisions providing for the indemnification of or contribution to a party with respect to a liability where such indemnification or contribution is contrary to public policy. We express no opinion as to
(a)&nbsp;any provision for liquidated damages, default interest, late charges, monetary penalties, make-whole premiums or other economic remedies to the extent such provisions are deemed to constitute a penalty, (b)&nbsp;consents to, or restrictions
upon, governing law, jurisdiction, venue, arbitration, remedies or judicial relief, (c)&nbsp;waivers of rights or defenses, (d)&nbsp;any provision requiring the payment of attorneys&#146; fees, where such payment is contrary to law or public policy,
(e)&nbsp;any provision permitting, upon acceleration of any Debt Securities, collection of that portion of the stated principal amount thereof which might be determined to constitute unearned interest thereon, (f)&nbsp;the creation, validity,
attachment, perfection, or priority of any lien or security interest, (g)&nbsp;advance waivers of claims, defenses, rights granted by law, or notice, opportunity for hearing, evidentiary requirements, statutes of limitation, trial by jury or at law,
or other procedural rights, (h)&nbsp;waivers of broadly or vaguely stated rights, (i)&nbsp;provisions for exclusivity, election or cumulation of rights or remedies, (j)&nbsp;provisions authorizing or validating conclusive or discretionary
determinations, (k)&nbsp;grants of setoff rights, (l)&nbsp;proxies, powers and trusts, (m)&nbsp;provisions prohibiting, restricting, or requiring consent to assignment or transfer of any right or property, (n)&nbsp;any provision to the extent it
requires that a claim with respect to a security denominated in other than U.S. dollars (or a judgment in respect of such a claim) be converted into U.S. dollars at a rate of exchange at a particular date, to the extent applicable law otherwise
provides, and (o)&nbsp;the severability, if invalid, of provisions to the foregoing effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With your consent, we have assumed
(i)&nbsp;that each of the Debt Securities, Warrants and Units and the Applicable Indenture, warrant agreements and unit agreements governing such Securities (collectively, the &#147;<B><I>Documents</I></B>&#148;) will be governed by the internal
laws of the State of New York, (ii)&nbsp;that each of the Documents has been or will be duly authorized, executed and delivered by the parties thereto, (iii)&nbsp;that each of the Documents constitutes or will constitute legally valid and binding
obligations of the parties thereto other than the Company, enforceable against each of them in accordance with their respective terms, and (iv)&nbsp;that the status of each of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>March 15, 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 5
 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g457972g0315091637763.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Documents as legally valid and binding obligations of the parties will not be affected by any (a)&nbsp;breaches of, or defaults under, agreements or instruments, (b)&nbsp;violations of
statutes, rules, regulations or court or governmental orders or (c)&nbsp;failures to obtain required consents, approvals or authorizations from, or to make required registrations, declarations or filings with, governmental authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely
upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement and to the reference to our firm contained in each of the Prospectus and the Sales Agreement Prospectus
under the heading &#147;Legal Matters.&#148; We further consent to the incorporation by reference of this letter and consent into any registration statement or post-effective amendment to the Registration Statement filed pursuant to Rule 462(b)
under the Act with respect to the Securities. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of the Commission thereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:66%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Sincerely, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:66%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Latham&nbsp;&amp; Watkins LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d457972dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; in the Amended Registration Statement (Form
<FONT STYLE="white-space:nowrap">S-3</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-266547)</FONT> and related Prospectus of Sana Biotechnology, Inc. for the registration of common stock, preferred stock, debt securities, warrants and units
and to the incorporation by reference therein of our report dated March&nbsp;16, 2022, with respect to the consolidated financial statements of Sana Biotechnology, Inc. included in its Annual Report (Form
<FONT STYLE="white-space:nowrap">10-K)</FONT> for the year ended December&nbsp;31, 2021, filed with the Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/
Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seattle, Washington </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;15, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>d457972dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form <FONT STYLE="white-space:nowrap">S-3</FONT> </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Sana
Biotechnology, Inc. </U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table 1: Newly Registered and </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Carry Forward Securities </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Security Type</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Security<BR>Class&nbsp;Title</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Fee<BR>Calculation<BR>or Carry<BR>Forward<BR>Rule</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Amount<BR>Registered</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Proposed<BR>Maximum<BR>Offering<BR>Price Per<BR>Unit</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Maximum Aggregate<BR>Offering Price</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Fee Rate</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Amount of<BR>Registration Fee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="17" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt"><FONT STYLE="font-size:10pt">Newly Registered Securities</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">Fees to Be Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Common Stock, par value $0.0001 per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(1)(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(3)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Preferred Stock, par value $0.0001 per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(1)(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(3)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Debt</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Debt Securities</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(3)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Other</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Warrants</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(3)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Other</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Units</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(3)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Unallocated (Universal) Shelf</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Rule 457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(1)(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$350,000,000(3)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$110.20 per $1,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">$38,570.00(4)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">Fees Previously Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Common Stock, par value $0.0001 per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Rule 457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#150;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#150;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$148,735,500</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$92.70 per $1,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">$13,787.78(5)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center">Total Offering Amounts</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$350,000,000.00</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">$38,570.00</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center">Total Fees Previously Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">$13,787.78(5)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center">Total Fee Offsets</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#150;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Net Fee Due</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$24,782.22</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">An unspecified number of securities or aggregate principal amount, as applicable, is being registered as may
from time to time be offered at unspecified prices and, in addition, an unspecified number of additional shares of common stock is being registered as may be issued from time to time upon conversion of any debt securities that are convertible into
common stock or pursuant to any anti-dilution adjustments with respect to any such convertible debt securities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">Includes rights to acquire common stock or preferred stock of the registrant under any shareholder rights
plan then in effect, if applicable under the terms of any such plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">Estimated solely for the purpose of calculating the registration fee. No separate consideration will be
received for shares of common stock that are issued upon conversion of debt securities, depositary shares or preferred stock or upon exercise of common stock warrants registered hereunder. The aggregate maximum offering price of all securities
issued pursuant to this registration statement will not exceed $350,000,000. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">Calculated pursuant to Rule 457(o) under the Securities Act. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">On August&nbsp;4, 2022, the registrant initially filed this registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (File No.&nbsp;333-266547) registering, among other securities, the issuance of up to $150,000,000 of common stock of the registrant in an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity offering of the registrant&#146;s common stock, or the ATM Common Stock. The registration fee associated with the ATM Common Stock was $13,905. The
registrant sold $1,264,499 of ATM Common Stock, which equates to an associated registration fee of $117.22 based on the total registration fee paid in connection with the filing of the registration statement. Accordingly, the unused registration fee
paid in connection with the registration statement and the ATM Common Stock is $13,787.78. The remaining unused fees from the registration statement, $13,787.78, will be applied to the registrant&#146;s total registration fee. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g457972g01q01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g457972g01q01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2EH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *4R^$%<CA"24T$!       2QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1Q
MP"   "   < @4 )U-A;F%?1FEG=7)E,#%?3W5R(%!I<&5L:6YE7S$P+4M?,C
M R,E]V,@ X0DE-!"4      !"FM'L +3A<F$^Q'CJH'VV9.$))300Z
M#E    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M  3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T
M]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M!'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D5%
M5N=$8C4FQT                0FQD(%5N=$8C4FQT                4G
M-L=%5N=$8C4'AL0'8DI_         *=F5C=&]R1&%T86)O;VP!     %!G4'
M-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M    !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M       !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;V
MUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%
M)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M   ! !8DI_  $  0%B2G\  0 !.$))300F       .             #^
M X0DE-! T       0    >.$))3009       $    'CA"24T#\P      "0
M           0 X0DE-)Q        H  0         !.$))30/U      !( "
M]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M &       ! #4    ! "T    &       !.$))30/X      !P  #_______
M______________________ ^@     _____________________________P
M/H     /____________________________\#Z     #_______________
M______________ ^@  #A"24T$"       $     $   )    "0      X0D
ME-!!X       0     .$))300:      ,U    !@             '\@  "+
MH          0                         !              BZ   '\@
M                     !                         !     !
M  ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M!4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   '\@
M    !29VAT;&]N9P  "+H    &<VQI8V5S5FQ,<P    %/8FIC     0
M  !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F
M<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96
MYE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F
M)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M   $QE9G1L;VYG          !"=&]M;&]N9P  !_(     4F=H=&QO;F<
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M]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M     ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M !.$))300,     !ZI     0   *    "2   !X  !$<   !Z- !@  ?_8_^
MT #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0
ML*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,#
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M[F445";+;"&M:./<YQ1&XTO793*I[;:F6M#@VQH< X%K@"-WN8[W,=_)4@!
MY^\IF/;8QME;@]CP'-<W4$'5KFN"<3 U04PKN99;94 X.JC<3(!W"?:40"%%
MMC'/<QKP7LC>T<B>-REJFQNM2):G4>?R_X*3Y4NDDDG(?_TNWZA5TR[.OKR,
MJ^NR&N>RLN:QC S:Y[_:ZKT6[]]MW^!WJWTG*Z>X&C#M=8UTV5M<'@-8!5HQ
MUOYOZ6M_TOTGJ*OU#%RK,RVRK)Q:(?7L]1@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" (G ET# 1$  A$! Q$!_\0 'P !  (" P$! 0$
M  <(!08!! D# @H+_\0 91   00" @ !!@@'#0,'!P8/!0,$!@<! @ (% D1
M$A,55!87(564E=35"ADQ6)+2TQ@T-4%14W1UDY:TM=@BF-8C)&%Q@9&A)C)(
M5Y>Q\"4H-D-69&6&QO$G1$:$16:CIL'1X?_$ !X! 0 # 0$! 0$! 0
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MW4=*CCZAJX2VHTWV9HYP"-J3[D9$K4+&L:[+;\ 7UMU&;J77X-?^D'0^F_\
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M:#TAU7K,O0M+U*<=8Z5JAH4U/39M;#''#&X7>AFABU$ZH98A,ACD1C\WU?\
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ML8SC&Z>^-=]-L8SYMM-]==M<^?7;&,XSCGYH11(XX-<$$<?0BP1^()!^,_0
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MQ8DQ=5XBX6:+V-'B4P&@1TMKI!RCLBO/8JZ-1!#?=OA4SIXIKE9U'0>I.DK
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M61=HAMZO9QBJ>Y+;:8(K[XSC/@=JZ-3+=\GG;":S=/9-7SIYSS^G/T83PMZ
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MZ[Z9HNDZV'0PZ/4WU/K^LZ?JSU'J$(75ZI-4$,VH>:5BKN[Q[%C@6*>B'4=
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MG66Z3J]2/U_5I/3^J4KU*2<A4GU$.EU>JA%L5596D1-U'JVHZ*W_ /7S _\
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M 6!EW2'3RA5)B<9Q3UQTYVFGA#LU/I'4NE4UAU^MR*T7U,C9^$65;IBH)4,
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ML^D).HLZ9V)9H#^J8DDH2<L/4?2P !Z3]2@#4#5@#TEK !JE 5=2!V:&H50
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MN_ZO_P!&NH_R\?C 8U^:OWX_W/;9^[>/Z"ZG^\WH?_2SI7\W'],8/[O^K_\
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M,;)[[:Y[M1Z<Z_JXF@U7KKTQJ8'VEX=1ZZT<T3%6#*6CDU+(VU@&6P:8 BB
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M&\CSP:C7=I(I?ZDZE^E_HFJ]/:F&'1:P]5UFAETS:62-/LL,T\!A>1I^X>Y
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M8DV1?==[\U)U1"LDSP<?(KD$)5NJ4J=B??QDW\'/AXT!+G1K%8^-1<1[&2V
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MO]HBVLQ+ *5!5D</;?= C*[SN/"TIW&ZNLPG6+MDGV1MCL[$1(1Z'BM'G*J
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M[^,8\&O\Z/\ ] =]W\8QX-?YT?\ Z [[OXQCP:_SH_\ T!WW?QC'@U_G1_\
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M:3RV1<IA<1Z33*KI3V9K[JYM9\6<7]V>>4[,$BL:ZY;:UZ2A)&/CM' $;*Q
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ML@2-T4'=(0';=QL4V%"@#DM1))/ H 6<EHB\T<C%=D6XHH4[M[#:2S75 70
M')LDT,MES+-\<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,
M<8QQC'&,<8R@_E(VK93K6/54;H;J_NF>D.GK=T4]E/0SW.H?7.GI[:YV]'.N
MVVN=?/YLXVVQYO-G/GWTW_>C_P DW^N%[_/.76?]T#\][3\_/_?QYH/?#LC,
M.EDEK^\4W!$Q4,DKVY*F>URU88<#G/8/>,;61UW?--&2.KQL_G!6%R^I%<[K
M89O2LRB"&^S99/1;>T$0G#)X<,C[B?\ P[VR<?.T,K_@%.1J)3IRLG)0JZ%
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MSMJB3-9-DQP$GZDP1DG.?1@"$@"@)M0 !X $\@ ^/C]V1#UZF77D".\I&Q[
M26J!L,W[L7@M,1EF%(PB-=1)6JZ?3?X)C#RV,O!KE!-VCA++=75SOJH@AHHM
M_L<O()/_ &8QA[[$=%0?O;WKD?.5C,0&J[IC"]^0MNH#;L3S?X>?QRE%3WO;
ME)T'"0LOL2Q*X:"_)P4V2B6S*(1N56%'S-F=K2U55(HS%6._!!D)H_@IR!0]
MN^L0^SB40(*IR27-]AX<HBMLR+)(2$4WJ7!LD(0L0=[V<T"&:E&XCA>2,YTD
M=(EMG2M+&5H!G!>8HG#T-VTH!O(5226L YHUXVG:RHGMI0=D6C.H/$H8_P#)
MC62P>6Q:=579.Z*D,U[N"0LHDQB5Q,%K&!B2 *,1:9*020D9H,$:M$#"#U$)
M)\BD[1JEPR(JEF&K7VHR+(%@)4 $WY8BQMOD>19K*[D31L[*J_8W&]TD:,MJ
M5!.X"N H.T[@/-T<L#V [!WY0DGN:BJGNN<6S!M9KTA#.K>E$MK;6=TBY[$2
MBW@UCPG2U346Q!Q#X\*KZM7$3+SP&5S 7ETM7Z>N1SJ)-F><<<;B-V0(VV<[
M K;9!$$*MM#;J&Y]VTC<(S\AKTEEEC9XTD9UW0#N,4W(93(&3>0$!(5"NX$J
M9+NMHR/;/(6]-! ZM[:L^9 8Y5WE">BR$6=[7C75AVK!=[$D&OPBC4^G<-B[
M$0I\'W& TSKY>0HNI2/^$B:1ET_'L1&BEE"*2RJ"6T\]_JV5&*@T5#$GGE6J
MAQ0YO*L7:E=F"IJ=/M/=5W4L>0[*/CAEOD7SQ6;<+[(=M#<YDMI(3 F'5CW>
MPGU^;Q*27;382ID8&%OOXJ652$J65BR]F/;%FM=)IS,%+436\J)2L\%E(E?2
ML\Z ]H,<04)0:X ]A'+EC'NWB2]NU6X(JJ!!]UG)$LY)<D@C4&/:SQB,*)-F
MSMUO+,GN4W98AKV<9*G7R[[H']H:^TM>U9_-HE<=V=AZVALNKZP*GL#KY/EX
MYI9IZ.UV4J%R!AEU=>Y=4T?@2@XD7%C9J(?'HX883>6O-),.((9R(AB;:J@H
MD;,&5ED7[H+;_<D@;==$J:(*K[2,O%))W4#NS*\DJJRLAC:MQ56CVK)&R!:)
M 86#N;D'/;[G'GH8XQF/2_A5Y_5XS_$EN3\#]YX_+_;_ +L9D.1C'&,_DU_"
M.NYW9NF9[2="U%.IK4]>RRNWU@R24P0P3BQF:2#,I)@,1=63"%&A5 ;%1XED
M3>"AQ%N@_4EC10N@YT;#/5_U%_V?O2'ISJ^AZQUSJNBT?4]?I>H)H-/IM;%'
MJ8M)I_LL<_VE=-+NC:3522O$LLD;-&-*PA92TM_SU^FKU-USIFLZ7TGIVLU7
M3M%J-$VLGFTDDD$NJF^T21=@SQ%)!' L2.T:.H<ZD&4,%2MS_!^.['9NXJM[
M60FV)3*;A%T;%XU,*YD\T?$9#)&9$ZQF?B(._DS]1P6-#W>\99O@K9^[=/1>
MNI-!!?#)=DV:_ _]KGIO3_T?>D>I^M?271]*O7=)Z7]7=3AZ'I(A'INJ:_H'
M1VZCT]5T>FV;'U.IVZ2?[.J&;N1[1W0S-[_Z .M=5]2ZZ?H77-?J-1H8M?T>
M).H:ES+/I(NH:EX-1&VHE+-(J1IWHED9NUL<7L956WXR_KA9RY&5ZSF1OB6S
MU-=5@Z(NEPSW3*FNVP]0)A3 [#%77SHZM6S5'".N^-FOJ5M4]]?^7_I?_:0_
M3?HO64/K)/TA>J.H=5;7IJ9NG:KJ>LU'0]>C3*S=,D]/K(.EKH)E_4)I--I(
M1 K Z3L3)'(O^FNI]#^E)>EMTO\ P/H(8!"8UGC@C35Q-1 G&M([_>0VYDDD
M8O1$N]"RGW09K*.&C5PLCLV57;H+*M]_/Z:"BJ>N^Z._GQKGTDMMLZ;>?7&?
M/KGY,?DY_P!">BGEU.CTFHG@;2S:C303S:5S;Z:66)))('-+;0NQC8[5LJ30
M\9_&<JJDDB(XD5'=5D'AU5B XY/# !AR>#Y.=CG3E,<8S'C/WKM_3"7^8N^,
M9D.,8XQCC&>;_=FT9[')-'(;'S)6.@G,=T-NG(=TN.<EGRY)^SV;K/FNR;C+
M9@DQ1WPU353TV4=[J.4U<>%RG_EM_P!OC]+GZ1?3'JSTOZ&],]=ZQZ8]/ZGT
MS'Z@U>KZ)K-3TS5]9ZAJ.J]2T+::;J&CDBU!TG3H>GP.-''+&C3:UIM5',!H
MVC_?OT0>F^B=0Z?K^JZ[2:77ZU-<VCCCU<23QZ6%-/!*)$AD!3N3M,ZF0J6"
MQ 1LOZT-OG2>R9K-0DP"RLB0.M8TL%W$&2:JCI[IJ3T(ZN!BSY;TEG>J'@4G
M#?*ZJJR&JZB>V_J<M]-/T7_L$_I3]>^O>@^M^@^L>I]2]0Z/TI/T)^C=<ZM-
M+K->B]63J@U/2=1U'4%Y]:FG_P 'PZC3=^66?3)/)$TG8.FCC\7]+_I_H_2-
M;TK5],@@T4G4$U:ZK2:=!'"3IS 4U"0I21%N\T;A%5'**U;Q(S7DY_H)GXWC
MC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&?S72NU+(-5[4Q.2=BG.,ZFO**[
M.J[G/;VXNFQB5MH-W5G\2C<R@_8J+).HI+)74$,',(S'J5LY\M$6D6=-2V1B
M8@1MLCZ01-SU'Q6F.Y84E"[H 2&C:BJNW)D6C?SSGDEW*(3*>&U5JTSP$A9W
M56$JFF,:BA&UK7)  S"6-?=GN-+-MZK3$UB2-F=:_) Z61.+3E6U73N'U%8%
M@]E$9U)K%L> PB1YK D_9O&XJ;6=#8*KK!FA\O,X\P#:C&;L<$:#8C[6VOK-
MJH"REU6,J$!8;N?"LW)4*Q/(R'E:W=-R[H=%O9V*,J,TFXNRJ2GT9U6P"6%4
M"/C8C]W)ZRFHZR;NBYBBJP[M^3P*LG59=W.S=YL:?>2.WPP^U-)#VPG,4J N
M0#;1U_&)6,"+3^;D*;DKA24)D84_<PC=C*4KJ51@[0Z@$-#&A<!#MJ)6< WN
M4D*N\#P:-G):-@[J8TU&E(*3S2A-S@-<S*A(H@CW-L8W8L5Z[=Z9=M'0_6<.
M7LJ2511L^[# HA>UGQ6;%H"0$P%6L+,-Q(2]M8*0''Z]!SNV M<1 K-A,B %
M,IFD@C>1,%)#Z_;C@6S*=H>18R8U*[ANW*"=GABJEB%((XNN+'=J&H0@L5C:
M4+(RL5(78Y7W@AE#.$7<"#SP03GFC9]N/]9[3565'V,/3KJDZE79]O\ &1>'
M<FZ>MT;E-HPYQ5*T:J )W0KB(3ZU+(C4%%R:R'T30)3#&LY+ I.',SV0*U8A
M''72J>QW>,++41"I DFU#W+=H7954M2\A>!1"C=><CN=R1QREX291ODGDB!=
M3'48G16=PH+U[O<0P+G91ABVI3.IEUQDIR?V#'[4([^2<\L /C\_C1V8RT=(
MH&'N&BQ,!WVG$YKJJSMBNA439B@3BSO@8Q'69D7K/1CTPSD215WI&%$@"J4
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M=K^O-V2-E$ZMM ++SI2%:6*%;,69QJVD,)RX%,W4BC)0F*8B9,Q$/S@@9(L
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MC<LL6LV8;K32T/<X$R%-NIZKX)6M$Y/MJ%=Y5C\J:M=U"0Y\".K-G$?:FC$
MB=B(U964V%:Y'-U?]9".?(^MC'V-)3J6FC6YG5D;VEU AC7SS]UU8@$D'Y%'
MGT1ZN,K?#417D9O>-1",VA#0^(7(DJ_4&ZP4ZG$UU0(>81(:*1:-XX$F 5B/
MD3>);,6*D35(+1W#?* U%=;GDV%V,98JQW#=]X7R58\V1XW7SY^<ZH0XC59
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M#KYFTA+24:.4EMG8<%MQ157;[V;VMO!9-I .[<!=@4!RQ R!J8R%VK([-O\
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MO7CYH]8N7FZ3+?/I/W"3I!9PWVUPFW40]=MNMA/_ #X_[9/_ &8_7'Z7.O=
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M163"Y]6?:^M3.X9838UU2ZZ(E*VK".O5S%:6( 7E3[221-RP,MW;21/HP^<
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M:;ZP-1, 1O!!8N=RHUL?))922<EM+ Q!*$%55!M>1:5?"TK 4+_C\WEM8A%
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M&92&>)A# \UAC>30UZ/9;Q">L #2=Q9%LDT R0>SQZC.8FD4* Q 5BRFA8+
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M[ZIZ:[[TX"]+;737&VW_ #E]G_:VQCSY^7^7.>;ZG_ZQ+_YSG-HQ_P"S0_\
MD'^T^?KGH1S#.G'&,<8QQC'&,<8QQC'&,<8QQC-6S!X?M-D[)VC8?,^2BRT'
M2E^6*'P@3A[@L@>7C>I+T?$8#JFFK<INQQOZC9ZBFXSKZS7&>3N.W;9VWNKX
MNJNOK7&1M7=NH;J*W\[202/W6 <TAMU^I!D_+E&540-F1/VB/NTV\:QH8W7*
MV\*:H,A]DOMT6^F7,S:M6R"29]7TB&<)XVV7VWSMMFW<>@-[$!2@!)-(?*CZ
M+^'C*B*,$D(H)?N$@#EQ_7/U;\?.;'*ZLKF<DM3$QA,;DI72%S.NM2!D4U?.
MM8)8OL7X=Q+"R^FV^ ,M^#@'V\.\_AR/LAAXC3?PZ?F@,RBE8@;E;@U[EO:?
MWBS7TLY+(C&V4$[62R+]K5N7]S4+'S0^F5\BGD_NE$%*,S<,ZPTY%B[!R'>,
MR(&&C1CI!>/GA$G#;:*M-$MLZ,#X ,411V])#+H<VV43WTT]#.AGF84TKD<^
M6)\@@^?J"0?P.9#3:=3:PQ@BO"@>"".!QP0#^\ Y98+!X?')!,96!C083)K"
M?B2DY/,&"#<M*R $&QC(1T=?::8<$%1,?&L1 _Q&^^K1BVT01UTUSMZ61)(
M))"@A03P 22:^EDDG\<U"J"S  %B"Q^6(%"_W  #Z#C()G72GJ39NZBE@]=Z
MFF&ZDMEL]WR>AXI_YYI/$P:4UD^,*HYQJ:E6D: >WW^F-5RFXEBH[V541UWY
MH)I5^[(Z\!>"1[5O:./@;C0_',V@A?[T2-9+<J#[FK<?WG:+/X9@2W0'I0=
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M@ ML'#"V:><YT:CA8YLV8LFVF=MLZ(-D$DM<[9SC3'GSR2239))/DGD_GD
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M8EIO836C9\]&K6%.$H#&S_P7BVSX66;,7)/*3TRH%.>PV!/4&7RRJD+R"QM
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M97-8L\ML98FTXM.)IODF)+5H7.GTXKHP'N "P3#1%76O=D4O[5 )4LIB38K
M4IV;=JFK\ 79N[.6,,+",!WL*RHZS/O9";9=^XLX\&B35"JH5M,IZ)=<Y$RA
M0\4"FE9H02N$Z=$[TO:=DT^[(5,DOL[3KN3OJ]E ![*(XD^5=D6N#;AZ3'DB
MALB-),WQTRX?5$\@W60VYMYWJKT_^4-P-&N./(H$<"K-IXF %,@5.V.V[):?
MY)VD6/I?(LT>3EI(K%HY!HQ'87#PHZ-Q.(@Q,9C$>$-DV8H%'P3! 8'$#6B6
M,)MF(T>U;LVB&F,:I((Z::_)KS,DL2Q-DDDD^22;)/[SFRJ% 50 J@  <  <
M #,_R,G'&,<8QQC'&,<8QQC*GVITSJ*W+,=V^9.W?#IZ2AL<@)@Q3_82Z:7T
M.16(EI0;C@TXQJ^;Q5F7R()3.3+LG3]%=TA@LZ336UTVQKC5)G10H",H)8!X
MT>B0 :WJ:L 9@^GCD<N3(K%54E)9(^%+%;",H)!8T3?G]^:B=ZL=-=:XB5"J
M(BH<.JN:#3<)>1ZW91#[A@MGV.^+N6,D'6D-F+*V&MA6<0+GMG9-_)W!NR%"
M15L4R?1=.D-Y$LVXO9.\4UJ"C*M>TK6TJH X I:%50R##!L6/[H1@5(<K(KM
M?NWA@^][-DFWL@W>9@/T.ZXBX9.(:] 3"7;V;+:QF]C3BP+-L*>6C-SU-2\!
M.:Q^$%E2N1E9@X"0V0QH8X!Q=N5;1A@WV)LVXA-N:+Z/1GDW*P*C:'555555
M#@J]* !; FS5^.>!4C31!66F;<R,S,[,[%&#I;$DTK 4HI1SQR;_ '/NI_4Y
M@/[(32>Q\)%1789[7LDOZ5%9D1BHHJI5:X]>'/71=P:8,(HR'D&:3]]J*6$M
M"Q1Z1?EM7CTH\67++*>VJDGMAA&H4'[U[N*Y)!(LV0*JJ&&AA E9@ )=ID8L
M0/96WDFE (!XH$\^2<WZ@0G79:!2W:@Y!"+"@=@3^Q9O,CT6FHZS!$HG-CFW
M<AG*Y:0M2IUL\5=N"GA-!.[O+40#2& V#1H(8L6B59#)N&\%64*H!4J0% "@
M"A5 >?)/)Y-Y:(1;3VV5U9F9B&#[F<DL203]:'T% < 9VZA@U&0JDF]+UB3"
MEJ>K(.:J989K-5)@VBPL BX'&(,</NRY(@R6C#!?8.Y%E2.CX"/1;L%=&J39
M'30[.SEW!#L0_P!VK)Y#55<^?%'SA%C6/MH08T!2MVX #@J39(VCBB>!QQE(
MJ\Z[^3E-+1"OZP[ 8/DV%<#:81C<%[K2Y_(Y]4T9*R(Y%*VF*,7M+V_.(O"=
M91(1,59$-W+D'$R+N*(.L1G?<9G9I-0+9HZ&XO;0J KD %A:4&:@3]2+JP#F
M"Q:;VJDA)"B.EG8ED%E4:GM@MG:/(!(!V\9.9:C^LG5NMSF@@]6=0>W>OL(Z
MH1(Q?$P4*UXM#JM%66O4\+/")K+!3>5CPFT_F"IH:D6:R&4QW=TP?%=D&#5=
MG3?+*W(9ZD:5@BTVY]H9AM'!(5:-4#R!R;T[4,*&BJ7$L(,C6NU ^P$,P! W
M&Q8)'!/TH;TWZM5M.KFVE$FE77.: (?U>GG7DE4]8]R;5[G,9%$;.,P30YA1
MG;:+)2GZ>##(<H!B%:@6QE)3:6$-3$CWR(%HNMY965* D4F59 [0K"05#4;0
MG>Y+6S&O' YSFAA5Y+8Q,%A>(HL[S@ARM\.!L0!:5!?WC9X&>A,=Z$==00F:
MA2 ^QYZPG%22.A'FMIW-:UFN(_3$M11;R*NH4]FLO,O(>#+IM!WM)P!79FR&
M0X++\LZ]AB?!\YGD)4C:I5Q(-B(MNOAFH>XCXNP+/')OJ&FB 8$.VZ,Q>^1W
MJ,BBJ[F- CR1R:%DT,QISR?/7N0LV30@[NI+?:OPU5S(@([!W-'RUN5[']B>
M L:N0D!F@UU9:(YJ:+"FI.3*/#J0$D\CVI3 )PH/VD:B0$GV?>+@&-"$8U;(
M""%\ T.+%U>#IHR /UG"A"1+("ZCP'(8%^.+-FN+K.W;7D_>LES*R?241F7A
M T[@X:NK"B-<6C8]7PFQ(G&!*P*(L)S#X#)X_'I*M$@ZVHD _(CU7S8.U' W
M#AT$%CAS6%U$J51!*L64LBLRL39*E@2+/FC5\BCSB3312;MP8!E",JNRJR@$
M#<%(!H&@?-4/ &7,:-46+1LR;:YT;LVZ+5#3.VV^=$6Z>J26N=]\YVVSKIIK
MC.VV<[;>;SYSG.<YYCYS?QG8XQCC&.,8XQCC&.,9X0=T'#RO_*>5AV58.5VS
M?K?U?KB3S_1+=QZEY25A=AII4-P*$44O2T6'0R-SA&W%?6:9V3<5FUREOIY]
M]%.V&FTS1G_Q)&"_^=8PZ?F04_\ ML\Z?VZM)?V42LW_ -C:1D>_J%#;_P!Z
M#(!L&Y9W#>S?<_O;#'S160K^3S[<F:(]K(>U@+.O.M%O5G!H"_R-]=H@0#S*
M= + M)JKHXU]I@9Z,QMLCHDFFEJJ!HH8&\?:(0]<'=*CLW/@$*52O@J?KF3R
M,LL^H7[WV68QV+&R*1%7B^06#O?%AA=9;CRE5S2UV$[$T1LX$[0C7I-"+FV;
MZ,]/;&LM(=D0T.\1E_A;.^!*HAEG1%GE'T,NDE5M5MLZ[:8RTZ*#&_.[OLEW
M_5$9/CZW\YOJW8K)'8V_9UD\<[NZH_(C^%YI "26-%+I[!NY/)X_9@4SY8*A
M*\! 9I!!)+2#LS-)T^43-1)\Y>.EA!T*%*B @%ZS2;["W@=[(F_HD)$023DA
M2D8 *D:-V+*2-QWR<$#@@\W?FZ^!E S+)+9#@Z^) &4':#'&;7Z$ \5X-GR3
MDF4IV<[4+PSJ;?%D6/6DUA_8_L&3H<W4L:KQ,"M&110U9H*(2R-39&1OB9.9
M1]]!&I*PQ),7O'U0#@\Q%CPA&.>W2]'CBN5%5@T<8<,6NR A8%:H AB%(-W1
M-@T-(Y9ML,CNK"64QE H%"V"D$&]P*V]V +  (O*B]9^T78$=3W63KS2S:;
M&$"Z451;QB2P>@6U\EY')+#E=D1N. S XE.X6RCD #(UV]<'G0S*TDD3XLFP
M%GHI@,LN5VDBCWR2/M.Z9T :3904(20=I)8[J%\"K(-\<\,T@CBBCW#9 CDK
M&)"2[. #;*%4;3=63?!6C?HIV)L>4V]Y(2_[.G,50A$TG'0RWY#+8DU>)$&
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M[J61Y7D4S?JF("LIW*Q%%MP0'=M(!(%_%9FJL8-(LB1)&XT]3*"75@$9 UJ
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ME)J@5()OQ0(LW\5D+(C LKHRB[*L"!7FR"0*^;SXQ>]*2G 4M)85<55R^.
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M:T11]QB+H*K.Q +$*HYI118_A8^I( .3-+VD#!=Q9E102%&YC0W,;H#Y-$_
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M_9DYD=95C);&=6Y(J9J0N\:YA=6&K&=$#/PE>Q_1N_?>9H>D0P"W+H1<3(#
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MB/\ IPXW=-_9S_G_ ,S';ZS^VTWY#Z?_ &'^'_#G'Q/_ (3=^=3T[_N[$?\
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ML_N!!IB;*W7B@*&;O7O5NCJJ)0HK7\+Q''5?5E+JAB^4#9]YHVA4\EX*>S%
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MN4Q*S*9@%V JQ5C18/M5@06"$<$W0)$FV1VNC\1LXO35<4A<78RR8F #2:P
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MA,"&Q"521R.>%PL;*LHG8LOG-:GI,-8/%XX,MB&P5R1=(9#;ZMSZB(E75H"
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M98E$=)";$#7K M'SA$B*'HZH,DMN=#S1#88V  T\H"D7L=W9Q'1!!JZ!-@@
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MP-;52"Z:SF"7.@2@X&TYY9;F$O.M4,C8E^+1L67Q651"R-9/8VA4"V*IUI'
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MVF[\R##T_ #O2QEVX]'&OB"GHYQGP7GSMG/I^EC.,8QC&N<9SG.<8GX_B?\
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M=P\#]PS+<C)QQC'&,<8QQC'&,<8SS@[8]@#-8=D:::-)(7'5_3/7+MYW O8
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M#.Z@V[$.3=%1@L4T8T6:E"2(LJ@DKN+!ELV:96!HGD@V+Y%6;NT%L7CD>)B
M&V[65@HH6KJRV!QN !H &Z%0A,/)B0N2PR(19AV$O\*5!7F:[)R^;/EZIG!N
MV;J*!!<?'32P8_/*ND5<N=H>/$,=H4# P<%'HR09C3(X4D;$C23;1=4RL3VX
MR#&(E7W*$0$DJI5@WNL[B6)()!-',VTBLJCNR@B3NLWL8O)0 9PR%#MH;0%
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MEEJEVXE :G/UYJ6=SE$JB(T:MI-E)XFQPFEJCR.^_=$HJPP8+SM 6@%J_NT
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MC3$N3S!#S\].I:^7;"6ZHI(9&I6YV)I#-GTZL\CGA3*R*J-&M!0"6.X@4-P
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M=8LDDDFJP0]J.4N5>D<ZC<=S$T268\%7)HJ1MHT .,U:@NH773L3.N_\NN"
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M/-.J6'&:'[)=-9:PZD+].X?-FD^@1J10RX EB@.P<ZD=-'SU?53/(=&R;?4
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M&)G9<CD\5BL4CD;+Q%H&'M!@"NM@+N6*F#1@HX(2QM&'8$<Q3V-[:Z+,%BF
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MPGP-1*H4 H-@"JW;C+  D@!BI;@DD&[%\8.EA9F8]RW;<P$L@1B0 ;0.%-@
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MJR8B00 (R6(EBQ)XMIJDV8CV+==TY64SC5-%+?;/Y/-RRAF(5;))  %DD^
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M?0V_[/DV?J?SQCV4+^;6'T-O^SY%GZ_A_#Z8Q[*%_-K#Z&W_ &?%GZ_]>/\
M9QC'LH7\VL/H;?\ 9\FS]3^>,>RA?S:P^AM_V?%GZG\\8]E"_FUA]#;_ +/B
MS]3^>,>RA?S:P^AM_P!GQ9'@D8Q[*%_-K#Z&W_9\6?J?^O\ Z!^6,>RA?S:P
M^AM_V?(L_7_H>/RQCV4+^;6'T-O^SXLGR;QG'LD5\V#_ *&V_9\FS]3^>,Y]
ME"_FUA]#;_L^+/U/YXQ[*%_-K#Z&W_9\BS]<8]E"_FUA]#;_ +/C&/90OYM8
M?0V_[/BS]?/G\<8]E"_FUA]#;_L^,8]DB_FT?]#;_L^+/U_'^/UQG03&#<DW
M>N1['.NK =MKKEHW\V-MG!7&VV,>K\V,[8UUQG./ESC7&,_DQR;->37(_P!G
M_5>/]>,[WLD7\VC_ )/R?\S;?)__ $^+/U.,Y]E"_FUA]#;_ +/BS]3QX_#&
M/90OYM8?0V_[/BS]3SYYQCV4+^;6'T-O^SXL_4_GC'LH7\VL/H;?]GQ9^IQC
MV4+^;6'T-O\ L^+-W9OZ_.,>RA?S:P^AM_V?(L_7SY_'&/90OYM8?0V_[/DV
M?J?SQG0&C!NS7;.P]CMGQ9#7S[-&^<^CJ0=:ZX\^4\_)KKC&N,?DQKC&,?)C
M'(L_7&=_V4+^;6'T-O\ L^+/U_Z\_P"WG&/90OYM8?0V_P"SY-GZG\\8]E"_
MFUA]#;_L^19\WS]<8]E"_FUA]#;_ +/DV?J?SQCV4+^;6'T-O^SXL_4XQ[*%
M_-K#Z&W_ &?(QCV4+^;6'T-O^SY-GZG\\8]E"_FUA]#;_L^1C/N@S:-L[9;-
M6[?.^,8VR@@DEG;&/EQC;*>NN<XQGY<8SY_-QC.QQC'&,<8QQC'&,<8QQC'&
M,<8QQC/YR[$DV\!8W,E1>_;*@.UKRQ+0?LNA+NMYCV)ZLWI-3TV,O&A<-F4U
M&K"1=97LLJWG4LG%>V)786 NI7(WDARR*BWV77H*-VSN=J2((OZX.L<L:@#@
MTVXNE;0K*Y-#;8SS&)42=H313;W(TY1I(9&+&B+3:$D)#%D= MDM1LY<#:PG
M752V^YB5S*SRK-^S4NA-N5'V&C%0S&[(6(6;T-654D:U)*1"+25J.D5<RJNC
M)B/1Z:,PH^6@I8V=@-W[WVVV;9;>ZD)0*W:!1XRX1C[W<,-Q%A@P!*V05H@"
MKUW&%YP^Y.Z5>.18VD4'MHA4[0:*,I(#4&!%$F\A!OW(NFFJ')RV5P$_*+$M
M;LS8L4ZY6W-NJ,_@R :H\PR'."G86W*FK""$K0&M'9GV\T& E8V#F%EKJ1EF
MZ6#1U1Y(Q-S"CR!0P"I&ID595:WW']6CL0EU7-E5Y\G@T[\B1V5+,\K"-VA=
M=J;03*\:*7KR%%!G- D V)MKJRJ'J/KC"P0>2]E#\$MR77#\:O<5A4L_A,]C
MEW25ZVG$IF,NC1NNFTS@S6S31,F)B!X9 W,#CNH<-#]B[=3<"HXHRR/(Q(C#
M($VP[E*E![0H(;:VW@D;MQ)+4><T5HTC5092KL^^?8ZL)"=Q8@KN4.; .W:.
M%LV,T6E9^RI_JE *BML+V,J.K9D7["@JT[.P^!R,#9PB"A[?V/UF8M1D,B<@
MF=?V?V!BY!_+',C.0L3I*2S,FZ*M(_,I.,'8M(N^5G4QLRB,M$6M2=E.%)(#
M+&15 ^T518 G*QMVX5C<2HC&79*JD.%$EJ7%,RM(IO<5%\D[6(&7?\GH%E,:
MZ?4]&I9%W\05CC67@8J+-QM:'2A]60>?RH?4LIFT4<Z)/(]/IM6+>)3&>"G[
M9D2:R\Z:U)CAA#+D<UPU!!F<@@W1-&QNVC>%/@JK[E4@D%0*)'.=&F!$" @B
MMP4$$$H&8(S*>0S)M9@>02;H\"Z/,<WQQC'&,<8QQC'&,<8SQP[UN+)=W9<$
MTA<8E)9UU[\G3;(.JW(8 5>Y=]@NX$['06+:!7#5FI[0*QD=3C)P53';KKA
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M@S=09(T33+)''( C!CN;<OZV2ZVN%-<-17GZT15UCE=]6\4KQ%I%*+M38_\
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M'8@*C,6LJ I-@&B10Y /D_'SEFDC4,6=%"UNM@-MBP#9X)'(!\CQF'+=BJ
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M#=%=U'98-(A^]&0H YWL75%5>1R;+#YH'CZ2-0I2%P#ME!;W<;$5"[,WGA:
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M92:_ZXF,17#2",0F2/8HM)4#08FP<PY8HH =/FQ$4XUUW:2)=G:92JZ:4 .
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M+9;?1.@<B19(J$,0HRINM(D##;=@V"*XL_B>6GD* QM%,&,TQOM.5IYF926
M(HA@;NO/TSUJYR9VXXQCC&.,9CTOX5>_U>,_Q);D_'\3_N_Z_P"N69#D8QQC
M'&,<8QQC'&,<8QQC,>,_>NW],)?YB[XQF0XQCC&.,8XQCC&.,8XQCC&.,8XQ
MCC&.,8XQCC&.,8XQCC&.,8XQGA:VH _<772&=>GL6,GC%/>5;L$Y?8\/)'\2
M-,(+).PELWDUG&)"'.1Z2,D3M4W!7DO:O )1$YAK($4QV=MF^WH=QD"RF2P
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ME,NZ-:SBRQ/6IO!H^YD"T*[F];+*E";9PQ;Y$0>%37).42!?+YTUU6;"&/\
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M7N6'M!NDDW(Z-LI)OVZ::#S1=+373&B2/'9C=TNKVDK=<\T?@^//\,H\4<H
MD1' L@.H:KX-6#5CSDFB1NH 4-! @ (*$#,&8H.'$J:CA8H6/;IM& T:/9B$
M6C%@Q:I)-FC-JBDW;-TDT44]$]-=<4-$W9))LDCG\3Y-G_J\L      !0 X
M \ #X S(>M)^YLOK%;[MXX^I_+_CDY@TX\P2DCN8IQB/:2M\$8QMW(\;X]M+
MQ\8^($QX10C[*\5D6T(E2+Y)EA7#?5V\7<>KRKMZ7)OBK-635<7XOSYH#_KS
M%"RU"R +^:'(%_2R37UYS.>M)^YLOK%;[MY''X_E^?S_ /3^&3CUI/W-E]8K
M?=O(X_Z'_'&/6D_<V7UBM]V\GCZG\O\ CC'K2?N;+ZQ6^[>./J?R^?S_ -?^
MK&/6D_<V7UBM]V\<?4_E_P <8]:3]S9?6*WW;QQ]3^7_ !^G_I^.,PAB/,9
MY /3D8CQ9Y%36LCC+L@IATY 'M1I(-@P'76$[*CB60YDN*W=M-TEE!I0@QWW
MV:O'"2D@U=$@$4>/(X-'GZB_X _N@@&K .TV/P-$6/QHD?N)&9OUI/W-E]8K
M?=O(X^I_(?\ KDX]:3]S9?6*WW;QQ]3^''_'_P!<8]:3]S9?6*WW;QQ]3^0_
M]<8]:3]S9?6*WW;QQ]3^0_\ 7&/6D_<V7UBM]V\<?4_D/_7&/6D_<V7UBM]V
M\<?4_E_QQCUI/W-E]8K?=O''U/Y?\<8]:3]S9?6*WW;QQ^/Y?\<9A&L>8LI
M8E;2,1YM)I /#"3<@14QH8*BHZH56 C'Y'43ATY'AESIM<8R55V;,ES!1=NF
MFJ_=;JS?%6:%D"N 35_/%T,C: 2U#<0 3\D"Z%_06>/Q.9OUI/W-E]8K?=O(
MX^I_+_CDX]:3]S9?6*WW;QQ]3^7_ !QCUI/W-E]8K?=O''U/Y?\ '&/6D_<V
M7UBM]V\CC_H?\<8]:3]S9?6*WW;R>/Q_+\/W_7_5S^&,>M)^YLOK%;[MXX^I
M_+_CC'K2?N;+ZQ6^[>./J?R_XXQZTG[FR^L5ONWCC\?R_P".,>M)^YLOK%;[
MMXX^I_+_ (XQZTG[FR^L5ONWD<?/^R_]XQCUI/W-E]8K?=O)X^I_(?\ KC'K
M2?N;+ZQ6^[>./J?R_P".,>M)^YLOK%;[MY''\/W?[K_WXQZTG[FR^L5ONWD\
M?!/Y5_O.,>M)^YLOK%;[MXX^I_(?^N,>M)^YLOK%;[MXX^I_+_C^[_KRQZTG
M[FR^L5ONWCCZFOW?[K_WXQZTG[FR^L5ONWCCZG\O^.,>M)^YLOK%;[MXX^I_
M(?\ KC'K2?N;+ZQ6^[>./J?R_P".,>M)^YLOK%;[MXX^I_+_ (XQZTG[FR^L
M5ONWCCZG\O\ CC'K2?N;+ZQ6^[>./J?R_P".,Z*:A'VF\SAHSSMX =C.,OUL
M8QKAP4]'.-O9V<YSG.=L;:^CC&N-=<XVV]+.-7%>?K_NKY_Z\?CC.]ZTG[FR
M^L5ONWCCZG\O^.,>M)^YLOK%;[MXX^I_+_CC'K2?N;+ZQ6^[>./J?R_XXQZT
MG[FR^L5ONWCCZG\O^.,>M)^YLOK%;[MXX^I_+_CC'K2?N;+ZQ6^[>./Q_+_C
MC'K2?N;+ZQ6^[>./J?R_XXQZTG[FR^L5ONWCCZG\O^.,Z U0CX7/HM&><>+(
M_+L_6USY_:#KTL>; _;Y,;>?&,^?S[:XQMG&N<YUPX^I_(?^N,[_ *TG[FR^
ML5ONWCC\?R_?^/[O]?TY8]:3]S9?6*WW;QQ]3^0_]<8]:3]S9?6*WW;QQ]3?
M[O\ ??\ NQCUI/W-E]8K?=O''U/Y?\<8]:3]S9?6*WW;QQ]3^0_]<8]:3]S9
M?6*WW;QQ]3^7_'&/6D_<V7UBM]V\<?4_D/\ UQCUI/W-E]8K?=O''U/Y?\<9
M]T-W6V=O$(((XQC'HY1<J+YVS\OGQMC=JWQKC&/-YLXSMY_/^3'F\^8X_P"A
M_P <9V.,8XQCC&.,8XQCC&.,8XQCC&.,9X(SR[KV@\SLDE>G9;L#U6N(?<TJ
M&T\WG=-A"?DY9'6J<_=)58(-VA&*EEN4V4SK;(3$XD<TMF!V!&YN5*)CFXEF
M):CW'<J1L$"1I(FP%]KG[0&V6]*7 -->T!&! XY\>:TDBLYEEEA<2'M[D'V4
MH&I 7$;<,M;BSJP8\4!EP!&MO=P+B[-LQG8NU>OE6=<[7'41#X]2;.M6,DED
MX&U=7UES"PIW)+"@-B+D!.'-G"X]$8B):@0^[".NC!Y,WN;;I,,CLA2*XUD:
M1.XQ?=07>RA5"LM'VDEN3SQ59N-\[S5*\21/VE$>VRP179V+(Q-;PJKP*!)!
ML5B.PUV]EZ.ZR;50TF$(L#NL^K"V9+FQ0D?V'Q6+5E6K8V^)=B)A$5$=60HH
MG'4XR%815NGO'3UX21B'$([05H;<AT:1/+OVL(=R#839+-51J;LB[.X\A!9]
MQ *62:.+8&5IRKG>!PJ+9,K+Q\4-HX+F@:NM?[-W7VMC?D^*KN.H)'"@QYU3
M%53FW;1E6JY"8-=S+"N?$,(#"FH/X,/3\X>R U[1DATHP%PIBS45&Q>1D"K+
M(.8DB,[(X8C>P110!K=]XDW0H4!R;\BN8EDF&F1T*@]M&=VLL/N'VJ!1+6;)
M("_ -\8WOWV!LNO+D8P>.6/?<,C KK'8=PCV/5BJ8C<EB/+* 21N,CZMM@3\
M#L9U%ZD78IKH "BXV)161GT)0PD<Y%X!,D5)@C1DW%8R3(J'NNR+M(L["&6W
M^HY(%4#>1J9&60*'E4")G A178L#0W@JU)0X) 4D$%A6>CM!2Z0S^BJ7G4N>
MQ4E+)G4]=RJ4D(*1;%X2]DD@B <L==0\JS<O6A.+KE7;M0"_;/'2#L5LU72<
M+:*:J;<\@"NZK8 =@-PIJ!(%@^#7D?!SJB8M'&S%2S(I8J;4L5!.T_*W='Z9
M+7*9?'&,<8QQC'&,<8QQC//OM#V).U5V,H^/LI(L)KF#49VR[5]A1K- >JJ9
MK6F8;&(Q&A#MP\;+*L$'4SLC21,U&;ADNY>0G*"JRK+5X@IO%&'C<D6Q>**,
MWX9V))KY]JUX_K7YSFFE*2QBZ18YII?Q2-0 #^]GL>/N^?(S9J-[@2"U[/@M
M:R^AI54CJSNO&>Q<+7.RN.R HE&QYF$QXV%FP((GG:&E_:<[$K1I-4B46-#&
MQ38PTBIP<ZCZ4/$$5F#A]DG;:E(%D,05-\CVF_%<58-Y,<Y=E5HRF^/NK; T
M 5!# #V\M[?-@<T>,V"QNX41K%]V0%'XL?<EZ !U"6&!!2S1V9ME_>OM<)5T
M9A3#?U.=9!+K&!$ZX$M7BN45CB2;E1PBTV6RWA82W;H@"0N+/A=E%B?P"G<?
MPR7G5.Z""3$$('%N9+"!?Q9@5Y^<C2O.VS0OV0DT%,#IPT82&T2'7UCL4/Q)
M[6\5M"H.O8F_)XUB.6$;$R)U[3'RL_'CI0Z:)MG!:L'"PA@%:8=H*7:*HP05
M-+W.%(<H\AC7=R1P5!  XWT2<JLP,K*0U%S%9(V!XX^XP6@#R"023R4)% <_
M*/\ >\M:+\'':%H20V=*I-&Y-:H1L4FX& QO6@6$T,P6O+:-24L/(JC,7R4C
MATG3$4:A"KX]%QCF1R(A%!R+C= 8 H)DD"@%5-*6/<*AF0 $7VP1O-T"0!9(
M&0NH,A CC+$@N+8*.WN*HY-$CNT3&M<@$D@<YBNR/:XJ;\F=9W;.D'$F@\@4
MJ!U,8LF]8!5Y=$Y Q,("2X)XQ54,QYR="EFQ4$X]2X)"'#QMNLR>.6BB#K9'
M$!J4BDHC> WG:0>0?@T00?KB68G2/,EJ>V6'C<INB.+%@V/D7]1GXE7E%&-0
M-;J;=B:3D]1RVJH/4%B HHC.H#,=K!CM[V&<J6N!S22-28>+QF6;60!<1J7,
M#I76,QE)9*0IS$Q&DW)9"5TY?9VW#JS.I.TC:8U#L=O)(VFQ7+>*!XP=4$[@
MEC*,BHP7<K;A(YC0 BE!WBC9VK=EJYS5$_*BQ1E&;'W,5?J<LNN3'7EOM7M.
M7!6-Q#YD"[(V^/I>&D8?/@I(3']CH>7.'C.4165HQ1P-61%KZ$5P,A%R!0-,
M2RT]*W<]SJR[3$G<:U()HC[I%WSQ8(ROVQ0&M+=3$-J.KAA,XC4JP(%AK!4T
M>+%@@Y^B7E')[%U;43F_4*:1]#KO8%>P[L,59VQ7!P/#A5J-X81ADB@:R&[4
ME9:^@2;BC$H!9$Q)8$@DX:LWYQ]LU;. TZD*1,I[BNT8*L"=E@AO(6RI Y8$
MUX^!U3#?<##M,JRG>A"[]NTK\MPP)%"A?DT#N%N^4(1IBSFT6F5/K!H"M<T&
MI%*4R&UZ]CEDGC,]D<>B0N<02BG[G:73&L&I^2M$G4B;DQYUP(8&I((B9,"P
MT?N833[UL/[MC24%8J H9BI<<!J4\55TI(/&6DU/;8!DI3(L=EU#$LRJ&5#R
M4MAS8- FJJXUJOO7="CFR8I,J?WG%J23NA<O7_KU!([,HH'9D8_604C)Y&XE
M\F7%-&L8C%=14 N1,RMTUDAV2%3PT0%!.WCAJTUN\">TJ]((4DD8@\%R  !?
MN+$B@* ^3E4U#VRLFYVG>.-0RU2"VW'X" $DD$DD #D9(V/* FWY2&UQ'^M\
MR)7X>NFP:"EE5O9O$A0RO9U7]7B;C<&S%@>B^%$ZW-UU(8[+ TH#BW!IR*.,
M6N(AF3>NC:5?LX +&0=L1K('"L=P9ME!>"&#@@@D#@FZHFWVDDA!$QD,C1LE
MBD94#V6\%"A!#"SR 5!L#)C>^9&6[1* 5_0<GD79 Y++CB$KI8K.(E'A=:.*
M#=Q1E9$@E]EI^VA2L3V5L&NMH41CX(R6EB4^CBFX$-KH>]AP8*MF<",!"' )
M+=RRH5>/=2L2"0!M/)XN1J+*HL;&4EP8]R@+V]N\L]U7N7;0).Y; %D1X3\H
MU60XE%+&FS>UZW#PVF^ZTAN*MG*T)?M(G+>JTUJ6)3Z-21DQ9E7\IE[(K(/4
MU85A\V%1@X&D#EZ79/U307(&PTSD,%VL2\*J?<+$JL5(-@ $?>W*2"!1X-YG
M5):LW<0+'J"ZG;[6A*APP%EF%^PJVT@V;L5%]J^5$D.]%=EMH1!XC$[WAW4N
MV^QM3(A[NJ6Z F@:O1PU"1N9@I"W)5F GE;K2B.20E7Q)F3 RYKE8;%YD<\(
M;4%633 R16S-&TR1O[&0VQ-5?)5@" W!6K*CBZR:PB.4JJB00O*GZQ' "CW;
MMI-,E@E>0;X8T:FO?NF2@,KL(=+X18\AM3,2Z:@8U28>3P(I&R=H=AR-PC @
M:&2#<%%\A]E\0L@=LV4RTZ_ ,(V 9OHX'8.AQ!B?IV=P6F4)<Q+[6L+'L)+<
MF_("  &S1)L5H)RK.&#%Z@"QAE(W2;Z"FEK[I9R20% ('F[FTI9D\L1A+6UE
MTS):5F,+D_P=?B"A=A+(K)FK@*)/#Y57<[%MF#.6QARW+8%NUG D$8#R04;"
ME S;9FW<O<755K:X<,+L @CDBF4^#Q?D@@@WF\;L^X/&T;*U42&# @$,K#@C
MFCX(((.37RF:8XQGF%W=F%T1NVZY;/9%V@KOJ<K7LD>R^Q>G]<";,L=A;Z$@
M&X$,[''8K^U9P"K!G#=21%B0@L$=^T9&HLVE!1JP9CV9#J@5"C4L32[AM65M
MJE/G;[D4L35VPI>1\YQZAI%=+:98=I+- @=MX(H/[78)1L;5Y-V0 +BR(7W;
MMI1GK!1=;]K@LX<7S8_835]VKA\+C[.S15&T8V3)_!<O"9/#V4,B799RXDL1
MA4O<%ZY0$@-&,DD:$$0,*,VS23&JF5VB([:Q_JV8E=\GR"ILQT"RTW-@;B/-
M5DD=88TF#]QI+F50'$<?-%2 JRV55@5H43M!-#;>R8;M+U.ZQ]O9B [/R^QX
M@$HW>1U1*+)'0I_>596@S).T#?J#T<@$;A\K@[\0Y&/A"<GCY ^$-M7K79P1
M#NVZ3*(S%++"#$%8R4X4ML9>*X+$@V#=$ @^+RTHFABG83,RB,LA8+W$<7?*
MJJE:H@%2;NR1QFV3D?=?3Z==>I/CM%<5^UK:U\PFA+$K^]!-.$7S+%JID@T0
MFT E-8555Q@.6C,O0#^W!!K,B!FHN_,*:-AA,>R>;P"DRR#M)&R(TBM'O%[*
M+*P9V!!6Z(HA@.2#62PD@:)N])(CR+&R2;#]^P&4JB&PU6#8(OP<]-^<V=>?
MS2U%V\M!&NNNUH[=J^W9^VI]>-<Q&<PZX:$#QKIMM$Y)=*<3F[=6["O6N"1T
M*R9P+#_>&FX_>9LT1FZ84$+921V2W$[^D\2W(G:A"*CLK))<Y(2U]@D8GW4&
M!C%+9)%9Y,<[U$_>G+M(BLLD06"C( U2&) *2RI$A):AS9&>BA_RI56 K*E
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MLEC:.8QA %O9(9?)Y;:%7C_W:L?-DW\5SRZ<2F0ER.Y$L55]U0Q9JYYWW1_
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M7N]:#JR%G/\ DY!(60T=EEODP_5?;MM31TDX:*/S#YSNEN0)/7CU3T5%LXY
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M_&*EC$@VF]?,069<W@1N;%=EYC&62DML(ZN^,-4=&^6G>@5)"EJ FF+;F7<
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MYVRR+]\JNT1K8W!2QW$;>!3&ZJ9>G9.P[9UEUG(MK%IQY)^EO2.3/JY?$Y4
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M\Z\D<F?.QT=,Q63&,LJ\W61.'9*_8EA#5Q(TZ=QE.]:0,J.T:,Y+40LA_5L
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M8QQC'&,<8QQC'&,<8QQC'&,<8RCD)ZC"V*TK@<Q0W?57%.UK?MU0BHHVJS(
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M[0*V@+Q0-$ 79 .9_9HQ14NC ,"ZN0S!FWMO/AK8DV18).TB\RQ'H5UT(BM
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MR/Z ^CO[!T?YS_SL?BN^@?YLD#^E2C/_ .4''^,KUR/_ ,H];_F:8_[8,?T
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M !@__-Q_C*]<_P!X];_F:;^1_P#1\8_H#Z._L'1_G/\ SO\ Z?G./Q7?0/\
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MQE>NO[QZW_,TO\C'] /1W]@Z/\Y_YV/Q7?0/'_HR03Z5*,_^^0<?XRO7(_\
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M_P 97KG^\>N_S=-_(Q_0'T=_8.C_ #G_ )W_ -'QC\5WT#_-D@GTJ4?\0?\
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M2($ZV9&@3_9HJKJT+"7FFS4D/7SHZ9.-=D7"2:F,Z\D@CR"+%BQ5@^#^X_7
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MNHJ<[ EJ!I,O.I2A*FMC&93M4$H'9,DL2C31>6.6Q30I,P"=R-E.Y6*@W^I
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MH^OMOU"]%2"*WC:_68,'*D6#S9$E6]Y3.+#E2;)KNN.<L"KB,R##D=N^U_\
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M]A1:*J'XHVC/CK%GWQCP,H];OPYAH?VBDF9>'8G&YIPD[<@6EQV'(55D4[U
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MKJ.**)Y>[[ZC_39.%,*ZUCC#AA8!!0 DTH+.%MB >.?/QYRTLIC,?!*D2,P
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M.OU,7'--#,JD%TIUJ:%0[6TA2!J:*2Z,M%I')A<(C821:LATJD]>SPIW*J[
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MK,:YE-$#(HW9,Z^$20BQ"K"K EJAAP[ *M-W: ;3VHP4QHW(6CB[D3L/OJZ
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M# :N$6.J?MTGE?9&D",L>X6Z%F4D$FF"*2"."2U#Y/GP,PD2(R*TA#4C[48
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M,IMUU%EI>['06 UA&G'P/9F68P@E!ZW! (YM*BV#Y%>83%TV<G91OH(9NW"
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MRXTVS1<]$+(%A!$9W:AEDW*I/;*Q#DL"57EC8JB";^G/.LA><KW/9ID:+:7
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M1]QEX&P!>31)-D*U4!0NQ"-==A;RO)6A:>@-YU$]-32%WY:$[[(5U"G)=(A
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MDB8*KV<G/C0EK% 2C4P,>R=)T@DI;[*QV4P(??1V2"^VNX[05!>Q]T+9)!!
MR/M:C?:$,@0D;XR!W&*C<P8JFTCW[C0'@MFQ3+RE590H!6SLM#G+*56'&YM-
M$8F>M[KO$&C6(0.38BCLX%GTIMH57TZTF9';5S63>&R,MO)A.=B9O>(MT'>6
M\+IF8L >%*K820DLPL J%W+0^]N H\"[&2=4@"VM,P9J+Q**5MMABX5MQ^[1
MY')VY<BIK;&7*  SF( C.:SFE<UO94 G[Y8*D-F(JQ1A$UH.9AD"KB3"2D:%
MHA')S4^'&,E=I*P;AGA1PQ-)C<70H2K$;E9E9>;4J:Y- $$W5$^.:L7LD@D
M90=C(CH_%,'!- 78*BKL#R*^:\Y#O9+L+&+[,@K)LQG1>,]C1,%K6O+.H.3H
M]=[6I,G+!0,*]$=J08HX,8W7.(R[=%HX$*2@(BPL-85 "%?N62FYUST"*,H"
MJ]S]668K(.XK[2>8C1**:!H&P"=U\9S-+(LA#N(_U@5%>,B-T+ "I@" [*>
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M7D$>>*I>EYM'P(X7$/D<INQQ%VT617WQ8;6*V#1JQ='\P#_ @'.A&W*K45W
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M"[+&Q';#.&!/"[R/<U L0NXT/%5WISHY:DRFIB5=DI)8S40.K"AJ[B@H[:D
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M"L)IT1M^YBVYG8D* Q9 AM550/:!X LBS=YKL7\GA3L!JJ%UI7LJL>($:WM
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LC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g457972g0315091637310.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g457972g0315091637310.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  1 .T# 2(  A$! Q$!_\0
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M^52T44 >8^-/^2Q>"?\ KG-_Z$M6/BQ]WPY_V$5_E110!K?$S_D0KS_?A_\
M1BUTFD?\@6Q_Z]X__01110!S/@7_ (_?$7_7]_2LOP/_ ,E2^(/_ %UM/_09
M*** +/Q;_P"11M?^PE;?^A5!\5_^/?0/^O\ _P#9&HHH N?%'_D5[+_L(V_\
MS5_XD_\ ).==_P"O8_S%%% $&F?\D?M_^P&/_1-5?A'_ ,B%#_U\S_\ H9HH
;H \3\)?\G#77_83G_P#1M?4U%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g457972g0315091637763.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g457972g0315091637763.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  , *0# 2(  A$! Q$!_\0
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L?^S=!BO;=+B:(28,6-DKH!\S_-PH.X8'..U%=RJ*@PBA1DG &.3R:* /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g457972g23i89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g457972g23i89.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5'J:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 W+C$M8S P," Q,38N
M,SEA8F%F-RP@,C R,B\P,B\R-2TR,3HU-SHR,2 @(" @(" @(CX*(" @/')D
M9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R
M+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(@H@(" @(" @(" @
M("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T
M+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @
M>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+V<O(@H@(" @(" @(" @("!X;6QN<SII;&QU<W1R
M871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O(@H@
M(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E
M4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @
M(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*
M(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B R
M-2XT("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP
M.D-R96%T941A=&4^,C R,BTP."TP,E0P.3HQ,CHT.2LP-3HS,#PO>&UP.D-R
M96%T941A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C(M,#@M
M,#)4,#DZ,3(Z-#DK,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @
M(#QX;7 Z36]D:69Y1&%T93XR,#(R+3 X+3 R5# Y.C$R.C0Y*S U.C,P/"]X
M;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @
M(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'
M26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @
M(" @/'AM<$=);6<Z:&5I9VAT/C<V/"]X;7!'26UG.FAE:6=H=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R
M;6%T/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!
M45-K6DI29T%"06=%03-!1&-!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T
M46ML3D$K,$%!04%!04)!03-!04%!045!)B-X03M!441C04%!04%104(O*S1!
M1&M&:V(R2FQ!1U1!04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#
M=V='0F=G3$1!;TM#=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&
M0E%417AW8D=X<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92
M;V9(>#AF)B-X03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G051!14%!=T52)B-X
M03M!04E205%-4D%F+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)
M1T%104A#06M+0W=%04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=1
M1D)G8TE#46],14%!0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX
M459%1T4R16EC645537!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L
M47I25&MQ2WE9,U!#3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92
M<5,P5G1.5DM"<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT
M<V)7-799,U(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6
M;'!E66U:)B-X03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1
M241"455%0E%914-!341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X
M03MO8DAW1DU(4C133D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*
M16=X9%5K=V=*0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3
M:W1-5%4U4%)L9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58
M<#=F2#$K9C-/16A984AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:
M-F9K<4]K<&%A;G%+;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03=2*V)V
M-7%1*U-.3FEI=%DQ=61B)B-X03MV9S,Q5T8O<U)O3FI,24)U4EA91'8Y1UHR
M:3!F:DAF-E$T=7$Q27A$>DQX9E1F2C,U=V9M86XV574W="\P9$U367)I*VQA
M2S-/-7(V)B-X03M-2T)V:#=F0VQ-,C@X*VXP+W!!,SAU8G)O-',R8F-N8CAD
M16)D9CA!3TXO-6EA96XQ;E1R,GIU3&A+,&IG;6MH;% X07%S-DEV,W--)B-X
M03MG3S%C571I0WE06BM33SA4*VA2.'8O;3,K6FYK:E=&,&IZ2D9C6#A3:TQ*
M65AT5&-!2%E.1$UE5$XW5DQ+93)(3&]S3V%01D-H-6IK)B-X03MJ2'%S=4]8
M1$U8.3<V971P:E!B>%1'3C1J2VEV-E5G-'5N258T=4%44F@P3V,V4E)D,'%9
M1F1I<G-69&ER<U9D:7)S5F1I<G-69&ER)B-X03MS5F1I<G-69&ER<U9D:7)S
M5F1I<G-646UR879P;6MA9DYQ1W S2U=L;$%/57,X:&]O.79%:SEG3GIK;U%-
M:E%&;&I+46E,3'=0>G0O)B-X03MZ:W9F4WEY5W9L1S)7,V=&5B]33C!O959V
M.'%/22]!;R]W0F9L.&AM-S O6DDU-40X039V3C)L,&=0:3AM,6IZ=#5V,6QY
M,G V>&0S)B-X03M)2G(V8E1/27A8*U=.4T58-D)M,&AP.&-/55$T1712:VQZ
M2E-1:VMK:S%*-FY,;6Q..4DX-&5A=$AK16UM871D,FA(-TUC>FA$+W)*)B-X
M03M8:3,P:DM:-$E4-6=&=&IN;DAK4SEB.&LO=T1/4S)O=T]L<C5U='AD=T4P
M3V\R>7%K<2LW>$-I3B]S95!Y3V%Z561K9S<T>EAK-T1$)B-X03LR:C!N.#-V
M,FLV=G!M<C9F1'%';5A+6&1L3T]553A:<7 Y=D5%9'=D>&UJ;D%X3D556&%2
M:TI#=VDX:7EF2S,U>2\W:R]W03=*3E!V)B-X03M(4#%66F)#,$<Y3TU5<V-4
M=%$Y=FEL634P=6<Y3VYS8SEY-E!6*W)04C5B0CE445%1,CA%9'9!9VIG:%99
M-&\Q1D961D9&541W04=C)B-X03LR5%IS=3A8-$915V]A2F\K;WHR;'AF5V-.
M>E!9>65T6GEY24=A2U0K6D-D>"]N-%I/3U-545%$>EEM25!.1S5":S1K059/
M=TA5-'$X)B-X03MY.#-F.#5!*U-.0FYE,'-Z2G).-4=A3TQ5<4E&66116FTR
M4"MW1%IS8TA:;5-9<RMK96)H-61D:F=A-6YY66=0*V-Q:S4P4&QG.$LO)B-X
M03MA*W9B,"M8,68K3UI8.&IF,'9S+V$T,SAP:BMB.7).+TIN-38K4W9-='A(
M674X;6QA:DM1<V-&,WA#3W@O6FIL56Q39EIU2E!B35!0)B-X03LR9&MX:2M9
M.&Y+=S9Y17I827!N-2]W1'I6.'4K4C4W3TA6<F4W;F4K5C-I*W%P1S1!:DE"
M-65P2D8O3C)Y=E1A3V5917A),C<R9695)B-X03MX>%9D-W-S<V)U3SES<F4X
M:41,1F-X2DUG86=93$EO659O4TLP3UES;S!A8G=70U,O;E8U8U1Z,G9K-S9P
M9"]81&-I>6$V2W@K:TI7)B-X03LR5VQ(3$9A:T-T37I2;THK1C1L:7%T>'9Z
M8V9%-$XW5')Z<"M9+VQ4>61#<F%X9$@V>DE/54YJ0U!5=4A(4V]3;T-J,UEG
M92M5-F93)B-X03MZ>6XP:C1T;6)01$=055AL9#$O>FQ414IQ5W9L>&YH0BLQ
M3&1H1TLW+W-R1315.4\U>EIX-T@W-69:*S%W2F1P:G!(-U=795,O=T1N)B-X
M03M)1'EH-6AU;S='.5(Y1W8U4T9H5S194$$W1V=#<DU/3D=0.$%L2T(W,7I&
M,4A:=51'3$AQ1&LT9&1#6G)K6' K835Z2%EQ>#=Z9C4K)B-X03LX<2M5<EI:
M9&%V5FAK:T998E9">FYK+S%9>'94+TM.0C<U9F<P,#AP.4EA<W5A34)C:3AS
M=B\X06Y+9E1)-6U';BM8-7)I14@T6&YU)B-X03M%9UEJ,U9)-7=0.$%G<S)5
M97@U9%IF6B]9-$UU,#0Y06DY1B\U>6<X=#-->7@V='!.>'!Y3G0V,%1R8W%V
M=7<T>$Y4-4$U2$HR4DUF)B-X03M3469S6E$W4V=E64EE;T1Z9F]-=FQI-3AY
M,E9Y="]P5G)B>3-4>5=X1$U69U%Y3V]5;&%0469:86TO5VUA,W=*0UEG4E5I
M6$XX5U!$)B-X03MX1&-*5"M8+T%/6BMG965F<B\V2G0W<40Y2&5L-B\Q=$DP
M<C8O4&IW.4]36"]F4G)7;5<V;E-3=S%X5G8S3F5$57AY,U8W379Z1F-H)B-X
M03M#-G!Q;&IP5VY83W!8.&]G<S=33G!:-5<V0E9&9G!09T\U>55)1U)!2$UO
M;$E!5UAY1"M:;C5M870U,C%D<$I#,$=K5S=%5T9G1'-Q)B-X03LY3V-L3FUK
M6614,C9$3W P;6MJ:&HO4S9L-3=5-FLU5"]265IM631Z<U9D:7)S5F1I<C!8
M.&MV3DAM,U-F3DUD;F\P3%AT:F1'=7!7)B-X03M4349I5TIF=%1L,BM'37AJ
M.6\Y96U92&%'2$A+1GDR235F<6,S435*:61$8V1F,79Q-U0Y4G-D4G,T<C)W
M;E,V=$IG5$9017=:1T%*)B-X03M";U(W:D]:;$5X3DAM-S!%15=(>C<O>FMD
M-40Q1TQ75C@T,DUB4U=C-E)X-F<V5DQ1>E)$9VMJ539+>4)6<C)).7AM.#=,
M,4E-9D10)B-X03M0;S9R=$1!8C1W;F8U968X-4=A5DYA46%D-75$5W0U1V]J
M+U-I2UAI;#1I;DM65G%Y364Y05(S,GEN5F1L>4)V2'5/-7,P+V%%4TMN)B-X
M03MS6',K;C9L<"MP5W%896XS358S87EF66YG9%I%4'E:4U)M<&Q!>$Y%55A9
M9V=I=VE-:6PR2W9N,S@O=GI1=EI,.2]*96AY37%*4DY6)B-X03MM:2LS2DDY
M0TQD4TXV0W9X*THK2'-A-WIS,U)I=D5L.% Q=7$Q,G!..$5F:BMP1R]L>"]Z
M:G)93%IW-FPU>%9P<G%50C P;$=+2D=$)B-X03MU0DUY:TUZ94MG9T0S>4=Q
M-U5.,6HU9#=,5#EN9T,U."LU-F=V-5HO;#9T=CE82&QZ5'94<%1K8F%)=B]!
M36I#=E X04A.9"MB>3-F)B-X03M%9FTU=C5F2"].2'EE9"MF+W=$;DA04DQY
M,&QV9DM8*S0O545"65=$<WI7.'10,E9,1FUJ63ET*U!S3W5:*VTW56M$53EX
M,W5*;C=0)B-X03MJ25A(679$9DTO;6IZ0G%T<G K;&$R6&4V,$E45WEY4S%%
M=U5S=C=U4W4Y67EL2VYF3GIH=WAI5$M02U1R33)756=)>35X9EI0;&XO)B-X
M03M!2E)V4W8X06U$="\K5%,U>658-GHW>3E(2&LK5690;7(S1VIF;D1Q=7)7
M>7$Q>%DV:UHT5F9D96%%1F$K,6,V8E1113E/26YQ2%)A)B-X03MJ2G=:>DQU
M+U5Z=CAT4'EE=69/1&YZ;#4T;6QU23<Y=E=T-U5S5F4T52\W<VQ954MX:V99
M5F%B94%P6$,Q975'3#DS:C9/5' Y2C1N)B-X03MR>6(R.7!T=DDS:W4R=%)A
M439&64QB,&]9>F)23E=N.'A:4U<K;DY19%)K2G-Y4'ID:TU544M!1'A(.#@O
M=T%N=$LP8E1J-6TX=7=F)B-X03M6-U9(5F12<U9Q63!$;FES<UE0,E)Y,EIE
M;31P5$YX,F1R<%100E!N,$QR3F)P04)X>"M,4&9Y03@T,UAM2'E98E<K:TUT
M.6\X9W1N)B-X03ML66MS.$I(2T9M2C=G5E0O04=/65AA5T%1>5=/56Y+,$]9
M>FAV>D1*4'I*.#@R=FMZ>790<7-G5U,W8RMJ65<W2"LX;EE';&%F<W%")B-X
M03MY8C)'62ML,#5Y>C1E;E9U>C5H:FIX1C@W*U)V24AM8C@P=&5U.5HQ83=D
M3$@Q2S,K<$]+<S<P<4E95BMZ54Q4+TI553EG9#=Q3E1$)B-X03M44D59:F9O
M2%598T5S.&I+4C)E+V%(*U1V-6-A4D%S565I5SDT-$9';G9L1C W2'A):T1)
M4#EI;WI36DYD;6MF<4DY,GIT66%82$5F)B-X03M31DAZ0BM3=C5C-GI!-DA3
M6710;DDK0S1S04QD;%!J=U0Y,F9P6$1I,2M70C4S-S!4,&U/4356-VYG,VUJ
M4F9/2#566#DO<&MD=V)N)B-X03M1=&1T8FDQ5U=H14TX8W-::DI:2VYH3D9Z
M0B]S2GID66-M4%5G2"M+2D(O2&LV=DQ#94%K8S1Y+TAZ6G(O=T$T<68X0515
M9CE'2"]9)B-X03MZ;4HR>B]".&8P3B]:9CA!1CA0,'9F8S!J=&YZ.2]Z:W@U
M,6M-,7 U4G1*0TDQ0S-E<# O85DO,TU:*U@R>C@Q.$TS;EI/;C4U1#=G)B-X
M03LV<G1,3GEG4&DX1GID=7!D:7)S5F1I<G-65'9Y>C54=G1D;&UK5U),3%,W
M36,Y4C%7-"M',W0P-V-J*S W9$929FE9-51M>D-(;DDX)B-X03MH,W0R2$-:
M*U$V;$UT8S@S,FM';5-E6%!+<5!:844Q4')T,#E"9&%G-B]T>FMF6FHO:VE'
M=S<Q3U8T.$)*-#4W>2MW93<Y8EIK>F=$)B-X03MG:'1(-U,Y2B]W0V-A4$\P
M:V0U8RM58G51;4M:5W5T3D)0,EA896%-9C9Y+T@Y0CAC,2]A,FXR1U%F1GDK
M>G,S3T(K1#9$:VIJ;&IA)B-X03M/4E$X8F=Q-DU!5EI32T5%2'%$;6E"9',X
M;S@V9C@T-V563EIA5S<P4GIO="LO>&5M9S4R<D@O:D9S57(O:T=G+VQZ6C9F
M=%-C3G!E)B-X03MO9F$T3V)146QU4%-8:T8O-5HO3F(X<TPQ<C(S864R=&Q9
M5G8W3FI,85-!2&(Q5G!X*VE64FTQ:FUW86=5969C968T.7IR>FEZ6419)B-X
M03LU9EDY4B],6"]N25,Q,6TV9S!J>DY&2%DS.'A%8T8O2#A.=DDU,D-U<D4K
M;7I(=EAJ.',Q=7(W34U">%$S2&,U,FTQ-&UE1U=X974V)B-X03MR9DIP*VU8
M;"LT-4IA45-4<W93;VE1=5(K1V%U165)9V0W;FLP2'I&*U)':FYZ3BM:8W5R
M86XK+V%Y5U15<%,R-&4U9'=%2BM4=5@K)B-X03M9>F]U,&-N:#1E161D=F<V
M6%%X-#AP:V5M+WAF52MC,C=T,DMU>%8X=R\X04]3;FQY,S W>FIA-G)B<'=4
M5TE#.#%"44=E06A(654X)B-X03M52U8Y.2LK9$8R5FQ-<UII9C184SEP67=*
M:5AE*VI03% O2TXV5B]Z0C(O+T%#85A.1&PK<RLX=35J>69+9FYF5$)Q=C4P
M,S)L:SA2)B-X03MF-G9(86QV1#%P1E-V+T1:,'5N;G<V8U,W;W5H,45E3%!8
M95$K=31)66])631)545C35-H230Q1D%Q<4M!065!1V-U5&4W=C$K0E=.)B-X
M03LO;59B4EA0-64K6DDU4E96,#(V;$$O>6]O;6M8+VAL1UI':TY:62\Q9S V
M:BLW;#=I.&XO04]C5EA9<#5N46XT5DYI=TAU,S%G2#E1)B-X03MZ6CES:C9F
M:BMH=T]Z1'1)935*+RMC;G1A;&XX,#9B;S19+U8W1S Y8W(R.5<T8V<O=T1#
M4G)L=EI'3V]'6&57=G1/9G%%6'90:VYY)B-X03LS8BM7+TMU;39.0V=2<E=&
M4D]25#1P;4A+5FE2,7$U3V%855I4:VU:9#=T8U=-46E):F]N955T:G-665(K
M8S-L,D184'DW,5I(44Y0)B-X03M94DYF5W(Y,64S0F1Q9C8P65IF<'I-,$=5
M=WEJ>C(K8FHV=DAX67DX-2\U>%4O-F%J+V]W+W=#>&Y-+W1N*T0T+V]C2'-V
M.$%I*T@V)B-X03M8=G5A4C)Z-&HX+S9Y,G,K9'1A,4EK<W,Y,TM):515*VMJ
M8TEX.4-+0FY986)(=UDT:GEE83%-*TQ*22MA45IE,'5X5C)+=7A6;'9L)B-X
M03MF>4]L,UE.-6<X=S-*,&YY=D$Q1&-K5FYU;B\S>F%2;C=B;BMB-TLY*VU9
M=6)5565#031P+V0W,TIW-F5X>%0R:#DO=5%V;6YZ:$IQ)B-X03LP55=M861B
M:E,O3&QM4V),4V]I4T]21D1,32]75U9Q8G,S>4=3=S1/2#%(95HU;CAD1T]B
M4'AB1&%)-DUC>DEA13@X:C9W*VHK8TY')B-X03LQ3E-13&$X:&%3:'!7375&
M:T9F9$-2;$=O:'@T-41Y8G103&AY02MB-V9Z:C-P6%EQ,#9+-FQ(05I'0D1+
M4E5%2'%#359F3D@O3U)()B-X03MK1%-.078W1%=T2&=7,&<Q27E2,TYT1T]-
M87I*4F<V2TYL-6AJ541B8C-Z;V5Y.51+64U:8C V8G1$04DQ2618<F9K,B]V
M.$%Z5"M4)B-X03MC16MJ1U,K=F1.=6)1=60R95--4U<S22LW1DMN3EAN:4UE
M;SAH24@Y3'-C12M0140S:#5"+W=!-'HV;D)A*V0W>7=M4$=3+W,S5T=V)B-X
M03M5>5%U<FQF*T%$2#9-,G9A,$-C65!C6%AD;7EQ6DAE*VY--3$S3'-69&ER
M-7HO-7EK,5=+8E<Y1#!T4W!K<S=E8653;35(,6PQ54$O)B-X03M20EA..3)0
M0V]Y;#,O;R]T9%(R;DQE264Y95=F*U5B,'(O;41T+SA!:S!U85A,.5HY-61T
M2&LK6C<U5F(O;DEP47=Q4# W0V9P17%K)B-X03MF:FY1>"]X5"].9$Y)9C16
M.%@Q5FY.3S9D:7%3*V1L5G9*;79+=W%R861D9V<Y0T1!*U<T4#=Y4'9$1$E0
M4V9C.%(O-7A9+S0V;FU$)B-X03LO:D)B+W=$13-Z8SES9E1(-'5S-TTO:2M(
M-E5L+W=#8VMB2V%Z+TU31SE'>3-6;D1,1R]58V\R6D-.>#(T02]4;'9:56=C
M5F1X82LP)B-X03M14FM".&XP=F\K<#(K<3946C9N8D=S1C="2&-2-S$K1U)1
M=T9F875C+T]":DEG.4AC>&M#3$-,>4-867%X<CAY.51H,#-Y0C5G=35J)B-X
M03M24EEZ4DQ8=DI/<&AJ2#!U-'I),&M/3$Q%96)6;FQW=THX;FLO=T1Z:7 O
M,#%(+U)H+S)--7,K,F8T4&HK:#$S6F8X048X4#!V9F,P)B-X03MJ=&YW4$]:
M1$Y)6F8W>FME9BMT6&9P;F)$:SAR2S=..#%M1D1S5EA'2U5)<VA29VI':711
M,$HY:F=T4$-A=#9.;S-K6%)V3$]L42M:)B-X03MV4#1:5FQ(4%-V3%-N:F,S
M6DA2<'4X55AJ6&8X03)":S%%<VMU1$8X6F1!-7505'AX:FIY9D%-5#@S96-D
M63@P86=,<2]:631)4C9D)B-X03ML65%J:&(R,%$R16-563)554%Q92M:3T1"
M2$=+2'HW,TAZ6C5:1%I34$PR;#)+=7A6.49W+W=$3U-T=$8U=W4W4%5D3V5$
M>3AJ*VI$)B-X03M-1EE856))4T=K;&IB<W@O64%$3#=N3D%E>6EC64E0<2MX
M,U X;V=424DY3#),4CEC,&97<DIB,U-B>4LY=%AP4U=&9W="27)29TXQ)B-X
M03MB,D\K87%E3U5$56A29&A'46M,0G1'=39O<&1Y1E)14WI%,$%!-FMN24UN
M>DHO>FM$-2LP-WI.<D9J;VUI=4QY,C Q;CE3-&DK2EIB)B-X03MI5VDX67E+
M.&=O5VQ2,4HR>F]U>DY-8V-42U<Q+V,V8E@U>$UI360V93AF;'@U96XX=2M2
M.4@P931!1GIB459U1DA14WES6EI&*VAN)B-X03M)>E,V<DM-;5%Y1'1-1U!G
M9TEV;GHX,E!+97)E45!0:UAM5%)W67)#-750<FUN>G%+<$906&TX1$1P4W13
M0C!+;6Y9-79.1FUJ;GAC)B-X03M%=5E&1C%/<7AN1FLT-#AI.3 O3'(X,'9,
M,VY/=VHY1U9B9E=&5697=$YC9T]'02M*;S9N-# Y>#E.33 R<3!C.%(S*VYV
M9&YG,45C)B-X03MG,C4Y>DTX>$A)67HU-"]-3'DS-4\P-3=N53=H5W5I=&)B
M5#1Y1%!-,V)I=EIF1FIS4&YT;5)P.4Y02V%J>3<R;DYN:FI&;#AG96%D)B-X
M03MF,5AZ1G)D,7(R<$$K=&931FQ)0C1"54%663!*-TET0FY666-C8V-2161(
M;C@R4U4U8U(V=G10>7HO>6IE;&8X=V1V+T%-;6QZ:V-V)B-X03LQ;C-L-E=0
M2C@P,VXO<E)A+W=$8F1I+S5/3&Y14B]X5"].9$UF.&$K4#9(,5)N3G4V9&EQ
M5"MD4"M53S$S+W1N6&8X07E99DQC2#DU)B-X03M(,VAJ4#93.$TO-7AA;'!R
M975W,"LS8E%V6"]5:TDO-#)Z8SES1#!X.3=Q=7I/8W9G.4(O4%@X=C4O3EAL
M:&)V5#1Z2G$K:VQP8F5*)B-X03M2.%5S5$%E<D=/-6(T47EJ>$9/*UE06C)P
M1T]D2#9:3UAR34AI43(U:#4U*U)V-7=7;6EW<C57.'AY*VA9:'HK:C<U-CA9
M5UDQ355V)B-X03MG:%DQ1&9S;G)T,'IU,$Y#6FYJ:'HV:'A.1G%X16-%;C!8
M1DQ&3D5K<TQR2D9)07E325%Y<W S0D)'>$=A26EN8G)B;39T<E=#4S1U)B-X
M03MP56=T-&AY;&UL64EI<4\W33%!0FE!4V%#:S K879Z<2].165C2G@U93AT
M:#=J4TQ0;F,S5G=I="LO849#-TU"4W9P4DM'87 V.65G)B-X03M'9$)O3D@T
M6')N.5)D3G).5#1N<&AY-G U+WII<"\P,4@O4F@O=T)J3U4Y<R]W04AX+U%Z
M-TPO:2M(-EAV=6%2,GHT:#@Y-D\K:F5C)B-X03MT83 Q;#1R8C-K;VE&2V9U
M;5ET16%E-DU$;EEA869(:FEF2C5R55$T8VMH-7!&;#=3;C-K2%0Y3#%(>G!O
M=&IQ<$$P*S1U-&MU07AO)B-X03M'0F):0V1T;DY&*VY+3E1+56-C:DAN5&1P
M;VE744$X;C)U='!:4E=Y44Q$2$AB44%E;D5&5EDP0V1/2S!O=$TU1&E*3#!L
M4&E0>FQR)B-X03ML.7)F;6)59%%V3'1R>#5*-4)&33-4,&QC:4U)3VEQ1C9!
M6C)'1$=)44%!<#5R551-<&MK,FLR6$Y4<U9D:7%D*U-.2&)79D]':F%9)B-X
M03M!5U<V=316;&]+,&I$:'!$5#)11354<4HX1T]2.&TW5'<T<V=(;2MQ=E!V
M-5)E52]/5F)I-FI.;G%T044Q1S-O2$Y"<TI&4'=Y1#4W)B-X03LK0D=C,7!T
M8E!&<TXT.7IV8RML:&LU."LY-#=F+W=$3U!8-6HV3&1M9GDY9G@S47(X13!%
M>E=K.4(O34=)02MH>FTQ:C)N:&U05U P)B-X03MU=D]G>5)0;U V1D]B.&]F
M>C Q<&QT=%AV6EAT,C),,S)O=%!'0C=Q<GI..7DT4G)T3D1E22M554A36C5B
M12]A.4DO3&8X:'1'.')8)B-X03MC5W)A<$].53%E2VI19D1X9V=C9G1)<'%8
M661M8G T5GI8-G)T1U=18TUD;W5:<#E&2$=B3S5E<5IR6$Y11W4V1'!/=39:
M3G!M<E=Y)B-X03M85FQ/2U!%+UDY;55J9%=(66IF2C0X:V](:6EA3$=C0DE5
M951W2'I0+W=!-#%E64Q+-V$V.'$S-EA506)L1$)/,V\S2V(W05-!8T=P)B-X
M03LO3E9F;&TW=SER4DEQ62]5-G)*,F1)1S1&0U(K4R\X06Y*5D5&=71X<4MX
M1#11,S95:3)(>CEF;%1*;E!O*V1$+U,O<UEJ1G%E5FXU)B-X03MP=#57+W=#
M8V)T5W9,=U@O04IZ,4@T4U$P;'!B=5I:<%!A4V1T;"\R4$PU:DMS,V%S44MX
M:'-X.6YK;3AH=&MV-7%F:VYD*UEO3D5T)B-X03LO2S5S=$]T=$MI;&=.=$XV
M:V$X6$MS<%5X<$M386<X=5AZ<FU0;RLP0FHT:D]Y6DXR<3!H;4%),$ME<&%0
M85-75VLR5FY+5F%7,G0T)B-X03MO6$LQ2VQO,$-M;%%$4V]Z5WIL8VE83T$R
M95)Z+VMP-6QK+TYK96)H95=1,'-A:6PY-E)A6#9X=U5H:79$,"M&86EN,C@R
M9S$X4$$X)B-X03M/:F15-$(P:W9'-#=&4%HX,4QS2%EQ9TYF,"M8571#,4Q4
M;VU62F)Y,6UT-#-E=D5.3$=Y06UL5%-P>65/6$1)2'5+2D-X5'IJ.&YF)B-X
M03MY:C%Z>5!Q="]E86IE5S%Z2&1W3$-I,C5K2D)$:'%N;6EB6G-.9')9-6]G
M0455-&5K,'!X13)B=#9T;7-C,354*UI8-4,V4C5N=5ID)B-X03M6,&5:9$PQ
M:54X<'=62G0U,E!6;D,W;W@W<W98=4LW-7,Y2C)L3$=/1U<X6$(Q1VEJ:TYJ
M679.<E@X<79Z-3AV;')F4DI:;&=*,RMO)B-X03LV9VM54CDK16MK4"]!0DA-
M.#9Z5%0S;#EO8TUA8E51*VLO8BMT17 K5% U>F5:<#!8>DYQ1%$R-FUP82MV
M1&1C44YV9VII859A+U-0)B-X03MN9R]0-F9'4%%0:TM:9FQ-,"]R3#%442]Y
M8C!(45!+3W(V5'!H.516=%=S6C=/8E9R9V9%5$Y%54%#<CEI34UA.%(Y2D]A
M>DIR<%1Y)B-X03M#4BMM2G5N3VAP27AG66IM4GI19C5+9FQH<B]K8CE-+W!A
M-'1:+S!J.5<Y1#9O.&HP.40Q95A0,4DT=CDK:6Q+-5!8-G5/8F@T8C)V)B-X
M03MN.$=V4C9A5TLW<F0V9&UU8S4X.&8X-4UE4S5)<BLQ.#(R<59G=497,#%!
M:CEM5D%F4V,O-GEF1"]S4C0U=F5Y8RMX>&XS:#%085=()B-X03ML369&-%AM
M-F15-$5G9V<P23-"2%=U0E=6,VXU<2]M2&5A3V1(=61C=4I,0FLY3C!005-/
M:$9#<GI"4DMW238X;3-Z1VIO.%%L>$-/)B-X03LW:TA6-5-+=EII;5I4:G5X
M5C)+=7A6-VPO=T$T>BM42&XQ1S8X,EA+15%79V$Q,#AK9F%L8V9V6$@K;V@T
M+S=)*T=A8G1B4%%'361D)B-X03MY-UAS,T1Z;69G*VEC,$QT;EEQ-T9867$W
M1E=.>"ME.4]F6%@P;')3-FI68C V64Y16EEV<7I866=&>C91-'E.2TMX='-7
M:D,Q,G)M)B-X03M19$]E2&ES8W)R<E8P,41+3TMQ.'9S=$Y:.51E3%=R5%1F
M4E5R9%%Z5&5U6EDQ64=%;T]+=VLK;R]W1&5B<V]O=3%E;WEO475*4&-Z)B-X
M03M-=#9B=CEE,%!4<#193E$Q1S%S-3=J*S1I=4IO-&YK,W X0W515RMJ1T]/
M56A90DMM64A-<69M6%@W2'DO;U8Y<D8V>7)"6E%V3'=:)B-X03LQ47E-<6MR
M17!99V,S4'=Q3S5/2$9J335#239O>51%26U2-DLQ<'$K;EA7;%(V<DAC4B]5
M2DEH3TQN;7!J0U5Q4UA"-#!(8S%W4V=2)B-X03M,:#9S:$E%6#!B,#-6.4LQ
M4S,K<S9:97=8,75#5CEA,FQ36D]1-FIK:%E6=U1H2TIQ47!%6D-1<T<Q4%5T
M9C!,4S5);SE4,4LQ<UI*)B-X03MV-VQ,;6%/178O<6@R5W8P65E9-5,U06Q:
M5$$U;')89&1S=$4P>'13=7<W5WEY=U)(,"M*3F)M6DE%8C1I;S1H<%%4=C!W
M-#A:;6%()B-X03LT<F1:>D526E9D3C%J4V15:&%F5$PR,W9O55EO.'1T2VMY
M:&@Q57-H658Y<VI/16\W155S6D$X:F%&6'I:-5AF5D8P<$Y7<S,Q2C)D)B-X
M03M&<S%N:DUV3TUL6%1I1%AK<%5G<C$R4&AK+T)N=SA61VME2D<V<U=J-WDY
M<S=',6MU-S)E3S%T65)Y;'5*;E=/3D(P<7IS44(Y3U9X)B-X03MI4V%'-5I%
M9T-Y-GIV8D\K=%DW=7EN:G5R5UEC;W)I1C%K:F-D2W$V:V<O4FI+2D)O-T91
M45)943)G83%A835O=&QQ.6]R<&)8,%-Z)B-X03MW<$M!2$-U2V=-1DQ#=GE/
M4WDT>D-2:6594D-9;$5%9%<W1%AT1#%'96%$5#E2=&)Y93,O04PK2S-M:FQE
M4&5N>'%H2E@V8UI9-5)&)B-X03MK14M*9SAI,7%U=C9*<$IG1W%8.799;39F
M,#=F-GA)<V9.=D)E4D9E=4U-8W!F4TQP6E1!-6Q78E4Y3E=W5%5'=316<TI&
M4C0W<WE))B-X03M)5U=79VI:6DLX4T@U1&IV=EA"=T<V<F1014MV;W%#-W14
M9$=Z13!:=3%J17I7+TEE;TDR2E5/57)Y-&QL27)G-%16.49T5G=*45=T)B-X
M03MA4' K=&%69&%6<4U1;7-R>4UX>E)N=U!19SEI1'5$,D]4>'I-2D-1-6AJ
M2TEK2U!*.&8O04IK9FQZ<2]K;E=483-)33)N5&MT<#DK)B-X03M".$UQ1#EL
M=C5:1B]A6"M'9%1P9%9(3D=X>C9H-2]5-EDT:C5-4GI,8UHR2W5X5C)+=7A6
M;&8U9"]L,W)(;EA7571,4E=I<TEI1&8V)B-X03MG5G%K2V5(648R+UI8*T94
M;4QQ=%9(1$=Z>C9">4Y.<&IL4&LK=W1$,%A4=$4P;3$P;E1O=E)S<D]-4G=P
M,4Y"=5-4,UII86LY>FY+)B-X03LU36AN27E03791=VE):6AY4C)16D]X5C)+
M=7A6,DMV350U43$X961:=%%I,"LT4B\P-'5O46%M,3%%8DE75%<X34TV+U9F
M5EIV5V16)B-X03MK44XV24\T*TMG>EDK4$AW-G-F5%96=F1N<EA,-'5)35HT
M>6$V,V94:T]L."MF4FPK<#969E0K9&1#,4M+4&Q:5U9P<456>DQY56-8)B-X
M03MU1&)E:T]*4$DX=E-B;T\R+V)-5T5W36-H,4I(-E<V551X9SE+4#9%;#%8
M4G17=#EC,2LT6%%K,38S,7E+1DE(85-"1FA%55%I344T)B-X03MM6DA%6$E'
M4W-F23%*,C<U8D1*17AI3TQH-&9F*TQ9;4I"3S$R;48W-64Q4E!Y=W5F3'%3
M1R\Q46%,2EE)-4E8,5HO<7!I2'A0>$$U)B-X03M.,UDO335#3U=0:D-F26-6
M+V%S<UHX27@U;FAR-T9N;DAY-7%U<654-V)4<DYI3&TR:W1*<')D5$=05U<S
M9%=E24=:6EEA;FI596]P)B-X03M1:T1L=&AW6EEX>45N;'8Y<DQ,07EJ4550
M2D=G-G)A-GAQ;7(V:$AE44YE4E%13$AE>5=":VLY175F56505&]O-%%12#1Q
M>&1M238P)B-X03M!1TA56DEM26E+,C=R+S,R-TA&06=K;2]J6#9&=#=P;7$R
M2&U06$PT84%0349V<DUC06=:6DQ:5$5);VA%,79-3&QK+V1&9UI+<'DS)B-X
M03M9+T1J1V-:46E/3&@T9F8X.75Q4T-*13%D;S-Z;&]&>G%V:V]A4&(R55)D
M<$Y01#)+379P3$9$9'=34V]R3TEW55-.1S=#;TA4=&MC)B-X03M'45)Y8U)0
M9G8X0W5A2$9'<3=V=D-V<$=J,V1P-7@Q,B]W1%)%5VXS=')P-E=Z<59!85-$
M-G=*9F="<4-Q=6TU1R]B<&M:>D)X>$A5)B-X03M%+V]:4FEE36YP42]3>#EV
M2T=R<C59,4M#1WI69%1N.'AN5F)C:&]W>&DO4W%43$YZ<E-V,5I3844X<6)5
M<G1L+VIX-'=B,C1++S)0)B-X03LV,FYW>G<Q,31R+S)6+V-N+VY44W(V.6HP
M=39T3%EA9TY,=FMV2G1-3$EN,6A"1DI(4E1)5E1N1S!G:U5-=U=Q-SES;W=4
M07-%,5EQ)B-X03LK-75Y4DIO:F]895,Y2W9R2U!63'$W=&AP-#%3*V4X:#!W
M36HO5C!-56-D1TU:6D]C:E)M4F=R1F%T=#-X>GI";T$S47$K.6-C4TQ*)B-X
M03LV;$$V2C59,61F>7%G.'1Z4"MJ.59B4S)S,F--<F5L33A25#=38V=A13=L
M5#AJ;&U43DAX*U!N2&ET:$1'9D-%95(T85$R;&%.<3%X)B-X03MR;6=81&%%
M;6<R*VAX5$I/-GE13W-W;&E-46=G14Q/-6DU15-6:S1M;T<S9D102D52:T],
M:31V9BM,55)*23)Q:T(U-#%I>C!$>E9C)B-X03LS9#EB=S,X97%A4W1N0D)C
M4U)W0TUX>7EL,4141TY:16TY5F5A>&PU9FA(=S!)>65N9UIW04<Q4W8W=G4X
M.6M:2F--<E!55CDO=T-/)B-X03LY:T=H84Q$8V9L;'!M:F%X1UE9;C!A,W1B
M-D]4-%=J+T%.1U9(<E@W3$HK0D=5-4UL6FI+4#@T,3@R5T](-W-24#@S.4-#
M+TMU,#%/)B-X03M84D<X=V%V3#8K<6%Y26E:-D9E5G)B<#96<V%.=5!52$MB
M-7E(2F%Y431U1U!+4#-N;BMR-$QG0G)I4$TO:CEV>%IR;4DS3WA6038S)B-X
M03MO96LV-7!S=6TV=&%P9#)5=V\X56<W.6U5:F172%EJ8UI02&ML03-%,%=-
M-$-1;SAN>B\U,B\U>'(Q83%K:W5V2VLT=G)89&A96$1")B-X03M*,3EK8S!J
M9C9E2BME8GI4.7%X3S Y:C-U<7ID;DAN1#502F19.'-E63E':TUE<F%:8S)2
M2&5A2C!5+TII3THK9S5S-%IO5"MK9W5V)B-X03MN:&Y(;4-L;5=T85IA4C5A
M.'<V>DMS5VQA8F,S<G0P.4=*,T@P<T)11#-*>75E8450<4E$6D1$3UA)1C9Z
M-4LO-7AR,6TW:U,V.#%4)B-X03MJ5')51W!S64=74S1F,EIX>6IJ2'DU2#)'
M87959'%X1S!.>C-U9F@W3THS;CAN,$1O5V<V4&]/;7AA8G!&<6QP6E$O6FEJ
M2%4Y,EEM)B-X03MP6FHS66UU85!*:VQ-,TDR6&)19TEI:'E2*U%:3WA6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6)B-X
M03LR2W5A;$1Y<'AP=EAP5$97:S1C1C15-%5(2&HP<#)P5$97.%9D:7)S5F1I
M<G-64W<O=T-'2VUV,4MV979P6EHV+TY'>5HU5VPR2W5X)B-X03M6,DMV+SEK
M/3PO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL
M<SX*(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*
M(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E
M/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM
M<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/D9A;'-E/"]X;7!44&<Z2&%S5FES
M:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM<%109SI-87A086=E4VEZ92!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW
M/C8Q,BXP,# P,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C$P
M,#@N,# P,# P/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0
M;VEN=',\+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53
M:7IE/@H@(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F
M.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y#
M96YT=7)Y1V]T:&EC4W1D/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1&86UI;'D^0V5N='5R>2!';W1H:6,@4W1D/"]S
M=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S
M:6]N(#$N,# P.U!3(# P,2XP,# [:&]T8V]N=B Q+C N,S@\+W-T1FYT.G9E
M<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I
M=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1&:6QE3F%M93Y#96YT=7)Y1V]T:&EC4W1D+F]T9CPO<W1&
M;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*
M(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM
M<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A
M=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @
M/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(#QI;&QU<W1R871O
M<CI#<F5A=&]R4W5B5&]O;#Y!9&]B92!);&QU<W1R871O<CPO:6QL=7-T<F%T
M;W(Z0W)E871O<E-U8E1O;VP^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/D134# S.3PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @1%-0,#,Y+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @(&1E;'1A)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @
M(" P,BU!=6<M,C R,B P.3HQ,CHT,B8C>$$[15-4(%1I;64Z(" @(" @(" @
M(" @(" P,2U!=6<M,C R,B R,SHT,CHT,B8C>$$[4V-R:7!T(%9E<G-I;VXZ
M(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" R-2XT
M+C8F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X
M03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@
M96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S
M<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N
M="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0V5N='5R>4=O=&AI
M8U-T9"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N
M="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X
M03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @
M(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(#QX;7!-33I296YD
M:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @
M(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#ID-#0Q9#8Y-2TU,F,R
M+34Q-&8M838V,2TV-60Q,C0U93-D86$\+WAM<$U-.D1O8W5M96YT240^"B @
M(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z9#0T,60V.34M-3)C
M,BTU,31F+6$V-C$M-C5D,3(T-64S9&%A/"]X;7!-33I);G-T86YC94E$/@H@
M(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z-6-C
M8F)F8F0M83<V,2TY,#0P+6)D,V4M9#8U9C V.#4S8F$V/"]X;7!-33I/<FEG
M:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII
M;G-T86YC94E$/GAM<"YI:60Z8S$Q-3<Q,#4M-S-A."TP,#0P+6%A-V$M.#<U
M,68W.39A9C!E/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12
M968Z9&]C=6UE;G1)1#YX;7 N9&ED.F,Q,34W,3 U+3<S83@M,# T,"UA83=A
M+3@W-3%F-SDV868P93PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @
M/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C5C8V)B9F)D+6$W
M-C$M.3 T,"UB9#-E+60V-68P-C@U,V)A-CPO<W12968Z;W)I9VEN86Q$;V-U
M;65N=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F
M875L=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ
M1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @
M(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HU8V-B8F9B9"UA-S8Q+3DP-# M
M8F0S92UD-C5F,#8X-3-B838\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C(M,#@M,#)4,#DZ,3 Z,#$K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R(#(U+C0@*%=I;F1O=W,I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#ID-#0Q9#8Y-2TU,F,R+34Q-&8M838V,2TV-60Q
M,C0U93-D86$\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C(M,#@M,#)4,#DZ,3(Z-#DK,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E($EL;'5S=')A=&]R(#(U+C0@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^
M"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,38N
M,# \+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( $( YP,!$0 "$0$#$0'_
MQ  ?   " @(# 0$!            "@@)!@<#! L% @'_Q  Z$  !! (! P,#
M @,' 0D    $ @,%!@$'"  )$0H2$Q05(18B,3A!%R,R=WBVMQ@:)"8T0E%2
M8I'_Q  = 0 " P # 0$             " 4&!P$"! ,)_\0 11$  @(! P,"
M P0&!P8$!P   0(#! 4 !A$2$R$'%"(Q00@5,E$C)#9"8746-7&!D;2U)3-#
M4G;!)S1$8E-R=)*5L;/_V@ , P$  A$#$0 _ &(^\KW8I/@C"5C3&C08R>Y-
M;1AUS4>5*!IEXO6-.(-)AP;23!Y\HGK-/2HD@#3H0I#L6EV*D9:=',$'!AI[
M:O23TOBWK-9R^:>6#;F-E$+K$W:DR5M465ZRS^#!6@B>-[<R$2D2QQ0LCL\T
M&3^IGJ%)M**#&8I(YL[?B[J-(O<CHUF=HDL-%\IIYI$=*T3<H#&\DJLH2*6I
MJG=DWN7\Y8H+;'-3E5(4(RULMS 5/V'(6O9]SA134X)89/H8<O7*31&\M.H<
M8J\5,M/P_N6#(0L*:PZ"WJ%OUB].]EROB]G[9CO)5)A>W02KC:DS)\+%+SQ6
M+EX\@AK,L)6;P\<TR,'.>5O2[?.ZXTR&Z-P/4:P!(E:Z]B_:B5N&4/422&K4
M'!Y$$<H:,\I)%$X*CCMG8G[E'$,9Z_\ "[E4[=).$3DU==H5HMFC;M*89_O5
M,1\,5/R-)GVEI0K!,7-6X1!Z,X%;"D%/9'SS5]:O3S=3"CN_;(IQS? +%ZM5
MS5.+G@ O,L$=R CP5DAJ-VR.HO'P&T6/2?>^W%-S;&X#:>+E^S4GLXJU)QY(
M2)I9*LP('#1RV%ZQ\(1^>-6:=F7N%<T.3%PVMQSY;:?FU6K142QFR[F*KB*#
M+0\\Z:T$!0MHTYX6+"_6$PPF2DHD^MQT6MR/A2URD"O"\S;F<^KFP]H;=J8O
M/[6RT/MLU*WM\0M@WHIH A=[V-MJTC^TA)CBE2Q)*!),@CG''9%Z],]Y;GSM
MG(87<6,E]QBHQW\FT'LY(Y2X5:E^L5C3W,@ZWC:!(R4B8R0GS*6"NL*UL.CH
MT:.C1HZ-&CHT:.C1HZ-&CHT:.C1HZ-&CHT:.C1HZ-&CHT:.C1HZ-&CHT:.C1
MJHCN+=XOCIP%051\(5N/D&X$A\34E7E!Q&*TDIC#X)VR[1\!X]1%)96V4+$,
M@RMI/'>$*;A1HDUN81JFP?2;/[X*W/ZIP0<J^5LQ,YL=+=+ICJW5&UME(*M*
M7BK(P9#,TJ&(YSO3U*PNT U4#[SS)4%<=!(JB#J'*/>GX<5E8$,L822PX*L(
MEC82A0+DKWL.X3R1D)!"]U2NEZ>4MW E'T0X7KL,05><X^ FUQY;NP9?+K.$
M-EHD[8^ \KY<L1XC3SC&6LV]Z/;#V_'&1AXLQ;4 M<S82^[,/WEK2(*,7#<E
M>W55QXZI&*AM+AG/5'>6;=Q]Z28NLQ/34Q):DJK\N&LHQN2\CPPDL%#YX102
M-5AV.\72X&.2-NM]HM,@ZO+CIUCGY:;,=<5G.5+<*DRRGUK5G.<Y4I>59SG.
M<Y\]:/7ITZB".K5K5D X"5X(H4 'R 6-% '\ -4.:U:LL7L69[#GR7FFDE8G
M\RTC,3_CK-M=<@M\:@.8DM4[HVKK<X9:5LD4;8%KJRL91G&<(6F%E0D.M*QC
MVN,/)6RZWE3;K:VU*3GQY#!83*HT>3P^,R",.&6[0JV>?X@S1.01\PP(8'R"
M".=>NEF<OC7$F/RF0HNOR:K<L0'^P]J101Y/(((()!!!.KU>&GJ,N3VH9.)K
M/*B-%Y':V^5D8RQCAQ-7W% A>Y+>2@)2.8CJS</I6<K=5'6:-$EI5Y+:7KJ
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MJ>Y?2M,#L'";SBS$ER;*Q8:>7'M16%(4S%+W2I',MF9Y7KNR1<F-!,"9 L1
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M]J-<GX)R4'%<&, /*>OT_P!P87>N/3=]2E#4S4U=,/F50DR12TV[ZUW/($T
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MKSA#3 X[3CSSBLX2AM"E*SC&,]+_ !QO+(D4:L\DCK'&BCEG=V"JJ@>2S,0
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M\5L=49@WL\="6]O 2"09&+//893TM9FF9.$*J'AV?MFMM+!5<3 5DE7F>]9
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M2V.W9[RKXJ(L0;+O)&C]VO0S:59/;-#[H1FZ:UN&E(G,$5KX9J]7H,4<;I'
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MDY8_![&2DVQ!*LT\>2>.C$UE84,X=KD$$LYA:,Q=;1EY)%,7:'+? $\#:6I
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M.I#(,!V-RC?-$8)RC#+I(C,@ \4PVM3H[1PCCJ$()9RNLV'0[9Q48=3(N=W
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M4*0X,6ZVM*LM/B<WB,]56[ALE3R59@/TM.>.8(6'(255/7#(//5%,J2*00R
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#-?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g457972g85h19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g457972g85h19.jpg
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M4W)SD9.BL;*TQ-'_Q  = 0 " @,! 0$             " 8' P0% 0()_\0
M3Q$  @(! P," P,(!@4* PD  0(#! 4 !A$'$B$3,10B00@542,D,C4V876T
M0E)Q=H&U%B5TD;,F,S=B8W."H;+!<K'"%S1#1$559(.2_]H # ,!  (1 Q$
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M:'!XT+)(@C) ^(2-K'#=\]B&)Q''@RFZM\=3<A-C=OU[=?% \&E4E]"-8&)
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MMGVC/VXQG]UJ/^;9O5]="OV1R']XKG^6XG5@'K%_U9G;S^[<+^<:QR#=)O\
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MZ3R2.0JCV Y/))"@$D [%2I9O68:=."6U:L2+%!7@1I)99&/ 5$4$D_4^.
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MCCAGO"5KQC*_&%*\><_FC>IV,==N8^VGIVJ-JQ3LQ^?DGK2O#,GD _+(C#R
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M26W'D,XPTE>$8PGF>_E<IE7CERF2OY*2)#'%)?N6+CQH3W%(WL22,B%O)52
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8^Z'_ -.K4N5IJ?Z.&C1PT:.&C1PT:__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
